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Abstract
Obesity  is  becoming  one  the  leading  causes  of  mortality  in  the  western  world.  Although 
environment is a factor in its development, it is highly heritable and despite a number of genes 
that have been found to be associated to the disease its genetics are still poorly understood.  
Discovery of genetic pathways that influence obesity risk can provide a better understanding of 
the  pathophysiology  of  the  disease  and  identify  possible  pharmacological  targets  for  its 
treatment.
This project was designed to investigate possible genetic associations between five candidate 
genes and severe obesity in both adult and child French Caucasians (n=2,822). Tag SNPs were 
chosen along with a selection of common SNPs not in the HapMap database and genotyped 
using  Sequenom iPLEX assays.  Putative  associations  were  discovered  to  obesity  in  three 
genes,  SIRT1  (corrected p-values: 0.034, 0.019),  APLN (corrected p-value:  0.017)  and  IL11 
(corrected p-value:  0.016),  although associations  do not  withstand genome-wide  correction. 
SIRT1 and  IL11 SNPs  were  subsequently  genotyped  within  a  family  cohort  for  which 
transcription  data  in  adipose  tissue  was  available.  In  this  cohort,  SIRT1 genotypes  were 
nominally  associated  with  BMI  (corrected  p-values:  0.014,  0.019,  0.014) and  a  significant 
difference in expression levels of the gene was observed between lean and obese individuals 
(p=1.6x10-35) providing suggestive evidence of a role of this gene in the development of obesity.  
Expression  and  genotypes  of  another  gene,  IRS1 were  also  analysed  and  although  no 
significant associations to obesity were found, an association between SNP variation and gene 
expression was discovered (corrected p-value: 1.0x10-5).
4
Another aim of this project was to investigate the possibility that DNA methylation influences 
obesity risk. Firstly, a method for the measurement of the quantitative trait of DNA methylation 
status at individual CpG sites was developed using direct sequencing. Next, methylation in the  
leptin gene CpG island was measured in a subset of 184 case-control samples and a nominal  
association was discovered between the quantitative measurement of methylation at a single 
CpG site and obesity (p=0.013).
In summary, putative associations to obesity have been discovered with genetic variants as well 
as transcription levels and CpG methylation. Replication in other populations is required in order  
to confirm these associations.
5
Acknowledgements
First and foremost, I would like to offer thanks to my supervisor, Dr Andrew Walley for giving me 
the opportunity to work on this project. This thesis would not have been possible without his 
continued support and expertise. I am also indebted to Prof. Philippe Froguel who, as well as 
my second supervisor and the head of the department, was responsible for establishing the 
collaborations that provided the DNA samples from the French case-control cohorts.
I would also like to thank the members of the Section of Genomic Medicine for their help and  
guidance throughout.  In particular Mario Falchi for his statistical expertise and for his help in 
analysing transcription data. Jo Andersson for her help with the analysis of the Swedish data set  
and M.Sc. student researcher, Hang Yee Wong for her contribution to this project. Also to the 
department secretary, Pat Murphy for helping the department run smoothly and for assisting me 
in many different ways.
I would also like to recognise the contribution of our collaborators to this project.  Firstly the 
group at the Pasteur Institute in Lille, France for providing DNA from the adult and child obesity 
case-control  cohorts.  Secondly,  the  Department  of  Molecular  and  Clinical  Medicine  at 
Gothenburg University, Sweden for providing DNA from their obesity sib-pair cohort together 
with the corresponding transcription data. I also like to thank the participants who took part in 
these  studies  as  subjects.   Without  these  DNA samples  this  project  would  not  have  been 
possible.
Lastly,  I  am forever  indebted to my wife  Emma and to my parents for  their  understanding,  
patience and encouragement when I needed it the most. 
6
Table of Contents
Abstract.................................................................................................................4
Acknowledgements...............................................................................................6
List of Figures and Tables...................................................................................14
Chapter 1
Introduction.........................................................................................................19
1.1 Obesity overview.............................................................................................................20
1.2 Energy regulation in mammals........................................................................................21
1.2.1 Rodent models of obesity........................................................................................21
1.2.2 Central nervous system control of energy regulation...............................................23
1.2.2.1 Orexigenic signals in the CNS.........................................................................23
1.2.2.2 Anorexigenic signals in the CNS......................................................................27
1.2.3 Insulin as an adiposity signal...................................................................................30
1.2.4 Leptin as an adiposity signal....................................................................................31
1.2.5 Other adiposity signals............................................................................................32
1.2.6 Gastrointestinal signals...........................................................................................33
1.2.7 Lipid metabolism......................................................................................................35
1.3 Heritability of obesity.......................................................................................................37
1.4 The genetics of obesity....................................................................................................40
1.4.1 Monogenic obesity...................................................................................................40
1.4.2 Syndromic obesity...................................................................................................43
1.4.3 Common polygenic obesity.....................................................................................44
1.4.3.1 Linkage studies................................................................................................44
1.4.3.2 Candidate gene association studies................................................................46
1.4.3.3 Genome-wide association studies (GWAS).....................................................50
7
1.4.4 Missing heritability...................................................................................................54
1.4.4.1 Copy number variation (CNV) .........................................................................55
1.4.4.2 Epigenetics.................................................................................................56
1.5 Aims................................................................................................................................. 61
1.5.1 Candidate gene association studies........................................................................62
1.5.1.1 Sirtuin-1 (SIRT1)..............................................................................................63
1.5.1.2 Apelin (APLN)..................................................................................................64
1.5.1.3 Interleukin 11 (IL-11)........................................................................................65
1.5.1.4 Adiponutrin (PNPLA3).....................................................................................65
1.5.1.5 Nesfatin-1 (NUCB2).........................................................................................66
1.5.1.6 Insulin Receptor Substrate 1 (IRS-1)...............................................................67
1.5.2 Epigenetic variation in the Leptin gene (LEP)..........................................................68
Chapter 2
Materials and Methods........................................................................................69
2.1 Subjects........................................................................................................................... 70
2.1.1 Obese cases............................................................................................................70
2.1.2 Non-obese controls.................................................................................................70
2.1.3 Families................................................................................................................... 71
2.2 Protocols.......................................................................................................................... 71
2.2.1 SNP identification strategy.......................................................................................71
2.2.2 Genotyping..............................................................................................................72
2.2.3 PCR......................................................................................................................... 73
2.2.4 Agarose gel electrophoresis....................................................................................73
2.2.5 Sequencing of PCR product....................................................................................74
2.2.6 CpG island identification and primer design............................................................74
2.2.7 Bisulfite conversion of DNA.....................................................................................74
8
2.2.8 Bisulfite conversion of DNA using Qiagen EpiTect 96-well format...........................75
2.2.9 Positive control nested PCR....................................................................................77
2.3 Statistical Analysis...........................................................................................................77
2.3.1 Qualitative trait analysis...........................................................................................77
2.3.2 Quantitative trait analysis........................................................................................78
2.3.3 Family-based association analysis..........................................................................78
2.3.4 Linkage disequilibrium (LD).....................................................................................78
2.3.5 Imputation................................................................................................................78
2.3.6 Analysis of transcription data...................................................................................79
2.3.7 Statistical power calculations...................................................................................79
2.3.8 Analysis of sequence data.......................................................................................81
2.3.9 Interpretation of bisulfite sequence data..................................................................82
2.3.10 Statistical analysis of CpG methylation data..........................................................82
Chapter 3
Investigation  of  genetic  variants  within  the  Sirtuin-1  gene  for  association  to 
common polygenic obesity.................................................................................83
3.1 Introduction...................................................................................................................... 84
3.1.1 SIRT1 regulates energy metabolism.......................................................................84
3.1.2 SIRT1 activity is regulated by metabolic factors......................................................85
3.1.3 SIRT1 mouse models..............................................................................................86
3.1.4 SIRT1 as a pharmacological target for treating metabolic disease..........................86
3.1.5 SIRT1 genetic variation and obesity........................................................................87
3.2 Results............................................................................................................................ 89
3.2.1 SNP Selection and Case-Control Genotyping.........................................................89
3.2.2 Genotyping within the Swedish sib-pair cohort........................................................95
3.2.3 Analysis of SIRT1 transcription................................................................................97
9
3.2.4 Sequencing of SIRT1 ............................................................................................102
3.2.5 Case-control genotyping in promoter.....................................................................104
3.2.6 Imputation..............................................................................................................107
3.2.7 Statistical power calculations.................................................................................108
3.2.8 Thesis-wide multiple testing correction..................................................................112
3.3 Discussion..................................................................................................................... 113
Chapter 4
Investigation  of  genetic  variants  within  the  apelin  gene  for  association  to 
common polygenic obesity................................................................................119
4.1 Introduction.................................................................................................................... 120
4.1.1 Apelin is upregulated in obesity.............................................................................120
4.1.2 Effects of apelin on energy regulation...................................................................121
4.1.3 Apelin mouse models............................................................................................121
4.1.4 Apelin genetic variation and obesity......................................................................122
4.2 Results.......................................................................................................................... 123
4.2.1 SNP Selection and Case-Control Genotyping.......................................................123
4.2.2 Sequencing of APLN ............................................................................................128
4.2.3 Thesis-wide multiple testing correction..................................................................130
4.2.4 Power calculations.................................................................................................130
4.3 Discussion..................................................................................................................... 133
Chapter 5
Investigation of genetic variants within the Interleukin 11 gene for association to 
common polygenic obesity...............................................................................137
5.1 Introduction.................................................................................................................... 138
5.1.1 IL11 inhibits adipogenesis......................................................................................138
10
5.1.2 IL11 variation and obesity......................................................................................139
5.2 Results.......................................................................................................................... 141
5.2.2 Genotyping within Swedish sib-pair cohort............................................................146
5.2.3 Analysis of IL-11 transcription................................................................................148
5.2.4 Thesis-wide multiple testing correction..................................................................153
5.2.5 Power calculations.................................................................................................154
5.3 Discussion..................................................................................................................... 156
Chapter 6
Investigation of genetic variants within the adiponutrin gene for association to 
common polygenic obesity...............................................................................159
6.1 Introduction.................................................................................................................... 160
6.1.1 Adiponutrin has a role in lipid metabolism.............................................................160
6.1.2 Adiponutrin is regulated by metabolic factors........................................................160
6.1.3 Adiponutrin gene variation and non-alcoholic fatty liver disease............................161
6.1.4 Adiponutrin gene variation and obesity..................................................................162
6.2 Results.......................................................................................................................... 164
6.2.1 SNP Selection and Case-Control Genotyping.......................................................164
6.2.2 Power calculations......................................................................................................170
6.3 Discussion..................................................................................................................... 171
Chapter 7
Investigation  of  genetic  variants  within  the  Nesfatin  gene  for  association  to 
common polygenic obesity...............................................................................172
7.1 Introduction.................................................................................................................... 173
7.1.1 Central action of nesfatin-1 to reduce food intake.................................................173
7.1.2 NUCB2 expression is regulated by metabolic factors............................................174
11
7.1.3 Peripheral nesfatin-1.............................................................................................174
7.1.4 Nesfatin-1 as a pharmacological target for the treatment of obesity......................175
7.1.5 NUCB2 variation and obesity.................................................................................175
7.2 Results.......................................................................................................................... 178
7.2.2 Power calculations.................................................................................................186
7.3 Discussion..................................................................................................................... 189
Chapter 8
Investigation of genetic variation within the IRS-1 gene and transcription levels 
for association to BMI.......................................................................................191
8.1 Introduction.................................................................................................................... 192
8.1.1 IRS-1 and glucose metabolism..............................................................................192
8.1.2 IRS-1 and obesity..................................................................................................192
8.2 Results.......................................................................................................................... 194
8.3 Discussion..................................................................................................................... 197
Chapter 9
Investigation of DNA methylation for associations with human polygenic obesity
..........................................................................................................................199
9.1 Introduction.................................................................................................................... 200
9.2 Results.......................................................................................................................... 203
9.2.1 Developing a Protocol for Measuring CpG Methylation.........................................203
9.2.2 Locating CpG Islands within Obesity-Associated Genes.......................................206
9.2.3 Investigation of DNA methylation in leptin gene.....................................................210
9.2.3.1 Low volume bisulfite sequencing protocol.....................................................212
9.2.4  Investigation  of  leptin  gene  DNA methylation  levels  for  possible  association  to 
human polygenic obesity................................................................................................213
12
9.2.5 Analysis of LEP transcript levels............................................................................217
9.3 Discussion..................................................................................................................... 219
Chapter 10
Discussion.........................................................................................................222
10.1 Summary of thesis results...........................................................................................223
10.2 Future work.................................................................................................................. 227
References........................................................................................................236
Appendix...........................................................................................................262
A1. Tagging SNPs genotyped and the corresponding captured SNPs................................263
A2. Primer Sequences Used in Sequenom Genotyping Assays..........................................265
A3. Sequencing PCR primers..............................................................................................273
A4. Primer Sequences Used in DNA Methylation Study......................................................275
A 6. R scripts....................................................................................................................... 276
A 6.1. Correction of transcript data for covariate effects using linear regression............276
A 6.2 Correction of BMI or transcript data for effects of relatedness using clustering.....276
A 7. Statistical power calculations for locating SNPs in LD with associated variants...........277
13
List of Figures and Tables
Figure 1.1 Energy regulation in the hypothalamus 29
Table  1.1.  Hormones  released  from  the  gastrointestinal  tract  and  their  effects  on 
energy regulation
35
Table 1.2. Monogenic forms of obesity in humans 42
Table 1.3. Candidate genes with associations to obesity reported in meta-analyses 49
Table  1.4.  Genes significantly  associated  with  obesity  phenotypes  in  genome-wide 
association studies
53
Figure 2.1. Statistical power using adult case-control subjects 80
Figure 2.2. Statistical power using child case-control subjects 80
Figure 2.3. Statistical power for analysing BMI in the French controls 81
Figure 3.1. SNPs analysed for association to BMI in SIRT1 region in the GIANT GWAS 88
Figure 3.2.  Schematic  diagram of  the  SIRT1 gene showing the positions  of  SNPs 
successfully genotyped in this study
89
Table  3.1.  SNPs  genotyped  within  the  SIRT1  gene  and  minor  allele  frequencies 
observed in the case-control subjects
90
Table 3.2. Allelic association analysis of SIRT1 SNPs to obesity in children and adult  
French case-controls
92
Table 3.3. Association analysis of SIRT1 SNPs to the quantitative trait of BMI in French 
controls using age and sex as covariates
93
Figure 3.3. Linkage disequilibrium (r2) plot of SIRT1 SNPs genotyped in the French 
control samples
94
Table  3.4.  Haplotype association analysis  to obesity in adults  using the four SNPs 
found to be nominally associated with adult obesity
95
Table 3.5. Association analysis of SIRT1 SNPs with BMI in the Swedish families 96
Table 3.6.  Haplotype association analysis of  SIRT1 SNPs with BMI in the Swedish 
families 
97
Table 3.7. Association analysis of SIRT1 SNPs with SIRT1 expression corrected for 
age, sex and BMI in the Swedish families
98
Figure 3.4. Box-plot of SIRT1 transcript levels in obese and non-obese subjects from 
Swedish sib-pairs
100
Table 3.8. T-test of SIRT1 transcription in obese and non-obese subjects from Swedish 
families 
100
Figure 3.5. SIRT1 transcription levels plotted against BMI in non-obese siblings 101
14
Figure 3.6. SIRT1 transcription levels plotted against BMI in obese siblings 102
Figure 3.7. SNPs discovered within the SIRT1 gene promoter region in samples that 
carried the minor allele variants associated with obesity
104
Table  3.9.  SIRT1  promoter  SNPs  successfully  genotyped  with  the  minor  allele 
frequencies observed in the case-control subjects
105
Table 3.10. Association analysis of SIRT1 promoter SNPs in French case-controls 106
Figure  3.8.  LD  (r2)  plot  within  the  French  control  samples  containing  all  SNPs 
genotyped and analysed within SIRT1 and its promoter region
107
Figure  3.9.  LocusZoom plot  of  imputed  SIRT1 SNPs tested  for  association  in  the 
French adult case-control cohort. 
108
Table 3.11. Power calculations carried out using MAF and OR observed for each SNP 
in the SIRT1 gene investigated
109
Figure 3.10. Sample size plotted with statistical power for a SNP with MAF=0.13 110
Figure  3.11.  Sample  size  required  for  varying  odds  ratios  in  order  to  achieve  a 
statistical power of 95% for a SNP with MAF=0.13 
110
Figure 3.12. Statistical power against effect size in French controls assuming a MAF of  
0.13 and SD of 2.1
111
Table 3.12 P-values after correcting for multiple testing using permutations and taking 
into account all SNPs investigated in this thesis
112
Figure 4.1. Map of APLN gene with positions of SNPs genotyped in this project 123
Table 4.1. APLN SNPs successfully genotyped with minor allele frequencies observed 124
Table 4.2. Allelic association analysis of Apelin SNPs to obesity in children and adult 
French case-controls
125
Figure 4.2.  Linkage disequilibrium (r2)  plot  of  APLN SNPs genotyped in the French 
female control samples
126
Table 4.3 Haplotype analysis in the child case-controls using the two SNPs nominally 
associated with obesity
127
Table 4.4. Analysis of APLN SNPs for association with the quantitative trait of BMI in 
French controls using linear regression with age and sex as covariates
127
Figure 4.3. Map of APLN gene showing positions of PCR products used to sequence 
the promoter region and the two translated exons
129
Table 4.5. P-values after correcting for multiple testing using permutations and taking 
into account all SNPs investigated in this thesis
130
Table 4.6. Power calculations carried out using MAF and OR observed for each SNP 
investigated in the APLN gene
130
Figure 4.4. Sample size plotted with statistical power for a SNP with MAF=0.06 131
Figure 4.5. Sample size required for varying odds ratios in order to achieve a statistical 132
15
power of 95% for a SNP with MAF=0.06
Figure 4.4 LD plot (D') of APLN gene and the surrounding region 136
Figure 5.1. SNPs analysed for association to BMI in IL11 region in the GIANT GWAS 140
Figure  5.1.  Schematic  diagram  of  the  IL-11  gene  showing  the  positions  of  SNPs 
successfully genotyped in this study.
141
Table 5.1. IL-11 SNPs successfully genotyped with minor allele frequencies observed 142
Table 5.2. Allelic association analysis of IL-11 SNPs to obesity in children and adult 
French case-controls
143
Table 5.3. Association analysis of IL-11 SNPs to the quantitative trait of BMI within the 
French controls using linear regression and age and sex as covariates
144
Figure 5.2.  Linkage disequilibrium (r2)  plot  of  IL-11 SNPs genotyped in  the French 
control samples
145
Table 5.4. Haplotype association analysis with obesity in adults using the four SNPs 
found to be nominally associated with adult obesity
146
Table 5.5. Association analysis of IL-11 SNPs with BMI in the Swedish families using 
the QFAM test and the within-families model of association correcting for age and sex
147
Table  5.6.  Association  analysis  of  IL-11  SNPs  with  IL-11  transcript  expression  in 
subcutaneous adipose tissue
149
Figure  5.3.  Box-plot  of  IL-11  transcript  levels  in  subcutaneous adipose  tissue  with 
obese and non-obese subjects from Swedish sib-pairs displayed separately
150
Table 5.7. T-test of subcutaneous adipose IL-11 transcription in obese and non-obese 
subjects from Swedish sib-pair families
151
Figure 5.4. IL-11 transcription levels in subcutaneous adipose tissue plotted against 
BMI in non-obese siblings
152
Figure 5.5. IL-11 transcription levels in subcutaneous adipose tissue plotted against 
BMI in obese siblings
153
Table  5.8.  Thesis-wide  correction  of  p-values  for  muliple  testing  using  1  million 
permutations from association analysis of IL11 SNPs and obesity
154
Table 5.9. Power calculations carried out using MAF and OR observed for each SNP 
investigated in the IL-11 gene
154
Figure 5.6. Sample size plotted with statistical power for a SNP with MAF= 0.30 155
Figure 5.7. Sample size required for varying odds ratios in order to achieve a statistical 
power of 95% for a SNP with MAF= 0.30
155
Figure 6.1. SNPs analysed for association to BMI in the PNPLA3 region in the GIANT 
GWAS
163
Figure 6.1. Map of adiponutrin gene with positions of SNPs genotyped in this project 164
Table 6.1. SNPs successfully genotyped with minor allele frequencies observed 165
16
Table 6.2. Allelic association analysis of Adiponutrin SNPs to obesity in children and 
adult French case-controls
166
Figure  6.2.  Linkage  disequilibrium  (r2)  plot  of  Adiponutrin  SNPs  genotyped  in  the 
French control samples
167
Table 6.3. Association analysis of Adiponutrin SNPs to BMI in the French controls 169
Table 6.5. Power calculations carried out using MAF and OR observed for each SNP 
investigated in the adiponutrin gene.
170
Figure 7.1.  SNPs analysed for  association to  BMI in  NUCB2 region in  the GIANT 
GWAS
176
Figure  7.2.  Map  of  NUCB2  gene  and  surrounding  region  with  positions  of  SNPs 
genotyped in this project
178
Table  7.1.  NUCB2  SNPs  successfully  genotyped  with  observed  minor  allele 
frequencies
179
Table 7.2. Allelic association analysis of NUCB2 SNPs to obesity in children and adult 
French case-controls
181
Table  7.3.  Allelic  association  analysis  of  NUCB2  SNPs  to  obesity  in  non-diabetic 
children and adult French case-controls
182
Table 7.4. Association analysis of NUCB2 SNPs to BMI using linear regression with 
age and sex as covariates
183
Figure  7.3.  Linkage disequilibrium (r2)  plot  of  SNPs genotyped in  NUCB2 and  the 
surrounding region in the French control samples
185
Table 7.6. Power calculations carried out using MAF and OR observed for each SNP 
investigated in the NUCB2 gene region
186
Figure 7.4. Sample size plotted with statistical power for a SNP with MAF=0.06 187
Figure 7.5. Sample size required for varying odds ratios in order to achieve a statistical 
power of 95% for a SNP with MAF=0.06
188
Table 8.1. Association analysis of IRS-1 SNP, rs2943641 with BMI corrected for age 
and sex in the Swedish families
194
Table 8.2. Association analysis of IRS-1 SNP, rs2943641 with IRS-1 transcript level  
corrected for age, sex and BMI in the Swedish families
195
Figure 8.1.  Box-plot  of  IRS-1 transcript  levels  in  subcutaneous adipose tissue with 
obese and non-obese subjects from Swedish sib-pairs displayed separately
196
Table 8.3. T-test of subcutaneous adipose IRS-1 transcription in obese and non-obese 
subjects from Swedish sib-pairs
196
Figure 9.1. Electropherogram showing the sequencing of the CpG island within the 
POMC promoter
204
Figure 9.2. Bisulfite sequencing of POMC CpG island in two samples. CpG sites are 
highlighted and differences in methylation status can be observed at CpG 3.
205
17
Figure 9.3. CpG plots of the region covering the promoter region and start of the leptin  
gene.
206
Figure 9.4. CpG plots of the region covering the promoter region and start of the FTO 
gene
207
Figure 9.5.  CpG plots  of  the  region covering the  promoter  region and  start  of  the 
PPARγ gene.
208
Figure 9.6.  CpG plots  of  the  region covering the  promoter  region and  start  of  the 
Adiponutrin
209
Figure 9.7. The region of the leptin gene analysed by bisulfite sequencing with CpG 
dinucleotides numbered and shown in bold
210
Figure 9.8. Electropherograms showing differing levels of methylation at CpG site 6 
from the bisulfite sequencing of Leptin within three obese individuals
211
Table 9.1. Variation in levels of DNA methylation at six CpG sites sequenced in the 
Leptin promoter CpG island between different DNA samples
212
Table 9.2. Association of obesity and BMI with the percentage methylation at the three 
variably-methylated CpG sites in the Leptin gene CpG island
214
Table 9.3. Association analysis of SNPs in the Leptin gene region with BMI in French 
controls using linear regression and age and sex as covariates
215
Table  9.4.  Association  analysis  of  SNPs  in  the  Leptin  gene  region  with  CpG  5 
methylation in French controls using linear regression and age and sex as covariates
216
Figure 9.9. Box-plot of LEP transcript levels in obese and non-obese subjects from 
Swedish sib-pairs
218
Table 9.5. T-test of LEP transcription in obese and non-obese subjects from Swedish 
families
218
18
Chapter 1
Introduction
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1.1 Obesity overview
According to the World Health Organization (WHO), global obesity rates have doubled since 
1980 and in 2008 there were 1.4 billion adults (age > 20 years) classed as overweight and at  
least 500 million classed as obese1. This means that more than one in ten of the world's adult  
population is obese. Body weight is classified using body mass index (BMI), which is calculated 
as a persons weight in kilograms divided by their height in metres squared (kg/m 2). Overweight 
individuals are those whose BMI is between 25 kg/m2 and 30 kg/m2. Obese are those whose 
BMI is greater than 30 kg/m2. Those whose BMI is between 35 and 40 kg/m2 are classified as 
severely  obese  and  anyone  with  a  BMI  greater  than  40  kg/m2 is  morbidly  obese.  These 
classifications are based on the likelihood of  a person developing one of  the many serious  
conditions associated with increased body fat. Of all associated diseases, type 2 diabetes (T2D) 
has the strongest correlation to obesity2 and according to the WHO, obesity is the cause of 44% 
of  all  cases  of  T2D1. Other  comorbidities  include  cardiovascular  disease,  hypertension, 
dyslipidemia (abnormal blood lipid or cholesterol levels) and coronary heart disease along with a 
number of cancers that affect the oesophagus, pancreas, colon, rectum, breast, endometrium 
and kidney2. Additionally, obesity is associated with respiratory disorders (reviewed by Murugan 
and  Sharma3)  chronic  kidney  disease  (reviewed by  Ting  et  al.4), musculoskeletal  disorders 
(reviewed by Wearing et al.5) and liver disease (reviewed by Batty et al.6).
Because of these associated diseases, obesity is one of the leading preventable causes of  
death worldwide1 and the related health care costs make it one of the most serious public health 
problems in the modern world. Currently these costs are estimated to be as high as 1.2% of  
gross domestic product (GDP) in the USA7 and between 0.09% to 0.61% of GDP in European 
countries8.
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1.2 Energy regulation in mammals
Obesity is caused by excessive fat mass resulting from an increased storage of surplus energy 
in the form of lipids in adipose tissue. It develops as a result of a disruption of the homeostatic  
system that regulates energy intake and energy expenditure. In humans, body weight is a highly 
regulated trait. When normal-weight individuals eat a caloric surplus, they are found to increase 
their energy expenditure such that they maintain adiposity levels9. Conversely when subjects 
are fed a semistarvation diet  they are found to reduce their  energy expenditure as well  as  
experience extreme hunger10. To achieve this regulation a series of signals are produced in the 
adipose tissue and digestive system that relay nutritional status to the central nervous system 
(CNS)  which  then  adjusts  food  intake  and  energy  expenditure  according  to  requirements.  
Dysregulation of this system can lead to obesity and the study of obesity genetics has led to an  
increased  understanding  of  the  way  energy  is  regulated  in  mammals  which  is  not  only 
physiologically important but also has pharmacological implications as the basis for the design 
of therapeutics for treatment of obesity.
1.2.1 Rodent models of obesity
Many of  the  advancements  in  understanding  energy  regulation  began with  mouse  and  rat 
models of the disease. Many of the mutations that cause obese phenotypes in rodents have 
turned out to be in genes involved in the leptin-melanocortin pathway that regulates appetite 
and energy expenditure in both rodents and humans.
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The first rodent model to be reported was the agouti mutation in mice. Originally discovered in 
1902, the gene was cloned 90 years later11. The mutation that causes obesity is known as lethal 
yellow mutant mouse (Av) and these mice exhibit obesity, T2D and yellow coat colour11. The 
yellow  coat  colour  results  from  agouti overexpression  in  the  skin  which  blocks  alpha 
melanocyte-stimulating  hormone  (α-MSH)  signalling  at  melanocortin-1  receptors  in  the  hair 
follicle. Studies of this mouse strain led to the discovery of the melanocortin pathway, which is 
central in the CNS control of energy balance in mammals.
The autosomal recessive obese (ob) mutation was discovered in 195012 which causes affected 
animals to reach a body weight three times that of control mice. The gene responsible,  leptin, 
was identified using methods of  linkage mapping followed by positional cloning in 199413,14. 
Leptin is a hormone that is secreted from adipose tissue and is important in signalling the level  
of stored energy to the CNS (see section 1.2.4).  The  db/db (diabetes) mouse, discovered in 
196615, has a similar phenotype to ob/ob mice but also develops hyperglycaemia by 8 weeks of 
age which has resulted in their use as a model for the study of T2D. The mutation responsible  
was found to be in the leptin receptor gene (LEPR)16,17. 
The Zucker fatty rat was discovered in 1961 and is caused by an autosomal recessive variant in 
the gene denoted fatty (fa)18. These rats have early-onset obesity, which appears at 5 weeks of 
age. The  fa gene was subsequently cloned and shown to be  LEPR19.  Another rat model of 
obesity  is  the  Otsuka  Long-Evans  Tokushima  Fatty  (OLETF),  discovered  in  1984  and 
characterised  by  obesity,  adult-onset  hyperglycaemia  and  chronic  non-insulin  dependent 
diabetes20. This was found to be caused by a mutation in the gene that encodes the receptor of 
cholecystokinin (CCK), a gut hormone that is released after feeding and suppresses appetite21.
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A high-fat diet  (HFD) has also been used to induce obesity in otherwise lean animals. The 
C57BL/6J strain of mouse is often used for this purpose because they exhibit symptoms similar 
to human metabolic syndrome when fed the HFD (review by Collins et al.22).
1.2.2 Central nervous system control of energy regulation
Early lesion experiments in animals revealed the importance of the CNS in controlling body 
weight. These studies identified the hypothalamus as the area of the brain responsible and in 
particular the ventromedial hypothalamic nucleus (VMH)23 and the paraventricular hypothalamic 
nucleus (PVN)24.  Lesions in these regions result  in  animals which become hyperphagic (an 
abnormally increased appetite) and obese. Lesions in the lateral  hypothalamus (LH) on the 
other hand, produce aphagia (the inability or refusal to swallow) and weight loss25. 
The specific types of neurons within the hypothalamus that are responsible for energy regulation 
have  since  been  characterised  (see  Figure  1.1).  Neurotransmitters  in  the  CNS  that  effect 
changes in energy balance can be divided into two groups: Those that promote feeding and 
inhibit energy expenditure, which are known as orexigenic and those that inhibit feeding and 
promote energy expenditure, which are known as anorexigenic.
1.2.2.1 Orexigenic signals in the CNS
The most  well  studied orexigenic  neurons are the neuropeptide tyrosine (NPY) and agouti-
related peptide (AgRP) expressing cells of the arcuate nucleus (ARC) of the hypothalamus. The 
ARC is positioned in the brain adjacent to the median eminence, an area of the brain that is  
devoid of  the blood-brain barrier26.  Thus the ARC is able to receive signals from circulating 
hormones that have been released from the periphery27.
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NPY belongs to a family of structurally related proteins that include the peripheral hormones 
pancreatic  polypeptide  (PP)  and  peptide  tyrosine-tyrosine  (PYY)28,29.  NPY  is  expressed 
throughout the CNS but is highly concentrated in the ARC30. Its orexigenic effects have been 
demonstrated by infusing the peptide into  the brains of rodents which results in significantly 
increased feeding followed by weight gain31. In diet induced obese mice, NPY expression levels 
in the ARC are observed to increase when animals are placed on a low-calorie diet and lose  
their excess fat, which is congruent with a role for NPY in stimulating feeding32. 
Another important orexigenic signal is AgRP, a protein that shares sequence homology to the 
agouti protein responsible for the Av obese mouse described above33. It is primarily expressed in 
the ARC and co-localises with NPY33. As with NPY, the orexigenic effects of AgRP have been 
demonstrated by infusing the protein into the brains of rodents which potently stimulates feeding 
and results in weight gain34. Interestingly, administration of the N-terminal domain of AgRP also 
results  in  increased  body  weight  but  without  the  associated  hyperphagia35.  Additionally, 
reduction of AgRP expression using RNA interference results in increased energy expenditure 
and  loss  of  weight  without  changes  in  appetite36 suggesting  that  regulation  of  energy 
expenditure is important in AgRPs orexigenic action. AgRP is the endogenous antagonist of the 
melanocortin  3  and  4 receptors  (MC3R and MC4R) which,  along  with  proopiomelanocortin 
(POMC),  comprise  the  melanocortin  system  (detailed  in  section  1.2.2.2)37.  Furthermore, 
synthetic MC3R/MC4R antagonists produce a similar effect to AgRP when injected into rodent 
brains38.
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At times of negative energy balance, expression of AgRP and NPY are upregulated. This has 
been demonstrated during periods of fasting where both AgRP and NPY levels rise and this is 
primarily due to a reduction in levels of the peripheral hormones insulin and leptin along with a  
rise in ghrelin, all of which are important regulators of adiposity (see sections 1.2.3, 1.2.4 and 
1.2.6)39,40. At times of positive energy balance, expression is downregulated: Both AgRP and 
NPY gene expression is lower in rats on a high-calorie diet compared to a low-calorie diet41.
Deletion of  AgRP and/or  NPY genes in mice does not lead to the expected changes in body-
weight42.  It  has  been  hypothesised  that  animals  with  knockouts  in  AgRP  or  NPY  induce 
compensation mechanisms during embryonic development. To test this, experiments have been 
conducted which involve ablation of AgRP and NPY genes in adult mice. These studies resulted 
in significant decreases in food intake and body weight demonstrating that AgRP and NPY are 
important for proper energy control in the normally developed mouse43.
NPY and AgRP neurons project into the PVN as well as other hypothalamic areas and areas of 
the brain outside of the hypothalamus44.  Neurons expressing NPY and AgRP in the ARC are 
found  to  express  high  concentrations  of  leptin  receptor45 and  leptin  is  a  hormone  that  is 
important in signalling current adiposity levels (see section 1.2.3). NPY and AgRP neurons in  
the ARC also express the inhibitory neurotransmitter,  gamma-Aminobutyric acid (GABA) and 
projections that release GABA have been found to project onto POMC neurons in the ARC to 
inhibit POMC neuron action, the anorexigenic peptide of the melanocortin system (see section 
1.2.2.2)46. There is also evidence that GABA action from these neurons is necessary for the 
proper maintenance of feeding47.
NPY and AgRP are the most extensively studied orexigenic neurotransmitters but there are a 
number of others that have been characterised.
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Melanin-concentrating hormone (MCH) was originally discovered in rodents where it was found 
to be overexpressed in response to fasting and also in genetically obese (ob/ob) mice48,49. MCH 
is expressed exclusively in the lateral hypothalamus and zona incerta50. The role of MCH as an 
orexigenic  molecule  has  been  demonstrated  using  mouse  knockouts  which  are  lean  and 
hypophagic51. Additionally, centrally administered MCH has been shown to stimulate feeding48.
Orexin  A and orexin  B are two peptides derived from the same gene,  orexin  neuropeptide 
precursor (HCRT), which also act as orexigenic neurotransmitters52. Orexin expressing neurons 
are found in the dorsal, lateral and posterior hypothalamic areas52,53.  As with NPY, AgRP and 
MCH, centrally administered orexin peptides result in increased food consumption in rodents52 
and their expression is upregulated during fasting54.
Galanin is another neurotransmitter known to stimulate feeding and reduce energy expenditure. 
It is expressed in the gut as well as in the hypothalamus, particularly the PVN, ARC and LH55. 
As with other orexigenic peptides, when galanin is infused into the brain it leads to increased 
feeding56. Both insulin57 and leptin58 reduce galanin expression, and both these hormones are 
known to induce anorexigenic responses (see Sections 1.2.3 and 1.2.4).  Galanin has been 
implicated in regulating preference for high fat foods and GAL-null mice consume less food than 
wild type when given a high fat diet59.  Galanin-like peptide (GALP) is  structurally related to 
galanin. It is expressed in the ARC60 and injections of GALP into the brains of rats stimulates 
feeding which suggests a role  as an orexigenic  peptide61.  Its  role  in  feeding may be more 
complex, however, since in mice it has been reported to have the opposite effect62. 
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1.2.2.2 Anorexigenic signals in the CNS
POMC is the gene that codes for the anorexigenic proteins of the melanocortin system, which 
also includes AgRP and the melanocortin receptors. POMC is expressed in the ARC63 where it 
is translated into multiple peptides including alpha melanocyte stimulating hormone (α-MSH), β-
MSH, γ-MSH, adrenocorticotropic hormone1-24 (ACTH(1-24)), and ACTH(1-13)NH2 (desacetyl-
α-MSH)64.  α-MSH  is  the  endogenous  agonist  of  melanocortin  receptors  and  when  a 
melanocortin agonist is applied to rodent brains the result is inhibition of feeding and a reduction 
in body-weight. Melanocortin antagonists are found to produce the opposite result65. Deletion of 
the POMC gene in mice causes obesity and hyperphagia, which demonstrates that functional 
POMC peptides are crucial for proper energy regulation66.  POMC-null mice are not diabetic, 
however they do have reduced glucagon secretion in response to experimental hypoglycaemia, 
indicating  a  role  of  POMC  peptides  in  regulating  blood  glucose67.  POMC  expression  is 
downregulated  after  fasting  and  is  significantly  reduced  in  genetically  obese  (ob/ob)  mice 
compared to wild type68.
There are a number of different melanocortin receptors, of which MC3R and MC4R are the most 
important  for  the  regulation  of  energy  homeostasis.  Studies  in  mice  indicate  that  MC4R is 
involved in the control of  both feeding and energy expenditure69,70.  It  is also involved in the 
control of glucose and lipid metabolism, independent from it's role in controlling food intake and 
energy  expenditure71.  MC4R  is  widely  expressed  throughout  the  brain  and  spinal  cord72 
whereas MC3R is localised to the ARC and other regions of the hypothalamus73. MC3R then 
appears to function in negative feedback control between AgRP/NPY and POMC/CART neurons 
which have projections between one-another in the ARC 46,73. MC3R knockout mice are normal-
weight but display other symptoms of metabolic syndrome: they have increased levels of fat 
mass and decreased levels of lean mass, they are hyperleptinaemic and have decreased levels 
of energy expenditure74,75. The MC4R gene knockout on the other hand results in mice that are 
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hyperphagic and obese69. The various actions of MC4R have been located to different parts of 
the brain using knockout studies in specific neuron populations in mice. For example, MC4R 
expressed  by  SIM1  neurons  in  PVH  and  amygdala  control  food  intake  but  not  energy 
expenditure or glucose metabolism76 and MC4R expressed outside of the hypothalamus are 
implicated in the control of energy expenditure, hyperinsulinemia and hyperglycaemia77. 
AgRP/NPY neurons  seem to  primarily  sense  energy  deficits  since  NPY is  upregulated  by 
starvation but not affected by overfeeding78. On the other hand hypothalamic POMC mRNA in 
rodents  is  downregulated  by  starvation79 and  upregulated  by  overfeeding80 suggesting  that 
POMC neurons respond to both stimuli. These findings may suggest a reason why it is easier 
for individuals to gain weight than to lose weight.
Another  important  anorexigenic  signal  is  cocaine  and  amphetamine-regulated  transcript 
(CART), which highly expressed in the hypothalamic neurons and co-localises with POMC81,82. 
CART  has  been  implicated  in  feeding,  drug  reward  behaviour,  stress,  and  development 
(reviewed  by  Kuhar  et  al.83). Its  role  in  regulating  feeding  was  demonstrated  using 
intracerebrovasular injections in rodents which result in significantly reduced food intake84. Mice 
engineered  without  functional  CART gene  are  obese,  indicating  that  functional  CART  is 
necessary for regulation of energy balance85. When rodents are deprived of food, CART mRNA 
in the ARC, decreases86. As with NPY/AgRP neurons, leptin receptor has been found to co-
localise with POMC and CART in the ARC87. The mouse model of obesity,  ob/ob, which lacks 
functional versions of leptin have significantly reduced CART expression in the ARC and other 
hypothalamic regions. Injections of leptin into these animals results in normal levels of  CART 
mRNA  thus  providing  evidence  that  leptin's  anorexigenic  effects  act,  in  part,  via  CART 
neurons86.
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Figure  1.1  Energy  regulation in  the hypothalamus.  Circulating insulin  and leptin,  which are 
released in proportion to adiposity levels, stimulate and suppress activity of the arcuate nucleus 
neurons POMC/CART and NPY/AgRP respectively. These neurons respond by increasing or 
decreasing the expression of their neuropeptides which then act on downstream neurons in the  
paraventricular  nucleus  to  decrease  or  increase  feeding  and  increase  or  decrease  energy 
expenditure respectively.
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1.2.3 Insulin as an adiposity signal
There are a number of signal peptides whose serum concentrations are altered by adiposity 
levels, thus acting to relay the level of energy storage to the CNS. Insulin was the first such  
molecule  to  be  implicated.  Whilst  its  primary  role  is  in  controlling  serum concentrations  of  
nutrients, insulin levels in the blood are found to be proportional to the total adipose mass of an  
organism88,89. This  has  been  shown  to  be  true  after  fasting,  after  feeding  and  after  an 
intravenous  glucose  infusion90.  Thus  insulin  is  secreted  in  response  to  blood  glucose  in 
proportion to body fat such that a person with greater fat mass secretes proportionally more 
insulin  to  a  given  glucose  concentration90.  Additionally,  endogenous  insulin  is  found  in  the 
cerebrospinal fluid of mammals91 and it has been shown to be able to cross the blood brain 
barrier which demonstrates the possibility of it having a signalling role in the brain92.
Injection  of  insulin  into  the  brain  decreases  food  intake  and  body  weight  in  rodents  and 
primates93,94,95. Furthermore in humans, intranasal insulin has been shown to reduce body fat96. 
Conversely  administration  of  insulin  antibodies  results  in  hyperphagia  and  weight  gain97,98. 
Transgenic  mice  with  a  neuron  and  glial  cell  specific  knockout  of  insulin  receptor  are 
hyperphagic  and  obese99 and  selective  decrease  in  hypothalamic  insulin  receptor  protein 
following  administration  of  insulin  receptor  antisense  oligonucleotides  produces  the  same 
result100. Histological studies have shown that this insulin-mediated control of feeding and body 
weight is located in the ARC, PVN, dorsomedial and VMH of the hypothalamus98 and insulin 
receptor is highly expressed in the ARC101.
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1.2.4 Leptin as an adiposity signal
Leptin  is  a  protein  expressed  and  secreted  by  adipocytes  that  has  a  serum concentration 
directly proportional to the fat mass of the individual102,103. Intraperitoneal injections of leptin into 
mice decreases feeding and result in weight loss and reduced fat mass which is evidence that 
leptin is an anorexigenic hormone104. These experiments produce the same result in rats and 
leptin  is  found  to  work  additively  together  with  insulin105.  As  noted  previously,  mice  lacking 
functional leptin genes (ob/ob) are obese and so are mice that lack a functional leptin receptor 
gene (db/db). This is also true in humans who are have congenital leptin deficiency and it has 
been shown that  leptin injections significantly reduce fat  mass and  reverse obesity in such 
patients106. Its use as a therapeutic in common obesity, however is limited due to obesity being 
associated with leptin resistance107. Mice with brain-specific leptin receptor knockouts are obese 
whereas peripheral-specific knockouts are not suggesting that leptin's effects are controlled in 
the brain108. Thus leptin acts as a hormone to signal adiposity levels to the CNS in order that 
appetite and energy expenditure can be adjusted such that energy stores are kept in balance.
Leptin's action in the CNS has been well characterised. It inhibits hypothalamic expression of  
NPY and AgRP109 and upregulates POMC and CART82. Leptin receptor is found to be expressed 
in the majority of NPY/AgRP and POMC/CART neurons in the ARC110,87.  POMC neurons are 
depolarized by leptin treatment thus producing an anorexigenic effect46. Knockdown of leptin 
receptor in POMC as well  as AGRP/NPY neurons lead to increased body weight  in mouse 
models which demonstrates that leptin's action in the ARC is necessary for the proper control of 
fat storage111,112.
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Thus leptin is a crucial hormone that  works to create a feedback loop that ensures adiposity 
levels  are  kept  within  the  correct  range.  Any  increase  in  fat  mass  causes  an  increase  in 
circulating leptin which starts a signal cascade which then reduces fat mass. Thus stored fat 
levels are kept within a narrow range.
1.2.5 Other adiposity signals
Amylin is a hormone that is cosecreted with insulin by the beta cells of the pancreas. As such it  
is a hormone that is secreted in proportion to adiposity levels113. Administration of amylin into 
rats  reduces feeding and results  in  lower body weight  indicating a role  as an anorexigenic 
signal114. Its effects are thought to be mediated mainly by decreasing meal size 115. Conversely, 
administration of the amylin receptor antagonist AC187 stimulates eating by increasing meal 
size116.
Adiponectin is a peptide that is expressed and secreted by adipocytes. It has been found to  
stimulate  food intake and  deletion  of  the adiponectin  gene in  mice  leads  to  a  decrease in 
feeding117.  Additionally, adiponectin receptors colocalize with POMC and NPY/AgRP neurons in 
the ARC which supports a role in regulating energy homeostasis118. 
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1.2.6 Gastrointestinal signals
In addition to hormones that signal current levels of stored fat and thereby act to regulate long 
term energy needs there are also a number of molecules that regulate food intake in the short  
term. For the most part they comprise hormones secreted by the gastrointestinal tract to signal 
the  presence  of  nutrients  as  they  enter  various  parts  of  digestive  system.  The  stomach 
produces signals in response mainly to mechanical distention, whereas the intestine releases 
signals in response to chemical content of the food (reviewed by Powley et al.119).
CCK is produced in the mucosa cells of the intestine120 and has been shown to decrease food 
intake in rats and humans121 and rats without CCK receptor are obese21. CCK is rapidly released 
after protein or fat-rich food enters the duodenum122. It inhibits gastric emptying and gastric acid 
secretion and mediates digestion in the duodenum which in turn stimulates meal termination123. 
The inhibitory effect on feeding is short-lived, lasting less than 30 minutes and so CCK works to 
reduce meal size and duration but does not effect the onset of the next meal124,125. 
Peptide tyrosine tyrosine (PYY) is secreted from intestinal L-cells immediately after feeding and 
remain elevated for up to six hours126.  Administration of PYY inhibits feeding in rodents and 
humans127,128,129 and  as  such  PYY has  been  trialled  as  a  potential  therapeutic  for  treating 
obesity130.  PYY knockout  mice  have  a  reduced  food  intake  and  body  weight  compared  to 
controls131. PYY seems to respond more to protein intake than other nutrients: PYY levels are 
higher after consumption of a high-protein meal compared to a high-fat or high-carbohydrate 
meal  with  the  same  calorie  content131.  Fasting  PYY levels  correlated  negatively  with  BMI 
indicating a role in long-term regulation of feeding127,131.
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Ghrelin is a hormone that is unique amongst gut signals in that it is a stimulator of food intake 
rather than an inhibitor132.  It is secreted from the stomach and its levels are correlated with 
hunger133, rising shortly before feeding and falling sharply during food intake134. Carbohydrates 
are the most potent macronutrient suppressors of ghrelin, while fat suppresses ghrelin levels to  
a lesser extent135. Administration of ghrelin into normal weight subjects results in a stimulation of 
appetite132 and mice with ghrelin or  ghrelin  receptor  knockouts are resistant  to diet-induced 
obesity136,137. In addition, ghrelin is thought to be involved in long-term energy regulation as its 
circulating levels are negatively correlated with BMI138, are increased following weight loss139 
and its receptors are found in ARC NPY/AGRP neurons140.
There are a number of other hormones secreted from areas of the digestive system, the major  
ones are listed in Table 1.1 along with their site of production and known effect on appetite. 
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Hormone Main site of 
production
Primary actions
Cholecystokinin (CCK) Duodenum141 Inhibits gastric emptying142, and reduces 
meal size and duration143
Ghrelin Stomach144 Stimulates  food  intake132,  is  released 
just before a meal134
Glucagon-like peptide-1 (GLP-1) Ileum and colon145 Reduces  food  intake146,  induces 
glucose-dependent insulin secretion and 
inhibits glucagon secretion147
Obestatin Stomach148 Encoded by the same gene as ghrelin. 
Acts  in  opposition to  ghrelin  to  reduce 
appetite149
Oxyntomodulin Ileum and colon150 Suppresses  appetite  and  increases 
energy expenditure151
Pancreatic polypeptide (PP) Pancreas152 Decreases food intake153.
Peptide tyrosine tyrosine (PYY) Ileum and colon126 Induces  satiety  by  inhibition  of 
NPY/AGRP neurons127
Table  1.1.  Hormones  released  from  the  gastrointestinal  tract  and  their  effects  on  energy 
regulation.
1.2.7 Lipid metabolism
Since obesity is caused by increased quantity of stored energy in adipose tissue, the study of  
lipid metabolism is a crucial part of understanding the disease.
Most of the energy reserves in the human body are stored in the form of triacylglycerols (TAG) 
within  lipid  droplets  in  adipocytes.  There  are  two  important  processes  relating  to  lipid 
metabolism within  the  adipocyte:  TAG storage  and  TAG hydrolysis.  When energy intake is 
higher than expenditure, storage occurs. Within the adipocyte, free fatty acids are esterified into 
TAG and partitioned into lipid droplets. When energy demands increase, adipose tissue acts to 
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provide nutrients to other tissues via lipolysis which breaks down TAG into free fatty acids and 
glycerol. Lipid droplets are composed of a core of TAG and cholesterol esters, surrounded by a 
phospholipid monolayer, which contains lipid droplet associated proteins154,155. These proteins 
are thought to control the accessibility of lipases to their lipid substrates.
The perilipin  family of  proteins represent  the most  abundant  of  the lipid  droplet  associated 
proteins156.  They localise specifically to lipid droplets and have not been found in any other 
subcellular  compartment157.  Under  fed  conditions,  perilipin  inhibits  lipolysis  which  in  turn 
increases  TAG  storage158.  Conversely,  during  fasting,  phosphorylated  perilipin  results  in 
increased lipolysis159. Perilipin knockout mice are lean and resistant to diet induced obesity160.
Desnutrin  is  considered  to  be  the  major  TAG  lipase  in  white  adipose  tissue  (WAT).  It  is 
expressed  in  adipocytes  and  is  found  to  be  downregulated  in  ob/ob mice161. Furthermore, 
transgenic mice that overexpress desnutrin in adipose have increased lipolysis and fatty acid 
oxidation  in  WAT,  resulting  in  higher  energy  expenditure  and  resistance  to  diet-induced 
obesity162.  Adipose-specific  phospholipase  A2  (AdPLA)  is  a  membrane-associated  lipase 
expressed exclusively in adipocytes163 and AdPLA knockout mice exhibit unrestrained adipocyte 
lipolysis and are extremely lean164. These mouse models do not have elevated serum fatty acid 
levels  but  instead have increased fatty acid oxidation in  adipocytes.  AdPLA null  mice have 
significantly increased expression of uncoupling protein 1 (UCP-1) in WAT and brown adipose 
tissue (BAT)164 and this is thought to result in an increased metabolic rate and consequently 
protects against obesity. UCP-1 overexpression in mouse adipocytes increases mitochondrial 
respiratory uncoupling, (the generation of heat energy instead of ATP) and subsequently, results 
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in a significantly leaner mouse165. In mice, inhibiting lipolysis results in promotion of diet-induced 
obesity166. These results demonstrate the possibility that impaired lipolysis in adipose tissue may 
be a factor  in  the  development  of  obesity  and thus increased lipolysis  may be a potential  
therapeutic target for the treatment of obesity.
1.3 Heritability of obesity
The recent obesity epidemic is assumed to be due to changing environments such that calorie  
content  of  meals  has  increased  while  at  the  same  time  physical  activity  has  decreased 
(reviewed by French et al.167), although recent evidence suggests that total energy expenditure 
has  not  changed  between hunter-gatherer  and  Western  societies168.  However  there  is  also 
strong evidence of a heritable influence to obesity. 
Heritability (h2) is the proportion of phenotypic variation between individuals in a population that  
can be attributed to genetic rather than environmental factors. It is measured by estimating the 
contributions of genetic and non-genetic differences to the total variation of a phenotype in a 
sample from a population. There are three main types of heritability studies that have been 
carried out to try to determine the genetic component of traits such as BMI. These are adoption 
studies, family studies and twin studies. All three types of study have produced estimates for the 
heritability of BMI to be in the range of 40% to 80%. For a review of heritability studies in body  
weight see Andersson and Walley169.
Adoption  studies  work  by  measuring  the  correlation  between adoptees  and  their  biological 
parents. The advantages of this method are that they resolve the effects of genes from the 
effects  of  shared  environment.  This  is  because  adopted  children  share  genetics  with  their  
biological  parents  but  not  their  adoptive parents and share environment  with  their  adoptive 
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parents but not their biological parents. One disadvantage of this method is that the effects of 
age are not accounted for. There is also an assumption that adoptees are not selectively placed 
into families based on any shared characteristics and an assumption that there is no significant 
effect of the prenatal environment. An additional limitation of this study design is the relatively 
low sample sizes for  which data  is  available for  both  adoptive and biological  parents.  One 
notable exception was a study published by Stunkard et al. using the Danish Adoption Register 
which contained BMI data for 3580 adoptees. A strong correlation between adoptees and their 
biological parents was discovered but no correlation to their adoptive parents indicating a strong 
degree of heritability170.
The family study design most commonly uses parent-offspring or sibling-sibling data sets. The 
main advantage is the ease with which cohorts can be recruited. It suffers though, from the fact 
that environmental effects cannot be separated from genetic effects. Correcting the data using 
an environmental index is possible but this will not be able to separate all factors. One large  
study of BMI in Norway reported an average parent-offspring correlation of 0.20 and siblings 
ranged  from 0.21  in  brothers  to  0.26  in  sisters.  Second degree  relatives  did  not  correlate 
significantly171. This study estimated h2 of BMI to be0.39.
Twin studies were the first heritability studies to be performed and have been used extensively  
for  studying the heritability  of  traits  including BMI and other  body-weight  phenotypes.  They 
usually rely on using samples of  identical twins and samples of  fraternal twins. Fraternal or  
dizygotic (DZ) twins share on average half their genetic variants. Identical or monozygotic (MZ) 
twins share effectively 100% so are twice as similar,  genetically,  than DZ twins. If  a trait  is  
heritable  then MZ twins should  be more similar  than DZ twins.  The genetic  contribution to 
variation (h2) can thus can be calculated as twice the difference in correlation between MZ and 
DZ twins. Because twins are matched for age, any effects that age has on variation of a trait are 
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the same for  both twins. Furthermore they are statistically powerful: One thousand twin pairs 
provide 95% power to reject a purely environmental model with a false-negative rate of 0.05 if  
additive genetic effects explain 20% and shared environment effects explain 50%172.  Power 
increases if the actual genetic effects are higher. The main criticism of this method is that twins 
are not a random sample of the population, they differ in developmental environment and so 
may not  be representative.  However,  in the case of  BMI,  twins have not  been found to be 
significantly different  from singletons173.  Another  criticism is  that  twin  studies often use self-
reported zygosity measures which may not always be correct. MZ twins that are discrepant in 
height and weight could be incorrectly viewed as being DZ and this bias would lead to increased  
heritability  estimates174.  Twin  studies  also  assume that  the  shared  environment  is  identical 
between MZ twin pairs and DZ twin pairs and this may not be true175. 
Many twin studies have been performed over the years to investigate the heritability of body-
weight (for a review see169). When analysing BMI in adult twin samples, monozygotic twins are 
consistently more similar in BMI than dizygotic twins (h2=0.64176 h2=0.80177 h2=0.77178). When 
analysing BMI in adolescent twin samples heritability is also very high (h2=0.87 at age 11179). 
When skinfold thickness is analysed in adolescent twins the story is the same (h2=0.98 for trunk 
fat and 0.46 for limb fat180).
Studies that used twins reared apart are the most powerful study design since they can be used 
to easily separate the effects of genotype from post-natal environment. The correlation of MZ 
twin reared apart is s a direct estimate of the heritability. They are limited by the relatively small  
numbers of twins that are raised apart. Additionally they rely on the same assumptions of non-
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selective adoption and no effect of the prenatal environment, which may not be valid. In practise 
such studies have corroborated the results of studies of twins reared together with h2 estimates 
in the same range. One such study reported heritability estimates of 0.70 for men and 0.66 for 
women181.
1.4 The genetics of obesity
Obesity can be classified into three types based on the underlying genetic basis. In the first 
instance there is  monogenic obesity which is characterised by severe obesity without  other 
abnormalities and has a Mendelian pattern of inheritance. Secondly, there is syndromic obesity 
which includes additional phenotypes, often mental retardation and dysmorphic features. Last is 
common polygenic obesity which affects the general population.
1.4.1 Monogenic obesity
Monogenic diseases are caused by variants within a single gene and mutations in many of the 
genes involved in the regulation of appetite detailed above have been discovered to underlie 
monogenic  forms  of  obesity  in  humans.  Most  of  these  were  discovered  following  the 
development of mouse models of the disease which used linkage analysis to locate disease 
loci. These were crucial in the identification of the leptin-melanocortin signalling pathway that 
regulates metabolism in mammals and provided candidate genes for human monogenic forms 
of obesity. Table 1.2 lists the known monogenic forms of obesity.
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The first monogenic form of obesity to be reported was found in two severely obese cousins  
from a Pakistani family. A frameshift mutation in the leptin gene was found to be responsible, 
which when translated produced a truncated form of the leptin protein that is not secreted182. A 
similar mutation has also been discovered in a Turkish family in which subjects are severely 
obese and hyperphagic183. Since their obesity is caused by a lack of leptin in the blood stream it  
was hypothesised that infusions of recombinant leptin could help with reducing body weight.  
Indeed, daily injections of human recombinant leptin for a period of one year was shown to 
produce a vastly reduced food intake and fat mass and a reversal of obesity in such leptin-
deficient  patients106,184.  This  is  currently  the  only  genetic  form  of  obesity  that  successfully 
responds to pharmacological intervention. 
The discovery of the first Mendelian form of obesity caused by leptin mutations was quickly 
followed by the identification of other forms of monogenic obesity caused by variants in genes in  
the leptin-melanocortin pathway. These include a mutation in the leptin receptor gene (LEPR) 
that was found to cause hyperphagia and obesity in individuals homozygous for the variant.  
These subjects do not have functional leptin receptors185. There are also variants in POMC that 
cause hyperphagia and early-onset obesity in homozygotes186,187,188,189. These subjects also have 
pale  skin  and red hair  pigmentation due to lack of  melanocyte  stimulating hormone (MSH) 
action at melanocortin 1 receptors in skin and hair follicles.
A number  of  studies  have  also  found  mutations  in  MC4R which  cause  severe  early-onset 
obesity and hyperphagia190,191. Patients that are heterozygous for this mutation are obese but 
those  that  are  homozygous  are  more  severely  obese,  indicating  a  codominant  model  of  
inheritance and this fits with mouse knockout studies69.  MC4R is the most common form of 
monogenic  obesity known,  present  in  an estimated 1-6% of  all  early  onset  severely  obese 
cases192,193,194.
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A mutation in the gene encoding brain-derived neurotrophic factor (BDNF)  is responsible for 
another form of monogenic obesity195. BDNF is expressed in the VMH and is thought to have a 
role in controlling energy regulation downstream of the melanocortin system196. NTRK2 encodes 
the receptor for BDNF and a mutation in this gene has been reported which causes early-onset  
obesity197.
A compound heterozygous mutation in the prohormone convertase gene  (PSCK1) has been 
found which causes severe early-onset obesity along with hypergonadotropic hypogonadism, 
abnormal  glucose  homeostasis,  and  increased  plasma  concentrations  of  proinsulin  and 
POMC198. Prohormone convertase is expressed in neuroendocrine tissues and cleaves certain 
prohormones to their  intermediate or final forms including some that are involved in energy 
regulation such as POMC and insulin199.
Gene Position Gene function Inheritance References
BDNF 11p14.1
Neuron growth factor expressed in 
hypothalamus R 195
LEP 7q32.2 Adiposity signal R 182,183,200
LEPR 1p31.3 Leptin receptor R 185
MC4R 18q21.32
Key  receptor  of  the  melanocortin 
system C 190,191,192
POMC 2p24.1
Precursor  for  the  anorexigenic 
neurotransmitter α-MSH R 186,188,189
NTRK2 9q22.1 BDNF receptor R 197
PCSK1 5q15
Cleaves POMC and proinsulin into 
active hormones R 198
Table 1.2. Monogenic forms of obesity in humans. R = autosomal recessive, C = autosomal 
codominant.
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1.4.2 Syndromic obesity
There  are  around  30  rare  syndromes  caused  by  genetic  mutations  or  chromosomal 
abnormalities that are currently known to include obesity as a phenotype (reviewed by Farooqi  
et  al.201).  Phenotypes  usually  include  mental  retardation,  dysmorphic  features  and 
developmental  abnormalities.  They  often  include  hyperphagia  indicating  dysfunction  of 
pathways in the hypothalamus.
The  most  common  form  of  syndromic  obesity  is  Prader-Willi  syndrome  with  an  estimated 
prevalence of 1 in every 25,000 births202. It  is characterised by low birth-weight and feeding 
difficulties in infancy, followed by hyperphagia and obesity in childhood along with short stature, 
hypogonadism and mental retardation203. It is normally caused by a deletion or translocation of 
the paternal segment at 15q11-q13204 or by uniparental  disomy of  chromosome 15 where a 
patient inherits two copies of the maternal chromosome 15 and zero copies of  the paternal 
chromosome 15205. Alternatively it can sometimes be caused by defects in the imprinting of the 
paternal chromosome 15206. A smaller deletion (187kb) in the same region has been reported in 
a patient with hyperphagia, severe obesity, mild learning difficulties and hypogonadism but who 
lacked other symptoms of Prader-Willi207. This work has helped identify the genes responsible 
for the Prader-Willi phenotype, which comprise a family of non-coding RNAs.
Bardet-Biedl is another example of syndromic obesity, which along with increased body weight,  
includes  retinal  degeneration,  hypogonadism,  polydactylism,  renal  dysfunction,  and  mental 
retardation208. It is genetically heterogeneous with causative mutations having been located in 
severeal distinct  regions of the genome209,210. Its inheritance is usually autosomal recessive, 
however some cases of digenic and tri-allelic inheritance have also been reported211,212. 
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A translocation between 1p22.1 and 6q16.2 that disrupts the single-minded homolog 1 (SIM1) 
gene has been reported to be the cause of a syndrome of obesity, hypotonia and developmental 
delay213.  SIM1  encodes  a  transcription  factor  that  is  expressed  in  the  PVN  of  the 
hypothalamus214 and overexpression of the gene in  Agouti mice and diet-induced obese mice 
has been shown to eliminate hyperphagia and result in a reduction in fat mass215. Other obesity 
syndromes include Cohen syndrome, an autosomal recessive disorder caused by a mutation at 
8q22216 and Alström syndrome, which is caused by mutations in the ALMS1 gene at 2p13.1217.
1.4.3 Common polygenic obesity
Polygenic traits are those for which inheritance of a phenotype is caused by two or more genes 
in combination with the influence of environment. These phenotypes are often quantitative and 
vary on a continuous scale distributed normally. BMI is an example of such a quantitative trait 
with obesity found at the top end of the scale. If an individual carries many genetic variants that  
increase  BMI  then  obesity  may  result.  Any  such  genetic  variant  will  be  found  in  a  higher  
frequency within obese populations than in normal and lean populations. The search for variants 
that influence susceptibility to common obesity have taken three approaches: Linkage studies, 
candidate gene association studies and genome-wide association studies.
1.4.3.1 Linkage studies
Linkage studies have been used to identify genetic markers that are shared by descent among 
relatives with the same disease or phenotype. It relies on the fact that markers that are located 
close to one-another on a chromosome are more likely to be inherited together than markers 
that are far apart due to crossing over events in meiosis. Thus the more often an allele at a  
particular site is shared in relatives who also share the phenotype in question, the more likely it  
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is that the site is in close proximity to a disease causing locus. As discussed previously, this 
method has been employed successfully to locate the genes responsible for monogenic forms 
of obesity in mice. However, it is less suited to the investigation of complex diseases. This is 
because variants affecting polygenic obesity only cause a small change in risk and so some 
relatives  may  carry  the  risk  allele  being  studied  but  still  be  non-obese.  Conversely,  some 
relatives may not carry the risk allele being studied yet still be obese. This reduces the chances 
of detecting regions harbouring disease loci. 
The first genome-wide linkage study specifically designed for obesity phenotypes was published 
in 1997 and reported  a susceptibility locus on chromosome 2218. This was followed shortly in 
1998 by a study that used nuclear families ascertained specifically for obesity. This too found a 
susceptibility  locus  on  chromosome 2  and  others  on  chromosomes  5  and  10219.  Both  the 
chromosome 2 locus220,221 and the chromosome 10 locus222,223 were replicated in subsequent 
reports. Since then over 250 QTLs from more than 60 linkage scans have been published with 
around 50 of  these regions supported by two or more studies224.The strongest  evidence of 
linkage came from a cohort of Utah pedigrees at chromosome 4 with a logarithm of odds (LOD)  
score of 9.2225. However, despite numerous published studies, no linkage regions have been 
unambiguously replicated, even after meta-analysis of 37 of such studies226. This demonstrates 
the  limitations  of  the  linkage  method  for  investigation  of  polygenic  traits  such  as  common 
obesity.
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1.4.3.2 Candidate gene association studies
In a candidate gene association study, a gene is chosen based on possible functional links to  
the disease being investigated. Genetic markers within the gene are then measured in a set of 
samples after which associations to the disease are analysed. Samples can be either cases and 
controls  or  samples  of  a  population.  Associations  may  be  detected  if  one  of  the  markers 
analysed  is  a  variant  that  directly  effects  disease  risk  or  if  a  marker  is  within  linkage 
disequilibrium (LD) of a variant that effects disease risk.
LD is a measurement of the correlation of alleles at two or more loci. It is the occurrence of sets 
of alleles found together in a population more often than would be expected by chance given 
their respective frequencies. On the other hand, when combinations of alleles can be found in  
their  expected  proportions  they  are  said  to  be  in  linkage  equilibrium.  LD is  usually  higher 
between alleles in close proximity to one another due to linkage; that is, crossing over during 
meiosis makes it less likely that markers that are far apart will be inherited together. LD is also  
higher between alleles that have arisen relatively recently in evolution since there have been 
less opportunities for crossing over events to separate them and between alleles where there is  
a low rate of recombination. LD is measured using D, D' or r2. D is calculated as the difference 
between  the  observed  frequency  (x)  and  the  expected  frequency  (p  multiplied  by  q)  of  a 
combination of markers (A and B): 
DAB=x AB – pAqB
D suffers as a measurement because it depends on the frequencies of the alleles. Thus if an 
allele has a frequency of 1 or 0 then D=0. D' corrects for this problem by dividing D by the  
theoretical maximum of D, Dmax:
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D '= D
Dmax
Finally r2 is the correlation coefficient between a pair of alleles:
r 2= D
2
pApBq AqB
A D' or r2 value of 0 means that the examined loci are independent of one another whereas a D' 
or r2 value of 1 means that they are completely dependent. The measurement of r2 has a more 
strict  interpretation than that of D′ and r2 = 1.0 only when both loci also have identical  allele 
frequencies. Thus the allele at one locus will always be predicted by the allele at the other locus. 
LD is a useful tool in association studies because it allows a researcher to select a subset of  
genetic markers within a region of  interest  that  can predict the genotypes of  other markers  
within the region without having to directly measure them. These are called tagging markers or, 
since the most  commonly used genetic marker  is  single  nucleotide polymorphisms (SNPs), 
tagging SNPs.
A  catalogue  of  SNPs  and  corresponding  LD  data  is  available  to  researchers  from  the 
International HapMap project which has genotyped several million SNPs in 269 individuals from 
four populations227,228,229. Thus tagging SNPs can be selected such that association studies can 
be carried out without having to genotype every SNP within a gene.
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The main advantage of the candidate gene approach is the greater power to detect variants with 
small  effect  sizes that  comes  from  using  case-control  cohorts when  compared  to  linkage 
analysis using trios230. This statistical power is further increased by the fact that it is easier to 
recruit large numbers of the unrelated samples used in case-control analysis than it is to recruit  
families230. When candidate gene association studies were first undertaken, many associations 
to complex diseases, including obesity, were reported (reviewed by Rankinen et al.224). A large 
proportion  of  these,  however,  were  not  replicated  suggesting  that  many  were  not  real 
associations. This is probably because of the fact that on average, one in twenty statistical tests 
will result in a nominal significance of p<0.05 simply by chance, so failure to properly account 
for multiple testing meant that many associations were likely to be false-positives. Publication 
bias aggravated the problem since studies reporting statistical association are much more likely 
to be published than those that do not231.
Another issue with early association studies is the presence of confounding factors such as 
ethnicity, age and sex. If cases and controls are not properly matched then differences in allele 
frequencies between the two groups may arise because of one of these other variables. For  
example if there is a difference in allele frequencies between two ethnic groups and one ethnic  
group is more common in the cases than in the controls then it might appear as if there is a  
genetic association to the disease being examined when in fact what has been detected might  
be a genetic association with ethnicity. This is known as population stratification232.
It  is  also possible that  failure  to replicate associations may be down to genetic  differences 
between study populations. This can happen if, for example, a tested SNP is in high LD with a 
causative SNP in one population but not in another. The tested SNP may show association in  
populations where it tags the causative SNP but not in populations where it doesn't. However it 
should  be  noted  that  this  is  an  unlikely  explanation  since LD  structures  within  European 
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populations have  been found to be very similar when examining common variation such that 
genuine associations, such as those reported by GWAS have replicated well233. Therefore the 
most  likely  explanation for  the lack of  replication is  that  the original  association is a false-
positive234.
Several genes have been reported to be associated to obesity in ten or more studies including 
many genes of the leptin-melanocortin system (reviewed by Rankinen  et al.224), however this 
might reflect the fact that these genes present some of the more likely candidates so have been 
investigated  the  most.  In  fact,  meta-analyses  that  have  been  carried  out  have  found  no 
evidence of association between obesity and leptin235,236 or in leptin receptor236,237. Table 1.3 lists 
genes that are associated to obesity or BMI in meta-analyses. This includes ENPP1, associated 
after one meta-analysis238 but not conclusively supported in a previous meta-analysis239.
Gene Location Gene function References
ADIPOQ 3q27.3 Adipose expressed hormone 236
ADRB3 8p11.23 β3 adrenergic receptor, stimulates lipolysis240 241
ENPP1 6q22-
q23
A transmembrane  glycoprotein  that  is  expressed  in 
adipose
238
MC4R 18q22 Key receptor of the melanocortin system 242
IL1β 2q14 Proinflammatory cytokine 236
IL6 7p15.3 Proinflammatory cytokine 236
TNF-α 6p21.33 Proinflammatory cytokine 236,243
Table 1.3. Candidate genes with associations to obesity reported in meta-analyses.
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1.4.3.3 Genome-wide association studies (GWAS)
At the beginning of this PhD project, GWAS had recently become technologically feasible. This 
was  made  possible  by  array  based  genotyping  platforms  developed  by  Affymatirx244 and 
Ilumina245 that are able to measure hundreds of thousands of genotypes in a single DNA sample 
at  high  accuracy  and  relatively  low  cost  per  genotype.  Using  LD  data  gathered  from the 
HapMap project227,  SNPs can be eliminated from investigation so that a reduced number of 
variants can be used to capture the majority of the common variation (minor allele frequencies 
>5%), within the human genome. 
Typically,  GWAS involve  a  discovery  phase  in  which  hundreds  of  thousands  of  SNPs  are 
genotyped  in  a  subset  of  samples  using  genome-wide  arrays.  This  is  then  followed  by  a 
replication stage in which the most significant markers from the discovery phase are genotyped 
in a second set of samples. The two datasets can then be meta-analysed together in order to 
report more accurate odds ratios.
The advantages of this method are that studies are not based on prior data on the function of 
genes thought to be involved in disease, i.e. they are hypothesis free, yet they can still use the  
large number of unrelated samples used in candidate gene association studies which increases 
the power to detect modest effect sizes.
The first obesity gene to be discovered using a genome-wide association study (GWAS) was 
FTO (fat  mass  and  obesity  associated  gene)  which  was  reported  simultaneously  by  two 
research groups around the same time this project was started in 2007246,247. The function of 
FTO is  still  unclear  but  it  is  widely  expressed  in  the  brain,  particularly  the  hypothalamus, 
suggesting a possible role in appetite regulation248. 
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This  was  followed  in  2008  by  two  studies  that  reported  associations  between  obesity 
phenotypes and  MC4R variation. One study was designed to look for associations to insulin 
resistance  in  an  Indian  population249, the  other  investigated  BMI  and  obesity  risk  in 
Europeans250. The later of these also replicated the FTO association.
The next obesity GWAS to be published came at the end of 2008 from the Genetic Investigation  
of  ANthropometric Traits (GIANT) consortium, a collaboration of  multiple study groups each 
performing genome wide scans in different cohorts251. Data that included over two million SNPs 
in almost 40,000 subjects was meta-analysed and the most significant results followed up in a 
further set of almost 60,000 individuals. As well as replicating the FTO and MC4R associations, 
six new obesity loci were reported. Published shortly afterwards, in early 2009, a meta-analysis  
which included around 35,000 samples from Iceland, the Netherlands, North America (European 
and African descent) and Scandinavia, with a follow-up of  a further 35,000, reported eleven 
significant associations including seven novel loci252. This was followed by a case-control study 
that used 1,380 Europeans with childhood and morbid adult obesity and 1,416 age-matched 
normal-weight  controls,  followed-up in  around 15,000 subjects  and reported associations to 
three novel loci253.
Many of the associated variants are located within or near genes that are highly expressed in 
the CNS and in particular, the hypothalamus and are thought to be involved in the regulation of 
energy balance. This supports the theory, first put forward by O'Rahilly and Farooqi, that the 
heritable aspects of obesity are largely neurological in origin254.
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Some time after the practical work from this PhD project was finished, in late 2010, the GIANT 
consortium  published  a  new  meta-analysis  which  included  almost  250,000  subjects  and 
discovered a further  eighteen  novel  associations to BMI233.  Since then there has been one 
meta-analysis published which analysed associations to body-fat percentage and found novel 
associations at  two loci255 and another which analysed associations to childhood obesity and 
discovered another two novel associated loci256. The results of these GWAS are summarised in 
Table 1.4.
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Date 
published
Total  number 
of subjects
Phenotype Genes Ref.
May 2007 28,587 adults BMI FTO 246
10,172 children
July 2007 6,148 relatives BMI FTO 257
June 2008 77,228 adults BMI FTO, MC4R 250
10,583 children
June 2008 11,955 WC MC4R 249
June 2008 1,000 adults BMI CTNNBL1 258
3,812 adults Obesity
December 
2008
91,469 BMI FTO, MC4R, TMEM18, KCTD15, GNPDA2, SH2B1, 
MTCH2, NEGR1
251
January 
2009
69,593 BMI FTO, MC4R, TMEM18, KCTD15, SH2B1, NEGR1, 
SEC16B, ETV5, BDNF, AIF1 /BCDIN3D
252
February 
2009
8,128 adults Obesity FTO, MC4R, NPC1, MAF, PTER 253
8,855 children
April 2009 8,842 BMI, WHR FTO, MC4R, CTNNBL1, PTPN11 259
June 2009 118,691 adults WC, WHR TFAP2B, MSRA 260
47,633 women WHR LYPLAL1
April 2010 36,581 Obesity FTO, MC4R, TMEM18, SDCCAG8, TNKS/MSRA 261
November 
2010
249,796 BMI RBJ/POMC, GPRC5B, MAP2K5, QPCTL/GIPR, 
TNNI3K, SLC39A8, FLJ35779/HMGCR, LRRN6C, 
TMEM160, FANCL, CADM2, PRKD1, LRP1B, 
PTBP2, MTIF3, ZNF608, RPL27A, NUDT3 *
233
November 
2010
190,803 WHR 
(adjusted 
for BMI)
RSPO3, VEGFA, TBX15-WARS2, NFE2L3, GRB14, 
DNM3-PIGC, ITPR2-SSPN, LY86, HOXC13, 
ADAMTS9, ZNRF3-KREMEN1, NISCH-STAB1, 
CPEB4, LYPLAL1 *
262
June 2011 76,202 Body  fat 
percentage
FTO, IRS1, SPRY2 255
May 2012 25,637 Childhood 
obesity
OLFM4 , HOXB2 256
Table 1.4. Genes significantly associated with obesity phenotypes in genome-wide association 
studies. BMI = body mass index, WHR = waist to hip ratio, WC = waist circumference. * These 
studies also found significant associations to variants previously reported by Thorleifsson  et 
al.252 and Willer et al.263
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1.4.4 Missing heritability
Between them, these associations only explain a small proportion of the heritability of obesity. 
Speliotes et al. report that together the 32 SNPs associated with BMI account for 1.45% of the 
inter-indivudual variation in the trait with FTO, the variant with the largest effect size, accounting 
for 0.34%. This suggests that many more genetic associations are yet to be discovered. The 
situation is similar with other complex diseases and there is some debate as to where this 
missing heritability might be found264.
Due  to  the  large  amount  of  statistical  tests  being  performed  in  GWAS,  very  stringent 
requirements to correct for multiple testing are required in order to reduce the false-positive rate. 
As such many associations of small effect could end up being screened out. For example the 
leptin  gene  has  been  reported  to  be  associated  to  obesity  in  at  least  13  candidate  gene 
studies224 yet it has not found to be significant in any genome wide association study to date. In 
the most recent GIANT BMI publication233 a SNP close to LEP resulted in a p-value of 3.1x10-3. 
This is clearly well below the cut-off for a significant finding in a GWAS but it is possible that  
there is a weak association that is mistakenly being rejected.
Furthermore,  since  genome  wide  association  studies initially relied on  using  only  markers 
present in the HapMap, not all variants were being investigated. Phase two of HaMap contains 
3.1 million SNPs,  which is estimated to represent just one quarter to one third of all common 
(>5%) SNPs within the human genome229. More recently, imputation using genotypes from the 
1000 genomes project265 combined with higher density arrays such as the Illumina HumanOmni-
5 (n=4.3million SNPs) has meant that coverage has been expanded to include the vast majority 
of common variation. But  this also means that rare variants (<5%) are not covered by current 
GWA studies.  Genotyping  only  common  variants  is  an  approach  that  is  supported  by  the 
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common disease-common variant hypothesis, which proposes that a small number common 
variants  are  responsible  for  the  genetic  component  of  common  disease  rather  than  large 
numbers of rare variants. However, this hypothesis is now coming under challenge and it is 
thought that rare variants may also contribute to common diseases266. 
Another  issue  with  obesity  studies  is  that  many  GWAS  are  not  designed  primarily  for 
investigating obesity but use BMI in post-hoc analysis. This means that they are only reporting 
variants that control weight variation in the non-obese population and it is not known how much 
overlap there is with these and genes that predispose to the disease state of obesity. Better 
subject selection could improve results. 
For these reasons, the candidate gene approach to investigating genetics of common polygenic 
obesity can still be considered valid. Additionally, other forms of heritable variation, such as copy 
number  variants  (CNVs)  and  epigenetics,  may  also  have  a  significant  influence  on  the 
development of obesity. 
1.4.4.1 Copy number variation (CNV) 
CNVs are defined as deletions, duplications or tandem repeats of 1kb or more in size 267. In the 
last few years their importance in the pathophysiology of heritable diseases, including obesity 
has become increasingly recognised268.
A large deletion at 16p11.2 has been reported in patients with obesity and cognitive deficits.  
Similar deletions at the same location were subsequently found to be significantly associated 
with common polygenic obesity in case-control analysis269 and a duplication in this region has 
also been found to associate with reduced BMI, demonstrating how gene dosage can be linked 
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to opposite body composition phenotypes270. A recent study in patients with early-onset obesity 
found that large (>500kb), rare (<1%) deletions were present in significantly higher frequencies 
in obese compared to controls271. A genome-wide scan in European American childhood obese 
case-control subjects found seventeen rare CNV loci that were present in at least three cases 
but no controls272. Eight of these associations were replicated in an African American cohort.  
Another CNV at  10q11.22 has been reported to be associated with BMI in a Han Chinese  
study273.
1.4.4.2 Epigenetics
There is growing evidence that epigenetics can contribute to the development of obesity as 
well274. Epigenetics is the study of modifications to genes that do not involve changes to the 
DNA sequence and include DNA methylation and histone modifications. They are associated 
with the control of expression of genes (reviewed by Bird275).
Epigenetic variation between individuals can arise in three ways. Firstly, epigenetic changes can 
arise due to errors during cell  programming. Secondly, some epigenetic markers have been 
found to be heritable so variation can be passed on from one generation to the next. Finally,  
epigenetic markers can be altered due to environmental factors.
Epigenetic markers are mitotically heritable, which enables maintenance of tissue-specific gene 
expression.  There  is  also  evidence  that  they  can  be  meiotically  heritable,  which  means 
epigenetic markers can be inherited transgenerationally (review by Chong et al.276). The most 
established case of transgenerational epigenetic inheritance in mammals is imprinting in which 
a gene is expressed preferentially from either the maternal or the paternal allele only (reviewed 
by Reik  et al.277).  Non-imprinting epigenetic inheritance has been observed in  Agouti  (Avy/a) 
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mice278 in the form of a transposable element.  This mouse is also a model of epigenetically 
controlled obesity since mice with reduced methylation at the  Avy  allele develop obesity along 
with  yellow fur  colour.  Obesity  is  amplified  through  multiple  generations  of  Avy/a  mice,  but 
supplementing the diet with methyl donors prevents this amplification279. 
There is evidence from animal studies that prenatal and early postnatal environmental factors 
can  result  in  alterations  of  epigenetic  markers.  These  environmental  factors  include 
nutrition280,281, behavioural cues282,283, chemicals284,285, reproductive factors286,287 and radiation288. 
Furthermore these alterations may be inherited transgenerationally278,289,290.  A recent study in 
rats  found that  overfeeding led to hypermethylation of  CpG sites in the promoter  region of  
POMC  in  the hypothalamus. This resulted in a reduction of  transcription of  the gene which 
normally produces an anorexigenic signal to decrease food intake in response to leptin and 
insulin.  Thus  overfeeding  resulted  in  an  altered  methylation  pattern  which  subsequently 
modified energy regulation systems leading to an increased disposition to obesity291.
DNA methylation is the best-characterized epigenetic mechanism. It is a modification in which a 
methyl group is added to the 5 position of the cytosine nucleotide creating 5-methylctosine. In 
mammalian, adult cells it occurs at CpG dinucleotides, although non-CpG methylation is found 
in embryonic stem cells292.
As DNA is replicated during cell-division, the enzyme DNA methyltransferase 1 (DNMT1) is the 
principal enzyme required to copy DNA methylation patterns into the daughter strands. It does 
this by recognising hemi-methylated CpG sites, CpGs that are methylated on just one of the two 
DNA strands, and catalysing the addition of a methyl group to the unmethylated cytosine. DNA 
methyltransferases 3a and 3b (DNMT3a and DNMT3b) are also thought to be involved in this 
process, particularly in regions dense in methylated CpG sites. DNMT3a and DNMT3b are also 
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known to be important enzymes in the process of  de novo methylation. This requires another 
homologue, DNA methyltransferase 3L (DNMT3L), which is lacking in methyltransferase activity 
and acts  to recruit  DNMT3a and DMNT3b to  the DNA strand.  De novo methylation occurs 
during cell differentiation in order to establish methylation patterns particular to a specific cell 
type (review by Jones et al.293). The DNA methylation pattern is erased in the early embryo and 
then re-established at  approximately the time of  implantation294,295.  Differential methylation is 
established by de novo methylation by DNMT3a and DNMT3b296 and by a means of ensuring 
that CpG islands remain unmethylated. This second step is thought to be mediated by active 
demethylation297, although it may also involve blocking of DNMT3L by the methylated histone, 
H3K4 298,299,300. Once the methylation pattern is established in the embryo it is subject to specific  
alterations  during  development  and  these  can  include  both  de  novo methylation  and 
demethylation299,301.
It  is  estimated  that  over  60%  of  all  CpG  sites  in  the  human  genome  are  methylated 302. 
Methylated  cytosine  residues  are  less  stable  than  non-methylated  residues  and  can 
spontaneously deaminate to form thyamine residues303.  This means that  over the course of 
mammalian  evolution  CpG  dinucleotides  have  become  under-represented  in  the  genome, 
occurring at around only 20% of the frequency expected by chance304. However, there are also 
regions of the genome that contain a much higher frequency of CpGs, probably due to a lack of  
cytosine methylation in these regions throughout evolution. These are called CpG islands and 
the  promoters  of  around  60%  of  all  known  human  genes  contain  such  regions305,306. 
Hypermethylation in gene promoters results in transcriptional silencing of  the gene which is 
inherited  by  daughter  cells  and  is  understood  to  be  an  important  influence  in  cancer 
development (reviewed by Jones et al.307).
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During early years (0-3 years) monozygotic twins have identical DNA methylation and histone 
acetylation profiles, however differences begin to appear later in life308. Furthermore, twin pairs 
who had spent less of their lifetime together were those that had the greatest differences. This 
demonstrates the environmental effect on DNA methylation.
A recent twin study revealed a significant difference in the DNA methylation patterns between 
dizygotic twins compared to monozygotic twins which cannot be explained by underlying genetic 
differences309. Methylation at 12,000 CpG sites within gene promoters were measured in white 
blood cells and buccal epithelial cells of 20 sets of MZ and 20 sets of DZ twins matched for age 
and sex. A significantly higher epigenetic difference was observed in both cell types between DZ 
co-twins compared to MZ co-twins. This demonstrates the heritability of DNA methylation and 
opens the possibility that it may contribute to complex diseases such as obesity.
The most established example of an epigenetic disorder that results in obesity in humans is 
Prader-Willi Syndrome (PWS), which is characterised by obesity as well as learning disabilities 
and hypotonia. Its genetic causes have been isolated to chromosomal region 15q11-13, which 
contains a group of imprinted genes which are expressed either from the paternal or maternal  
chromosome  only  (reviewed  by  Buiting  et  al.310).  As  well  as  deletions,  translocations  and 
uniparental disomy it can be caused by deficiencies in the imprinting of genes in this region of  
the paternal chromosome.
Another  example of  DNA methylation  being associated  with  obesity  comes from studies of  
adults who were exposed to poor nutrition  in utero due to the Dutch famine of 1944 to 1945. 
These  individuals  have  an  increased prevalence  of  glucose  intolerance,  dyslipidemia,  early 
coronary heart disease, and obesity311,312. In a recent study, such subjects were found to have 
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reduced DNA methylation levels in  the imprinted gene IGF2 when compared to  unexposed 
siblings demonstrating that environmental conditions can cause lasting epigenetic changes and 
the that these epigenetic changes might influence obesity risk313. It is thought that this is due to 
a decreased supply of methyl donors such as folate and methionine during development.
Genomic imprinting has also been reported to influence common obesity at three loci in a study 
that used genome-wide parent-of-origin linkage analysis. A maternal effect was discovered for 
obesity at 10p12, a maternal effect for BMI was discovered at 12q24 and a paternal effect for 
BMI at 13q32314. In another study, TNFα promoter CpG methylation in blood mononuclear cell 
DNA has been demonstrated to  predict  response to  a  weight  loss diet  in  humans315.These 
results suggest that DNA methylation and possibly other epigenetic mechanisms can influence 
susceptibility to common polygenic obesity. 
Many studies have chosen to focus on CpG island methylation but recent evidence suggests 
that methylation in gene body regions may be critical to tissue-specific gene expression. DNA 
methylation in gene body regions has been found to correlate with increased expression rather 
than  decreased expression  that  is  associated with  promoter  methylation316,317.  The  active  X 
chromosome  has  been  found  to  be  hypermethylated  in  gene  body  regions  whilst  being 
hypomethylated  in  gene  promoter  regions,  supporting  a  role  of  gene-body  methylation  in  
stimulating expression318. Another study reported differential expression of a nitric oxide inhibitor 
gene due to differential methylation patterns in the gene body319. A more recent meta-analysis 
found that the relationship between gene-body methylation and expression levels follows a bell-
shaped distribution such that mid-level expressed genes have the highest levels of gene-body 
methylation, whereas the lowest and most highly expressed sets of genes both have low levels 
of methylation320.
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These results  support  a  role  of  epigenetic  variation  in  the  control  of  gene  expression  and 
therefore  phenotype  and  disease  risk  that  can  be  inherited  transgenerationally.  As  such 
epigenetic variation could explain some of the missing heritability of common obesity.
1.5 Aims
The  aim  of  this  thesis  was  to  add  to  the  understanding  of  the  genetic  and  epigenetic 
mechanisms that contribute to the development of common polygenic obesity in humans by 
studying candidate genes. When this project was started, GWAS had only just become feasible 
and  so  a  candidate  gene approach  to  studying  the  genetics  of  common disease  was  still  
considered  a  valid  choice.  As  this  project  continued  it  became  clear  that  GWAS had  not 
elucidated all of the genes responsible for the heritable causes of obesity and other common 
diseases and so a candidate gene method could still potentially find associations missed by the 
genome-wide method.
The specific aims were:
1.  Investigation of  common genetic  variation within the following genes for association with 
human polygenic obesity:
a) Sirtuin-1 (SIRT1)(see section 1.5.1.1)
b) Apelin (APLN)(see section 1.5.1.2)
c) Interleukin 11 (IL11)(see section 1.5.1.3)
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d) Adiponutrin (PNPLA3 )(see section 1.5.1.4)
e) Nesfatin (NUCB2)(see section 1.5.1.5)
f) Insulin Receptor Substrate 1 (IRS1)(see section 1.5.1.6)
2. Investigation of epigenetic variation in the Leptin gene for association to human polygenic 
obesity (see section 1.5.2).
1.5.1 Candidate gene association studies
Subjects used were 1533 obese cases and 1237 non-obese controls, all French Caucasians. 
Cases were 896 obese adults and 637 obese children. These were analysed separately but 
used the same control samples and as such are not independent data sets used for replicating 
results. Additional subjects included 732 Swedish Caucasians from 154 families that contained 
siblings discordant  for obesity and for  which genome-wide transcription data  within adipose 
tissue was available (see Materials and Methods for  details). SNPs that covered all common 
variation in each candidate gene were genotyped using Sequenom iPlex assays. It is important  
to note that while rare variants have been highlighted as a potential source of genetic variation 
that  could contribute to obesity risk,  this project  only investigated common variation due to 
statistical power limitations. Each candidate gene was chosen based on having functional links 
to appetite and metabolism. Descriptions of the selected genes are given below.
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1.5.1.1 Sirtuin-1 (SIRT1)
Sirtuin  1  is  a  nicotinamide adenine  dinucleotide  (NAD+)-dependent  protein  deacetylase that 
regulates transcription of a variety of genes including a number that have been implicated in the  
control  of  metabolism  in  humans.  As  SIRT1  activity  is  under  the  control  of  cellular  NAD + 
concentration it acts as an energy sensing molecule that alters transcription of certain genes in 
response to the energy status of the cell321. 
Most notably, SIRT1 inhibits transcription of PPARγ, thereby promoting lipolysis and mobilisation 
of free fatty acids from WAT as well as inhibiting adipogenesis322. Inhibition of SIRT1 in 3T3 L1 
adipocyte cell culture increases differentiation and overexpression of SIRT1 reduces it322. It also 
stimulates mitochondrial activity and thus increases glucose metabolism in the liver through the 
transcriptional regulator PGC-1α323. SIRT1 has also been shown to deacetylate the transcription 
factor forkhead box protein O1 (FoxO1), a key regulator of lipid metabolism 324. In pancreatic β 
cells  SIRT1 enhances insulin  secretion in  response to  glucose via  regulation of  uncoupling 
protein 2325. SIRT1 has also been discovered to alter expression of adiponectin, although the 
two studies reported opposite effects326,327. Another mechanism by which SIRT1 is  linked to 
obesity is an association with lower levels of nuclear factor-κB (NF-κB) activity. NF-κB is a key 
regulator of many genes involved in inflammation and its inhibition in mouse models have been 
shown to protect from diabetes and fatty liver328,329.
Transgenic mice that overexpress SIRT1 weigh less than control mice, have a lower WAT mass 
and  have  lower  plasma  levels  of  free  fatty  acids,  leptin  and  adiponectin330. They  are  also 
protected  from glucose  intolerance  induced by  ageing,  diet-induced obesity  and  genetically 
induced obesity324,328. Conversely, SIRT1 knockout mice have increased body weight, increased 
fatty liver disease, increased insulin resistance, increased glucose intolerance and inflammation 
in WAT and liver331,332.
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Activators of  SIRT1 including resveratrol  protect against obesity and insulin resistance in mice 
fed a high fat diet333,334,335,336. These activators increase levels of metabolism and lipolysis via 
transcriptional activation of PPARγ and PCG1α. Resveratrol has also been reported to increase 
lipolysis in human adipose tissue culture and this is mediated via SIRT1337.
1.5.1.2 Apelin (APLN)
The  APLN gene is expressed in adipocytes  in both mice and humans and its transcription is 
inhibited by fasting338. Expression of APLN in subcutaneous adipose tissue has been reported to 
be significantly elevated in mice and rats fed a high fat diet and has been correlated with serum 
leptin levels338,339,340. Intravenous injection of apelin stimulates glucose utilisation in muscle and 
adipose  tissue  in  mice  and  lowers  blood  glucose  levels341. Genetically  engineered  apelin-
knockout mice have reduced insulin sensitivity and are hyperinsulinemic342. Administration of 
pyroglutamated apelin-13 was found to improve insulin sensitivity in both apelin-deficient mice 
and db/db diabetic mice342.
The apelin receptor,  APJ, is expressed in hypothalamic neurons in rats343,344 and injection of 
apelin-13 and apelin-12 into the brains of rats has been reported to decrease food intake 345,346. 
Treatment with apelin has been reported to lower the mass of WAT in both non-obese and 
obese mice (on average a ~30% reduction in epididymal WAT mass was reported in both non-
obese and obese mice) as well as lowering serum levels of insulin and triglycerides347. Apelin 
treatment has been reported to increase expression of  UCP1 in BAT, a gene involved in fatty 
acid activated uncoupling of respiration347,348. In the same report, apelin treatment also increased 
expression of UCP3 in skeletal muscle347. UCP3 regulates fatty acid export and genetic variants 
in  its  gene  have  been  reported  to  be putatively associated  with  obesity,  although  these 
associations have not been confirmed in any GWAS to-date and so have not been robustly 
validated349,350.
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Plasma  apelin  levels  have  been  reported  to  be  significantly  increased  in  obese  subjects 
compared to non-obese controls and were significantly correlated with BMI351. A similar result 
has  been  observed  between  in  subjects  with  T2D  or  impared  fasting  glucose  and  this 
association is caused by a correlation of apelin levels to BMI339,352. In insulin-resistant high-fat 
fed mice, apelin and APJ expression in adipose tissue was significantly increased compared to 
controls339. Another study reported a correlation of plasma apelin levels with BMI in normal and 
underweight individuals and this correlation was even more pronounced in obese subjects353.
1.5.1.3 Interleukin 11 (IL-11)
IL-11 has also been reported to inhibit adipogenesis and suppress lipoprotein lipase activity in 
mouse 3T3-L1 preadipocyte cell culture354,355,356. Treatment of fully differentiated mouse 3T3-L1 
adipocytes with IL-11 has been found to lower transcription of leptin357. In human bone marrow 
tissue cultures, IL-11 inhibits fat accumulation in the adherent cells via a decrease in the number 
of vacuoles in macrophages and inhibition of preadipocyte differentiation358,359. 
1.5.1.4 Adiponutrin (  PNPLA3  ) 
Adiponutrin, also known as Patatin-like phospholipase domain-containing protein 3 (PNPLA3) is 
a cell membrane protein that is expressed in adipose cells360. It is a triacylglycerol lipase that 
has been shown to catalyse the hydrolysis of triglycerides in vitro361,362. In addition to adipocytes, 
it is highly expressed in liver and transcription of the gene appears to be connected to liver fat  
content363,364,365,366.  Expression  of  PNPLA3 is  nutritionally  controlled.  In  mice,  adipose 
transcription  levels  are  reported  to  be  downregulated  during  fasting  and  upregulated when 
fasted mice are fed a high-calorie diet360,361. Furthermore, expression of the gene is fifty-fold 
higher in obese compared to normal rats360. 
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In obese women, a three-week very low calorie diet has been reported to significantly reduce 
expression of the gene in subcutaneous adipose tissue367. A clamp study in non-obese, non-
diabetic humans found that subcutaneous adiponutrin expression was induced by both insulin 
and glucose368. Expression of Adiponutrin in subcutaneous and visceral adipose tissue has also 
been reported to be increased in obese compared to non-obese subjects in a Swedish study369.
1.5.1.5 Nesfatin-1 (NUCB2)
In the brain, nesfatin-1 protein is found in several areas of the hypothalamus including the PVN, 
the supraoptic  nucleus,  the ARC and the LH as well  as the nucleus of  the solitary tract,  a  
brainstem area with known roles in feeding370,371,372,373.  Neurons in which nesfatin-1 is located 
have also been found to express MCH, CART, α-MSH, POMC and NPY supporting a role for  
nesfatin-1 in appetite control  370,374,371,375.  Additionally nesfatin-1 has been shown to inhibit NPY 
neurons376.
Injection of nesfatin-1 into the brains of both rats and mice has been shown to reduce feeding 
consistent  with  a  function  as  an  anorexigenic  regulator  of  food  intake372,377.  Furthermore, 
knockdown of  NUCB2 in the rat hypothalamus using an antisense oligonucleotide increases 
food intake and body weight372. The nesfatin-1 protein can cross the blood-brain barrier in both 
directions378,379 and intraperitoneal injection of nesfatin-1 has been reported to lower food intake 
in mice380. 
NUCB2  transcription in  the rat  hypothalamus is significantly reduced after twenty-four hours 
fasting and this is restored after re-feeding372,373. In humans, a putative association has been 
reported between fasting levels of plasma nesfatin-1 and obesity in male subjects and BMI in 
the non-obese group381. A recent study using female anorexic patients reported a significant 
increase in circulating nesfatin-1 compared to age-matched healthy controls382.
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1.5.1.6 Insulin Receptor Substrate 1 (IRS-1)
IRS-1 is an intracellular signalling molecule that is expressed in all insulin-sensitive tissues383,384. 
It is a key molecule in the signal cascade, critical to energy regulation, that is triggered when 
insulin binds to its receptor. In addition to its role in insulin signalling, IRS-1 is also a substrate  
for insulin-like growth factor 1 (IGF-1) receptor which is thought to be an important regulator of  
cell  differentiation384.  IRS-1 stimulation in  response  to  insulin  and IGF-1 leads to  uptake of 
glucose by muscle and fat tissue and inhibition of hepatic glucose production. It also stimulates 
cell differentiation and growth, promotes lipogenesis and inhibits lipolysis385.
IRS-1 knockout mice are hyperinsulinemic and show mild insulin resistance but do not have 
altered glucose tolerance384.  Interestingly body weight  in  knockout  mice is  reduced by 50% 
suggesting a role of the gene in somatic growth. Furthermore, adipocyte cell lines from these 
mice were found to have a significant reduction in their differentiation and lipid accumulation 
compared to wild type suggesting a role in controlling adiposity386. 
Variants within the  IRS-1 gene have be reported to influence T2D risk387 including a recent 
GWAS  which  found  associations  between  rs2943641  and  T2D,  insulin  resistance  and 
hyperinsulinemia388.  There have also  been associations  reported between  IRS-1 SNPs and 
obesity and since insulin levels are correlated with BMI, dysregulation of the insulin signalling 
pathways could be a factor in the development of obesity387,389. More recently, a GWAS found a 
significant association between a variant close to IRS-1 and body fat percentage255.
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1.5.2 Epigenetic variation in the Leptin gene (LEP)
Methylation in the LEP CpG island has been shown to reduce activity of the promoter in human 
adipose cell  lines using luciferase assays390. The  LEP CpG island is differentially methylated 
across tissue types, which could indicate a role of methylation in the regulation of this gene391,392. 
Rats that  are  fed a  high fat  diet  and become overweight  have been found have increased 
methylation at one CpG site in the leptin promoter when DNA from adipose was examined. This  
methylation  was  associated  with  lower  blood  levels  of  leptin393.  These  results  indicate  the 
possibility of a role of DNA methylation in the LEP gene in the regulation of BMI.
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Chapter 2
Materials and Methods
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2.1 Subjects
2.1.1 Obese cases
Two groups of case subjects were used. The first set consisted of 896 unrelated morbidly obese 
(BMI  over  40kg/m2)  adults  (mean  BMI  =  47.5kg/m2±7.5kg/m2;  mean  age  =  44.3±11.9;  689 
females and 207 males). The second set consisted of 637 unrelated obese children (BMI over 
97th percentile for age and sex) (mean BMI = 29.6kg/m2±6.5kg/m2; mean zBMI=4.27±1.2; mean 
age =11±3.2; 341 females and 296 males). These were all French Caucasians recruited through 
a multimedia campaign run by the Centre National de la Recherche Scientifique (CNRS), Hotel 
Dieu Hospital, the Pasteur Institute, Lille and the Department of Paediatric Endocrinology of 
Jeanne  de  Flandres  Hospital.  Ethical  approval  for  the  studies  was  given  by  local  ethical  
committees.
2.1.2 Non-obese controls
Two groups of control subjects were used, both unrelated non-obese French Caucasians. The 
first contained 532 individuals from the Haguenau cohort (mean BMI = 21.3 kg/m² ±2.0 kg/m²; 
mean  age  22.7  ±3.5;  243  males,  289  females)394 The  second  was  705  subjects  from the 
Epidemiology Study on Insulin Resistance (D.E.S.I.R)(mean BMI = 23.3 ±1.8 kg/m²; mean age 
53.9  ±5.6;  282  males,  423  females)395.  Control  participants  were  pooled  for  case  control 
analyses, but prior to pooling χ2 tests for each SNP were performed to make sure there was no 
significant difference (p>0.05) in genotype or allele frequencies between the control groups. BMI 
was calculated as the subject’s weight (in kilograms) divided by the square of their height (in 
metres).
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2.1.3 Families
154 nuclear families containing 732 Swedish Caucasians were identified as part of the Swedish 
Obesity  Study cohort  (SOS)396 on the  basis  of  an obese proband with  at  least  one sibling 
discordant for obesity (BMI difference >10kg/m2). Mean BMI in the lean siblings was 23.4±2.8, 
mean BMI in the obese siblings was 37.7±5.3. Siblings included 132 males and 292 females. 
Gene expression data from subcutaneous adipose tissue was available for 359 out of 424 of the 
siblings396.  This  data  was  obtained  from an  eQTL study  which  used  an  Affymetrix  Human 
Genome U133 Plus 2.0 gene expression array to measure genome wide transcript levels and 
had been normalised using the Robust Multiarray Average method396.
2.2 Protocols
2.2.1 SNP identification strategy
In  all  cases  where  a  tag SNP approach  was  used,  tagging  SNPs were  selected  from the 
HapMap  database  (http://www.hapmap.org)  with  r2≥0.8  and  a  minor allele  frequency  ≥0.05 
using  the  pairwise  tagger  algorithm  in  the  Haploview  4.0  software397.  Additional  SNPs  not 
present in the HapMap were selected from NCBI database, each with a reported minor allele 
frequency ≥0.05. Coding SNPs were included regardless of frequencies.
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2.2.2 Genotyping
Genotyping was carried out on the Sequenom MassArray platform (Sequenom Inc., USA)398. 
PCR and extension  primers  were  designed  using  MassARRAY Assay Design  3.1  software 
(Sequenom Inc. USA). For a multiplex PCR, 2µl (2.5ng/µl) of each DNA sample were mixed with 
2.18µl H2O, 0.5µl Hot Star Buffer (Qiagen Ltd.), 0.2µl MgCl2 (25mM), 0.02µl Hot Star Taq (5 
units/µl), 0.1µl of 10mM dNTP mix (Bioline Ltd., UK) and 0.5µl of 1µM primer mix (See appendix 
for primer sequences).  Reaction conditions were as follows:  95°C for 15 minutes,  then five 
cycles of 95°C for 20s, 65°C for 30s and 72°C for 1 min, followed by five cycles of 95°C for 20s,  
58°C for 30s and 72°C for 1 minute, followed by 38 cycles of 95°C for 20s, 53°C for 30s and 
72°C  for  1  minute,  ending  with  72°C  for  3  minutes.  To  dephosphorylate  dNTPs  and  any  
remaining primers, 1.53 µl of dH2O, 0.17µl SAP Buffer (Sequenom) and 0.30µl shrimp alkaline 
phosphatase (SAP) enzyme (Sequenom) was added to each reaction. This was incubated using 
a thermocycler at 37°C for 40 minutes followed by 85°C for 5 minutes. 0.74µl of dH 2O, 0.2µl 
iPLEX Buffer  Plus  (Sequenom),  0.2µl  iPLEX Termination  Mix  (Sequenom),  0.041  µl  iPLEX 
enzyme (Sequenom) were added to each reaction. Extension reactions were cycled as follows: 
94°C for 30 seconds followed by 40 cycles of 94°C for 5 seconds and 5 nested cycles of 52°C 
for 5 seconds and 80°C for 5 seconds, ending with a final incubation of 72°C for 3 minutes.
For each reaction, 15–25nl of sample was dispensed onto a SpectroCHIP using the Samsung 
Nano-dispenser and the chip was then analysed using the Bruker Autoflex MALDI-TOF mass 
spectrometer. Mass Array Typer 3.4 software was then used to call the genotypes based on the 
calculated  mass  of  the  extension  products  and  the  experimental  mass-spectrum  result. 
Automated genotype calls were manually checked.
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Genotyping was considered satisfactory if  the success rate for the SNP was ≥85% and the 
genotype distribution did not depart significantly from Hardy-Weinberg equilibrium (p>0.05 for 
chi-squared  test  between  expected  and  observed  values).  Hardy-Weinberg  p-values  were 
calculated using the online Finetti HWE calculator (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
2.2.3 PCR
Primers were designed using Primer3 software (http://frodo.wi.mit.edu/). A standard PCR was 
carried out as follows (see Appendix for individual primer sequences and conditions). 5.2µl H2O, 
1µl  Amplitaq  Gold  Buffer  (Applied  Biosystems,  Life  Technologies  Inc.,  USA),  0.8µl  dNTPs 
(10mM),  0.8µl  MgCl2 (25mM),  1µl  Primer  Mix  (5µM  of  each  primer),  0.2µl  AmpliTaq  Gold 
(Applied Biosystems)(5U/µl) was mixed with 1µl of template DNA. PCR was then carried out at  
94°C for 10 minutes followed by 40 cycles of 94°C for 30 seconds, 50°C for 30 seconds and 
72°C for 30 seconds ending with an incubation at 72°C for 5 minutes. Annealing temperatures 
and  extension  times  were  altered  based  on  requirements  of  the  specific  amplicon  (See 
Appendix for details). GC-rich amplicons often required the addition of 2µl Q Solution (Qiagen) 
in a 10µl PCR (see Appendix for amplicons that required Q Solution).
2.2.4 Agarose gel electrophoresis
To confirm the presence of the correct sized PCR product, 5µl was mixed with 1µl 6X loading 
buffer (Fermentas GmbH, Germany). A 150ml 2.5% (w/v) agarose (Invitrogen) gel was made up 
with 1X Tris Borate EDTA buffer (Sigma-Aldrich Inc.) and 7.5 µl Safeview (NBS Biologicals Ltd.,  
UK). A 100bp ladder (Fermentas GmbH, Germany) was loaded alongside samples as a size 
marker. DNA was viewed using a UV transilluminator and photographed using LabWorks Image 
Acquisition Software (Ultra Violet Products Ltd, UK).
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2.2.5 Sequencing of PCR product
5µl  of  PCR  product  was  purified  by  mixing  with  2µl  ExoSAPit  (USB)  and  placed  in  a 
thermocycler at 37°C for 15 minutes followed by 80°C for 15 minutes. This was then diluted  
fivefold by adding 43µl dH2O. The concentration of the PCR product was measured using a 
NanoDrop ND-100 spectrometer (NanoDrop Technologies, USA). 3.2pmol of sequencing primer 
was mixed with 90ng/kb PCR product and made up to 10µl with dH2O. Samples were processed 
by the Imperial  College Clincial  Sciences Centre Genomics Core Laboratory (Hammersmith 
Campus) using the Big Dye terminator mix v3.1 and capillary gel electrophoresis was carried 
out to separate the sequencing products on a 3730XL DNA Analyzer (Applied Biosystems).
2.2.6 CpG island identification and primer design
Putative CpG islands were identified using Methyl Primer Express version 1.0 software (Applied 
Biosystems) and CpGPlot was used to display C+G composition, CpG frequency and position of  
putative CpG islands (http://www.ebi.ac.uk/Tools/emboss/cpgplot/)305. CpG islands were defined 
as  being  at  least  200bp  in  length  with  C+G composition>50% and  a  ratio  of  observed  to 
expected CpG dinucleotides >0.6399. Primers were designed to PCR within the CpG islands of 
bisulfite treated  DNA using Methyl  Primer  Express.  Sequencing primers  were  designed to 
sequence the PCR product using the online software Primer3 (http://frodo.wi.mit.edu/).
2.2.7  Bisulfite   conversion of DNA 
Bisulfite conversion  was  carried  out  using  the  MethylDetector  kit  (Active  Motif  Inc.,  USA). 
Conversion Buffer was prepared by resuspending Conversion Reagent with 700µl dH2O, and 
then mixing with 350µl Buffer A and 175µl Denaturation Reagent at room temperature for 10 
minutes  with  intermittent  vortexing.  Hydroquinone  was  prepared  by  resuspending  in  100µl 
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dH2O. Desulfonation Buffer was prepared by combining 22µl Buffer B with 88µl dH 2O and 110µl 
100% isopropanol. These three buffers were prepared fresh to be used on the same day. 200ng 
of genomic DNA was mixed with 7µl Hydroquinone and 120µl Conversion Buffer and made up 
to 140µl with dH2O. This was placed in a thermocycler for three minutes at 94°C followed by 
nine hours at 50°C.
500 µl DNA Binding Buffer was mixed with the converted DNA which was then pipetted into a  
DNA purification column. This was spun at 10,000 rpm for 30 seconds in a microcentrifuge 
(Centrifuge 5415 C, Eppendorf Ltd., UK), and the collection tube emptied. 200µl DNA Wash 
Buffer was added to the column which was then span at 10,000 rpm for 30 seconds. 200µl  
Desulfonation  Buffer  was  added to  the  column and  incubated  at  room temperature  for  20 
minutes before spinning at 10,000rpm for 30 seconds. 200µl of DNA Wash Buffer was then 
added and the column spun at 10,000rpm for 30 seconds. The column was then placed in a 
new 1.5ml microcentrifuge tube and 50 µl of DNA Elution buffer was pipetted onto the surface of 
the column filter. This was incubated at room temperature for 3 minutes before spinning down at  
10,000rpm for 30 seconds. The eluted solution was the purified converted DNA ready for PCR.
2.2.8 Bisulfite conversion of DNA using Qiagen EpiTect 96-well format
9 ml of dH2O was added to Bisulfite Mix (Qiagen) and mixed by vortexing until fully dissolved. 2 
µl DNA (5 ng/µl) was added to each well of an EpiTect Conversion Plate (Qiagen). 38 µl dH2O, 
85 µl Bisulfite Mix and 15 µl of DNA Protect Buffer (Qiagen) were added to each well and mixed 
by vortexing. The plate was span in a centrifuge (Sorvall Legend RT, Thermo Scientific) at 650 g 
to collect the liquid at the bottom of the wells. The conversion reaction was placed in a thermal  
cycler using the following programme: 95°C for 5 minutes, 60°C for 25 minutes, 95°C for 5 
minutes, 60°C for 1 hour and 25 minutes, 95°C for 5 minutes and finally 60°C for 2 hours and 55 
minutes.
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The converted DNA was spun in a centrifuge at 650 g to collect the liquid at the bottom of the 
wells. An EpiTect 96 Plate (Qiagen) was placed onto a QIAvac vacuum manifold (Qiagen) and 
560 µl freshly prepared Buffer BL containing 10 μg/ml carrier RNA (Qiagen) was pipetted into  
each well of the EpiTect 96 Plate. The converted DNA was then added to the EpiTect 96 Plate 
and mixed with the Buffer BL by pipetting 4 times. The vacuum source was switched on and 
once the liquid had passed through the membrane, switched off. 500 µl of Buffer BW (Qiagen)  
was added to each well of the EpiTect 96 Plate. The vacuum source was switched on and once 
the liquid had passed through the membrane, switched off. 250 µl of Buffer BD (Qiagen) was  
added to each well of the EpiTect 96 Plate and incubated at room temperature (15–25°C) for 15 
minutes. The vacuum source was switched on and once the liquid had drained through the 
membrane, switched off. 500 µl of Buffer BW (Qiagen) was added to each well of the EpiTect 96  
Plate.  The  vacuum source  was  switched  on  and  once  the  liquid  had  passed  through  the 
membrane, switched off. 500 µl of Buffer BW (Qiagen) was added to each well of the EpiTect 96  
Plate.  The  vacuum source  was  switched  on  and  once  the  liquid  had  passed  through  the 
membrane, switched off. 250 µl of ethanol (100% v/v, Sigma-Aldrich, Inc.) was added to each 
well  of  the EpiTect  96 Plate.  The vacuum source was switched on and left  running for  10  
minutes  after  the  ethanol  had  passed  through  the  membrane.  The  EpiTect  96  Plate  was 
removed from the vacuum manifold and tapped onto absorbent paper in order to remove any 
remaining ethanol. The waste tray of the vacuum manifold was removed and replaced with an 
EpiTect Elution Plate (Qiagen). 70 µl of Buffer EB (Qiagen) and 10 µl of Top Elute Fluid (Qiagen)  
were dispensed into each well of the EpiTect Plate. The vacuum source was switched on for 1  
minute to elute the DNA.
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2.2.9 Positive control nested PCR
This was performed to confirm that the bisulfite conversion was successful and included two 
reactions: an outer PCR followed by an inner PCR. 4.6 µl H2O, 1 µl Amplitaq Gold Buffer, 1 µl 
dNTPs (10mM), 1.2 µl MgCl2 (25mM), 1 µl p16 Outer Primer Mix (10µM), 0.2 µl AmpliTaq Gold 
(5U/ µl) (Applied Biosystems) was mixed with 1 µl of converted DNA. 10ng of unconverted DNA 
was used as a negative control. PCR was then carried out at 94°C for 10 minutes followed by  
40 cycles of 94°C for 30 seconds, 50°C for 30 seconds and 72°C for 30 seconds and ending  
with 72°C for 5 minutes.
This PCR reaction was then diluted 500-fold and used as a template in the following inner PCR 
reaction. 4.6 µl H2O, 1 µl Amplitaq Gold Buffer, 1 µl dNTPs (10mM), 1.2 µl MgCl2 (25mM), 1 µl 
p16 Inner Primer Mix (10µM), 0.2 µl AmpliTaq Gold (5U/ µl) was mixed with 1 µl of diluted outer  
PCR product. 10ng of unconverted DNA was used as a negative control. PCR was then carried  
out at 94°C for 10 minutes followed by 40 cycles of 94°C for 30 seconds, 50°C for 30 seconds 
and 72°C for 30 seconds and ending with 72°C for 5 minutes. The 10 µl PCR reaction was then  
mixed with 2 µl 6x DNA loading buffer and the sample loaded onto a 2.5%(w/v) agarose gel in  
1x TBE. The gel was run until the dye front was near the end of the gel.
2.3 Statistical Analysis
2.3.1 Qualitative trait analysis
Analysis  was  performed  using  PLINK v1.07  (http://pngu.mgh.harvard.edu/purcell/plink/)400. 
Association to obesity was analysed by comparing allele frequencies using the chi-squared test 
and one million permutations to give accurate empirical p-values that did not need correction for 
multiple testing. Odds ratios are reported with a 95% confidence interval.
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2.3.2 Quantitative trait analysis
Analysis for association to BMI was performed with PLINK v1.07 using the linear model with age 
and sex as covariates. One million permutations were used to correct for false-positives.
2.3.3 Family-based association analysis
Mendelian errors were detected using Pedstats401 while genotypes that resulted in tight double 
recombinants  were  identified  with  Merlin  and  treated  as  missing  data  in  the  analyses402. 
Association to BMI was analysed using the QFAM procedure in PLINK v1.07 using the within-
families model of association and one million permutations to correct for multiple testing.
2.3.4 Linkage disequilibrium (LD)
LD was  calculated  and  displayed  from the  genotype  data  of  the  controls  using  Haploview 
v4.0397.  Linkage  disequilibrium  blocks  were  identified  using  the  confidence  interval  method 
described by Gabriel  et al.403 as implemented in Haploview 4.0. Haplotypes were constructed 
and analysed for association using PLINK v1.07. Individuals who had missing genotypes were 
excluded from this analysis.
2.3.5 Imputation
Genotypes were imputed using the 1000 genomes phase 1 integrated variant set release (NCBI 
build 37)265. IMPUTE2 software was used for imputation404,405 and SNPTEST v1.1.5 for analysing 
the imputed data for association406.
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2.3.6 Analysis of transcription data
To correct for relatedness between siblings, regressions were evaluated with a clustering option 
within families using R v2.8.1  (http://www.r-project.org/;  see Appendix for R commands used). 
Data was analysed for normality using a Q-Q plot in SPSS v17.0. An independent samples t-test 
was used to compare transcript levels between obese and non-obese siblings and data was 
displayed  with  box  plots  using  R  v2.8.1  (see  Appendix  for  R  commands  used).  BMI  and 
transcript  data  were  plotted  using  Excel  2007  (Microsoft  Inc.).  All  r2 calculations  and  their 
corresponding p-values were calculated using R v2.8.1 (see Appendix for R commands used).
2.3.7 Statistical power calculations
Power calculations were carried out using PSv3.0.14407. Assuming an alpha of 0.005, (the p-
value threshold that would be used if testing ten independent SNPS) a MAF of 0.5 and an odds 
ratio  of  1.2  then  the  null  hypothesis  that  the  odds  ratio  equals  1  can  be  rejected  with  a 
probability (i.e. power) of 23% in the French adult case-control subjects (see Figure 2.1) and 
17% in the French child case-control subjects (see Figure 2.2). With a MAF of 0.05 this power is  
reduced to 3.3% in the adults and 2.9% in the children (see Figures 2.1 and 2.2). Statistical  
power will drop substantially if using a significance level of 5x10-8 (genome-wide significance).
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Figure 2.1. Statistical power using adult case-control subjects (896 cases and 1237 controls) 
plotted against odds ratio for three different minor allele frequencies (MAF) assuming an alpha 
of 0.005.
Figure 2.2. Statistical power using child case-control subjects (637 cases and 1237 controls) 
plotted against odds ratio for three different minor allele frequencies (MAF) assuming an alpha 
of 0.005.
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For quantatitive triat analysis in the French controls, assuming a statistical significance of 0.005 
(ten tests), a MAF of 0.5, a difference in mean BMI between alleles of 0.5 and an SD of 2.1 (as 
observed for BMI in all 1237 French controls) power is calculated to be 87%. With a MAF of 0.1 
this drops to 34% and for MAF of 0.05, 15% (see Figure 2.3).
Figure 2.3. Statistical power for analysing BMI in the French controls (n=1237). Difference in  
population means is measured in BMI units. This assumes a SD of 2.1 (as observed for BMI in  
all 1237 French controls) and a statistical significance of 0.005 (ten tests).
Power calculations specific for each gene investigated in this thesis appear in their respective  
results chapters.
2.3.8 Analysis of sequence data
Sequence  data  was  analysed  using  SeqScape  v2.0  (Applied  Biosystems).  Reference 
sequences  were  imported  in  Genbank  format  from  the  NCBI  website 
(http://www.ncbi.nlm.nih.gov/gene). Sequencing  data  was  then  aligned  with  the  reference 
sequence to locate variants within the test sequences.
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2.3.9 Interpretation of bisulfite sequence data
Sequences were viewed and peak heights measured using Sequence Scanner software version 
1.0 (Applied Biosystems). Peak heights of cytosine residues within CpG sites were measured as 
a percentage of cytosine at that site (i.e. the height of the cytosine peak was divided by the sum 
of the height of the cytosine and thymine). This figure gives a conversion rate and indicates the 
amount of methylated DNA copies in a sample at that particular CpG site. When the reverse 
strand was sequenced, percentage of guanine to adenine was measured.
For  quality  control  purposes  two  non-CpG  cytosines  (guanines  in  reverse  strands)  were 
measured and if either site was less than 95% converted the sequence was rejected.
2.3.10 Statistical analysis of CpG methylation data
Percentage  methylation  was  treated  as  a  quantitative  trait  and  analysed  for  association  to 
obesity using an independent samples t-test implemented by SPSS version 17.0 (SPSS Inc.). It 
was also analysed for association with BMI corrected for age and sex using linear regression 
implemented in R v2.8.1 (see Appendix for R commands).
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Chapter 3
Investigation of genetic variants within the Sirtuin-1 
gene for association to common polygenic obesity
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3.1 Introduction
SIRT1 is the mammalian form of the yeast protein, silent information regulator 2 (SIR2)408, a 
protein  known to  be crucial  for  the  lifespan extending  effects  of  caloric  restriction  in  lower 
organisms409. The SIR2 family of enzymes catalyse deacetylation of acetylated lysine residues 
of certain proteins in a reaction that is dependent on the presence of nicotinamide adenine 
dinucleotide (NAD+)410.
SIRT1 is localised to the nucleus and in particular, is associated with euchromatin411. It facilitates 
the formation of heterochromatin, the tightly formed chromatin that is associated with histone 
hypoacetylation and gene repression412. SIRT1 was originally thought to be a histone-specific 
deacetylase as the first targets to be identified were the histones H1, H3 and H4412. However, a 
number of non-histone targets of SIRT1 have since been identified including the transcription 
factors, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB)413, Forkhead box 
1 (FOXO1)414, FOXO3a415 and p53416,417. Many of these transcription factor targets are involved 
in the regulation of energy metabolism.
3.1.1 SIRT1 regulates energy metabolism
SIRT1 stimulates lipid mobilisation and inhibits adipogenesis in WAT by repressing activity of  
the adipogenesis factor PPARg418. In skeletal muscle, SIRT1 stimulates fatty acid oxidation by 
activating PPARa and PPARg co-activator 1 alpha (PGC-1a)419. In the liver, SIRT1 suppresses 
glycolysis and stimulates hepatic glucose output and this also occurs  via stimulation of PGC-
1a420. It also suppresses lipid synthesis and stimulates lipid oxidation421,422. SIRT1 also activates 
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the mitochondrial enzymes acetyl-CoA synthetase 1 and 2423,424 which is thought to result  in 
reduction of the rate of fatty acid synthesis. Therefore SIRT1 acts in multiple tissue types to 
stimulate energy expenditure and promote a reduction in stored triglycerides thus potentially 
influencing the fat mass of the individual.
SIRT1 has been also found to act on insulin receptor substrate-1 (IRS1) and IRS2 indicating a 
possible  role  in  the  insulin  signalling  pathway425.  Furthermore,  in  pancreatic  β-cells,  SIRT1 
suppresses  activity  of  UCP2  which  results  in  reduced  uncoupling  of  mitochondrial  ATP 
production and an increased yield of ATP from glucose oxidation and ultimately stimulation of 
insulin secretion426. This means that SIRT1 can potentially regulate the uptake of glucose and 
lipids from the blood stream as well as appetite and energy expenditure in the hypothalamus. 
3.1.2 SIRT1   activity is regulated by metabolic factors  
SIRT1 activity is dependent on NAD+ which links it to the metabolic state of the cell409. SIRT1 
converts NAD+ to nicotinamide, and nicotinamide can non-competitively bind with and inhibit 
SIRT1 activity thus providing negative feedback control to this mechanism427. NAD+ levels have 
been shown to  rise  in  muscle,  liver  and white  adipose  tissue  (WAT) during fasting,  caloric 
restriction and exercise428,429. Conversely, a high-fat diet in mice reduces cellular NAD+ levels430. 
This then provides one mechanism by which energy levels can regulate SIRT1 activity.
As well as activity of the SIRT1 enzyme, its expression has also been found to be upregulated  
by fasting in fat, muscle, and brain tissues431,432,433. Additionally, SIRT1 is downregulated in mice 
fed a  high-fat  diet434.  Nutrient  withdrawal  appears  to  stimulate  expression of  SIRT1 via the 
transcription  factors  FOXO3a  and  p53435 suggesting  a  positive  feedback  loop  since  SIRT1 
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regulates activity of  these same transcription factors.  PPARg has been reported to  repress 
SIRT1 expression, which would suggest a negative feedback loop436. SIRT1 expression in the 
liver,  however,  appears  to  be  regulated  differently;  in  mice  SIRT1 is  reduced  by  caloric 
restriction and stimulated by a high-calorie diet433.
3.1.3 SIRT1  mouse models  
Over-expression of  the  SIRT1 gene in  mice results  in  inhibition of  adipogenesis,  enhanced 
lipolysis and release of free fatty acids and this has been shown to occur  via repression of 
PPARg418. Transgenic mice that over-express SIRT1 weigh less than control mice and have a 
lower WAT mass330. Specific over-expression of SIRT1 in pancreatic β-cells, leads to enhanced 
glucose-stimulated insulin secretion and ATP production  via repression of UCP2437. In  SIRT1 
knockouts, the resulting  mice have a higher body weight than controls and exhibit increased 
insulin  resistance,  glucose  intolerance  and  inflammation  in  both  WAT and liver332,421.  These 
mouse models,  therefore suggest  an important  role  for  the  SIRT1 gene in  ensuring proper 
regulation of energy balance and body-weight.
3.1.4 SIRT1 as a pharmacological target for treating metabolic disease
Resveratrol, a naturally occurring chemical found in grapes and red wines, activates SIRT1 and 
its administration to several species of invertebrate results in extended life span438,439.  In mice, 
resveratrol has been reported to improve health and survival in animals fed a high-calorie diet 440 
and in rats it has been shown to reduce the symptoms of diabetes441. In diet-induced obese 
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mice, daily oral dosing of resvertrol has been shown to reduce blood glucose levels and improve 
insulin  sensitivity419.  This  result  has  been  confirmed  in  fa/fa rats  with  both  resveretrol  and 
synthetic SIRT1 activators334. As such SIRT1 activators have been the subject of research in to 
possible therapeutics for the treatment of T2D334.
3.1.5  SIRT1  genetic variation and obesity  
In  2007  when  this  gene  was  selected  for  study,  no  reported  associations  between  SIRT1 
variation and obesity were found in the literature.  Three such studies have been published 
since. Firstly, in a Belgian chort, one SNP, rs7069102 was found to be associated to obesity in a 
case-control analysis of around 1400 subjects (p=0.007)442. Another SNP, rs2273773 was then 
reported to be associated with BMI in a Dutch population (n=3575, p=0.001)443 and in a third 
publication that used two Dutch cohorts (n=6,251 from a population-based study and n=2347 
from a family-based study) two SNPs, rs7895833 and rs1467568 were associated with both BMI 
(p=0.02 and 0.008) and obesity (p=0.007 and 0.0009)444. SIRT1 mRNA expression has also 
been reported to be associated with obesity. In a Danish study, transcription levels in adipose 
were found to be significantly increased in lean compared to obese women (n=24, p<0.02)337. 
This  study also demonstrated an increase in  SIRT1  expression after  six  days  of  fasting in 
humans (n=9).
SIRT1 variants have not been found to be significantly associated with obesity or BMI in any  
GWAS to date. In the French GWAS, which used some of the same sample as this study253, no 
SNPs within the SIRT1 region were found to have a p-value of <0.05. The most recent GIANT 
GWAS233 found a nominally significant p-value of 1.2x10-4 to rs471962, a SNP within the SIRT1 
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region (data acessed online445, see Figure 3.1).   The SIRT1 gene contains a number of SNPs 
validated in the NCBI database but not present in the HapMap, which means that it is possible 
that a portion of variation in the gene has not been investigated for association with obesity or 
BMI.
Figure 3.1. SNPs analysed for association to BMI in SIRT1 region in the GIANT GWAS233.
In  summary,  SIRT1 has  an important  role  in  energy  regulation and as such  is  a  plausible 
candidate  gene  for  polygenic  obesity.  This  study  was  designed  to  investigate  possible 
associations between variants in the SIRT1 gene and common polygenic obesity in French 
obese cases and non-obese controls. A Swedish sib-pair cohort was used for replication and for 
investigating possible associations between SIRT1 expression in adipose tisse and obesity (see 
Materials and Methods for details).
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3.2 Results
3.2.1 SNP Selection and Case-Control Genotyping
Twenty-seven SNPs were genotyped within the SIRT1 gene including three tag SNPs which 
captured all twenty-one SNPs included in the HapMap database (mean r2=0.975)(See Figure 
3.2). Twenty-two SNPs achieved acceptable genotyping rates (>85%) with a mean call rate of  
90.2%. Eleven of these had minor allele frequencies lower than the required minimum of 5% 
and were not  taken forward for  statistical  analysis  (See Table  3.1).  Of  the three tag SNPs 
genotyped, two passed QC, rs12413113 and rs11596401. 
Figure 3.2. Schematic diagram of the SIRT1 gene showing the positions of SNPs successfully 
genotyped in this study. • tagging SNPs, █ SIRT1 exons.
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SNP Position on Chromosome 10 a
Position within SIRT1 
gene
Minor Allele 
Frequency
rs33957861 69646976 Intron 1 0.12
rs737477 69647605 Intron 2 0.06
rs2236318 69648569 Intron 2 0.45
rs34122272 69650069 Intron 3 <0.01
rs10823103 69650969 Intron 3 0.31
rs12413112 69651866 Intron 4 0.12
rs11599176 69653775 Intron 4 0.12
rs10997865 69655315 Intron 4 0.35
rs11596401 69656037 Intron 4 0.34
rs2894057 69656790 Intron 4 <0.01
rs35689145 69659767 Intron 4 0.08
rs33955981 69661358 Intron 4 0.31
rs41274092 69666657 Exon 5 <0.01
rs36067477 69666666 Exon 5 <0.01
rs3818292 69666901 Intron 5 0.04
rs34414573 69667359 Intron 5 0.01
rs11594238 69668495 Intron 6 <0.01
rs7073231 69669607 Intron 7 <0.01
rs10997871 69672935 Intron 8 <0.01
rs35592342 69674262 Intron 8 0.02
rs35224060 69676297 Exon 9 <0.01
rs2234975 69678078 3’ Untranslated Region 0.09
Table 3.1. SNPs genotyped within the SIRT1 gene and minor allele frequencies observed in the 
case-control subjects. aPositions in bp correspond to NCBI build 37.1 measured from the top of 
the p arm of the chromosome. 
One SNP, rs2234975 was found to be nominally associated with obesity in children (p=0.018, 
OR=  0.74  CI=  0.57-0.95)  but  this  does  not  withstand  correction  for  multiple  tests  using 
permutations (p=0.123). No association was observed between this SNP and obesity in the 
adult cohort.  Four SNPs, rs33957861 (p= 0.006, OR= 0.75, CI= 0.61-0.92), rs12413112 (p= 
0.013,  OR=  0.77,  CI=  0.63-0.95),  rs11599176  (p=  0.003,  OR=  0.74,  CI=  0.61-0.90)  and 
rs35689145 (p= 0.015, OR= 0.74, CI= 0.58-0.95) were nominally associated with severe obesity 
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in adults and two of these SNPs survive correction using one million permutations (rs33957861, 
p=0.034  and  rs11599176,  p=0.019).  None  of  these  SNPs  were  associated  with  obesity  in 
children.  All  associated  SNPs  had  a  greater  frequency  of  the  minor  allele  in  the  controls 
compared to the cases, suggesting a protective effect (See Table 3.2). 
91
Genotype Counts
Controls Obese Adults Obese Children
SNP 1,1a 1,2 2,2 1,1 1,2 2,2 1,1 1,2 2,2
Odds Ratio Adults 
(95% CI)
P-values Adults
Empirical Corrected
Odds Ratio 
Children (95% CI)
P-values Children
Empirical Corrected
rs33957861 874 254 21 663 133 14 482 121 8 0.75 (0.61-0.91) 0.0057 0.034b 0.85 (0.69-1.1) 0.15 0.66
rs737477 1051 132 6 449 56 1 504 69 5 0.94 (0.69-1.3) 0.72 1.0 1.14 (0.86-1.5) 0.38 0.95
rs2236318 319 568 223 249 388 146 176 282 124 0.91 (0.8-1.0) 0.17 0.68 0.99 (0.86-1.2) 0.94 1.0
rs10823103 503 475 111 378 311 66 286 223 62 0.88 (0.76-1.0) 0.086 0.43 0.93 (0.79-1.1) 0.35 0.92
rs12413112 876 238 22 671 149 7 457 119 7 0.77 (0.63-0.95) 0.013 0.085 0.91 (0.73-1.1) 0.40 0.96
rs11599176 886 261 25 684 156 8 463 122 9 0.74 (0.61-0.9) 0.0025 0.019b 0.87 (0.71-1.1) 0.22 0.77
rs10997865 480 511 129 354 323 81 249 264 71 0.9 (0.78-1.0) 0.14 0.60 1.02 (0.88-1.2) 0.80 1.0
rs11596401 468 520 123 339 329 70 254 255 72 0.89 (0.77-1.0) 0.083 0.44 0.99 (0.86-1.2) 0.94 1.0
rs35689145 948 187 9 693 107 1 526 80 4 0.74 (0.58-0.94) 0.015 0.10 0.79 (0.61-1.0) 0.076 0.39
rs33955981 518 456 115 389 333 76 280 243 60 0.95 (0.83-1.1) 0.47 0.98 0.98 (0.84-1.2) 0.83 1.0
rs2234975 952 220 7 720 132 9 499 75 6 0.87 (0.7-1.1) 0.19 0.73 0.74 (0.57-0.95) 0.018 0.12
Table 3.2. Allelic association analysis of SIRT1 SNPs to obesity in children and adult French case-controls. a 1 denotes the common allele and 2 denotes the rare 
allele, b Statistically significant p-values. Corrected p-values result from one million permutations.
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SIRT1 SNPs were analysed for association to BMI within the control groups using age and sex as 
covariates. No SNPs were found to be associated (see Table 3.3). 
Mean BMI (Standard Deviation)
SNP 1,1a 1,2 2,2
Empirical 
P-value
Corrected 
P-value
rs33957861 21.8 (2.1) 22.6 (2.1) 22.4 (2.2) 0.22 0.91
rs737477 23.4 (1.1) 22.3 (2.2) 22.4(2.1) 0.87 1.0
rs2236318 22.2 (2.1) 22.4 (2.1) 22.4 (2.2) 0.97 1.0
rs10823103 22.2 (2.1) 22.4 (2.2) 22.4 (2.1) 0.64 1.0
rs12413112 22.0 (2.0) 22.5 (2.1) 22.4 (2.1) 0.24 0.92
rs11599176 22.0 (2.2) 22.6 (2.1) 22.4 (2.1) 0.36 0.99
rs10997865 22.2 (2.0) 22.4 (2.2) 22.4 (2.1) 0.79 1.0
rs11596401 22.1 (2.1) 22.4 (2.2) 22.4 (2.1) 0.61 1.0
rs35689145 21.8 (2.1) 22.6 (2.2) 22.4 (2.1) 0.11 0.68
rs33955981 22.4 (2.0) 22.5 (2.2) 22.4 (2.1) 0.46 1.0
rs2234975 22.6 (1.3) 22.2 (2.2) 22.4 (2.1) 0.41 0.99
Table 3.3. Association analysis of SIRT1 SNPs to the quantitative trait of BMI in French controls using 
age and sex as covariates. a 1 denotes the common allele, 2 denotes the minor allele.
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A high degree of linkage disequilibrium (LD) was found throughout the gene especially between the 
four SNPs nominally associated with adult  obesity with r2 values ranging from 0.63 to 0.96 (See 
Figure 3.3). The two SNPs that were significantly associated with obesity after permutation correction 
were in strong LD with one-another with r2=0.96. One LD block was identified using the confidence 
interval method described by Gabriel et al.403 between rs2236318 and rs33955981. 
Figure 3.3. Linkage disequilibrium (r2) plot of SIRT1 SNPs genotyped in the French control samples. 
Black squares indicate 100% LD and white squares indicate zero LD. The percentage LD level (r2) 
within grey squares are displayed.
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Haplotype analysis using the four nominally associated SNPs revealed a significant association to 
obesity  (p=0.028  after  one  million  permutations).  Haplotype  analysis  performed  on  the  two 
significantly associated SNPs, rs33957861 and rs11599176 revealed a more significant association to 
obesity than was found for any individual SNP (p=0.001 after 1 million permutations) (See Table 3.4).
SNP 1 SNP 2 SNP 3 SNP 4
Empirical 
p-value
Corrected 
p-value
rs33957861 rs12413112 rs11599176 rs35689145 0.0083 0.028a
rs33957861 rs12413112 rs11599176 - 0.022 0.067
rs33957861 rs12413112 rs35689145 - 0.027 0.081
rs33957861 rs11599176 rs35689145 - 0.019 0.059
rs12413112 rs11599176 rs35689145 - 0.049 0.14
rs33957861 rs12413112 - - 0.0011 0.0030a
rs33957861 rs11599176 - - 0.00040 0.0010a
rs33957861 rs35689145 - - 0.020 0.062
rs12413112 rs35689145 - - 0.010 0.034a
rs12413112 rs11599176 - - 0.0029 0.0089a
rs11599176 rs35689145 - - 0.0054 0.014a
Table  3.4. Haplotype  association  analysis  to  obesity  in  adults  using the four  SNPs found to  be 
nominally associated with adult obesity.  a  Statistically significant p-values. Corrected p-values result 
from one million permutations. 
3.2.2 Genotyping within the Swedish sib-pair cohort
Genotyping was carried out in the Swedish families using the same set of Sequenom iPlex assays. 
Genotyping success rate averaged 94% for the five SNPs nominally associated within the French 
case control  analysis.  These SNPs were analysed for association with BMI using the  QFAM test 
within PLINK.  Four SNPs,  rs11599176,  rs12413112, rs33957861 and rs35689145 were nominally 
associated with BMI (p=4.5x10-4, 5.7x10-4, 4.5x10-4 and 0.057 respectively, see Table 3.5). These are 
the  same four  SNPs nominally associated with  adult  obesity.  At  each SNP,  the minor  allele  was 
associated with a reduced BMI with a difference of  up to 2.8kg/m2 between the two homozygote 
genotypes.  After  correction  using  one  million  permutations,  three  SNPs  remained  significant, 
rs11599176 (p=0.014), rs12413112 (p=0.019) and rs33957861 (p=0.014)(see Table 3.5). 
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Genotype 
Numbers Mean BMI ± 95% CI (kg/m2)
SNP 1,1a 1,2 2,2 1,1 1,2 2,2
Empirical 
p-value
Corrected 
p-value
rs33957861 487 133 9 29.2 ± 0.55 28.4 ± 1.2 26.4 ± 3.0 0.0045 0.014b
rs12413112 478 129 8 29.3 ± 0.56 28.4 ± 1.2 26.4 ± 3.3 0.0057 0.019b
rs11599176 481 132 9 29.3 ± 0.56 28.4 ± 1.2 26.8 ± 3.0 0.0045 0.014b
rs35689145 534 82 2 29.1± 0.54 28.3 ± 1.5 31.6 ± 8.9 0.057 0.088
rs2234975 522 91 11 29.2 ± 0.57 28.8 ± 1.1 26.8 ± 2.5 0.99 0.99
Table 3.5. Association analysis of SIRT1 SNPs with BMI in the Swedish families using the QFAM test 
and the within-families model of association correcting for age and sex as implemented by PLINK. a 1 
denotes the common allele and 2 denotes the rare allele, b statistically significant p-values. Corrected 
p-values result from one million permutations.
Haplotypes  of  the  four  associated  SNPs  were  imputed  and  tested  for  association  to  BMI.  After 
correction, five haplotypes were significantly associated; however p-values were higher than for the 
individual  SNPs  with  the  most  significant  haplotype  of  the  three significantly  associated  SNPs 
(rs33957861, rs12413112 and rs11599176; p=0.017; see Table 3.6.)
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SNP 1 SNP 2 SNP 3 Empirical P-value Corrected P-value
rs33957861 rs12413112 rs35689145 0.045 0.073
rs33957861 rs12413112 rs11599176 0.0053 0.017a
rs35689145 rs12413112 rs11599176 0.069 0.099
rs33957861 rs12413112 - 0.018 0.048a
rs33957861 rs11599176 - 0.011 0.033a
rs33957861 rs35689145 - 0.14 0.19
rs12413112 rs35689145 - 0.11 0.15
rs11599176 rs35689145 - 0.018 0.050a
rs12413112 rs11599176 - 0.011 0.034a
Table 3.6. Haplotype association analysis of SIRT1 SNPs with BMI in the Swedish families using the 
QFAM  test  and  the  within-families  model  of  association  implemented  by  PLINK.  a  Statistically 
significant p-values. Corrected p-values result from one million permutations.
3.2.3 Analysis of  SIRT1  t ranscription  
Gene expression data from subcutaneous adipose tissue of the Swedish sib-pairs was available for  
analysis. This data was obtained from an eQTL study which used an Affymetrix Human Genome U133 
Plus 2.0 gene expression array to measure genome wide transcript levels396.
There  was  no  significant  association  between  SIRT1 SNPs  and  SIRT1 transcript  levels  after 
correcting for the effects of age, sex and BMI (see Table 3.7). 
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Genotype 
Numbers
Mean SIRT1 Transcription (95% CI)
SNP 1,1a 1,2 2,2 1,1 1,2 2,2 Empirical P-value Corrected P-value
rs33957861 256 73 6 0.18 (-0.21 – 0.59) -0.44 (-1.2 - 0.28) -3.2 (-5.29 - -1.03) 0.90 0.89
rs12413112 254 71 5 0.19 (-0.20 – 0.60) -0.26 (-1.0 -0.48) -3.7 (-6.01 - -1.31) 0.66 0.66
rs11599176 254 72 6 0.19 (-0.20 – 0.60) -0.17 (-0.91 – 0.57) -3.2 (-5.3 - -1.0) 0.78 0.79
rs35689145 280 48 2 0.010 (-0.36 – 0.38) -1.1 (-2.1 – -0.11) -2.5 (-6.0 – 1.0) 0.060 0.072
rs2234975 285 42 8 0.0073 (-0.37 – 0.39) 0.16 (-0.84 – 1.1) 2.1 (-0.15 – 4.4) 0.63 0.57
Table 3.7. Association analysis of SIRT1 SNPs with SIRT1 expression corrected for age, sex and BMI in the Swedish families using the QFAM test and the within-
families model of association implemented by PLINK. a1 denotes the common allele and 2 denotes the rare allele.
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When  siblings  were  split  into  two  groups  of  non-obese  (BMI<30  kg/m2)  and  obese 
(BMI>30kg/m2)  and the transcription levels  corrected for age,  sex and relatedness,  the two 
groups were normally distributed as assessed using a normal Q-Q plot. Using an independent 
samples t-test, a significant difference in the level of SIRT1 transcription was found between the 
two groups (p=1.56x10-35, see Figure 3.4 and Table 3.8). When corrected  SIRT1 transcription 
was  plotted  against  BMI,  a  negative  correlation  was  observed  in  the  lean  group  (r 2=0.13, 
p=3.37x10-7, see Figure 3.5), however this was not the case in the obese group (r2= 0.012, 
p=0.17, see Figure 3.6).
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Figure 3.4. Box-plot of SIRT1 transcript levels in obese and non-obese subjects from Swedish 
sib-pairs.  SIRT1  transcription  is  the  microarray  signal  value  corrected  for  age,  sex  and 
relatedness. Mean transcription ± standard deviation were 2.26 ± 4.08 in the non-obese and 
-2.93 ± 3.13 in the obese group.
Number of 
Non-obese
Number of 
Obese
Mean Difference in SIRT1 
transcription (95% CI) P-value
190 156 5.2 (4.5-5.9) 1.6x10-35
Table 3.8. T-test of SIRT1 transcription in obese and non-obese subjects from Swedish families. 
SIRT1 transcription is the microarray signal value corrected for age, sex and relatedness.
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Figure 3.5. SIRT1 transcription levels plotted against BMI in non-obese siblings (n=196, r2 = 
0.13, p=3.4x10-7 ). SIRT1 transcription was the DNA microarray signal value corrected for age, 
sex and relatedness.
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 Figure 3.6. SIRT1 transcription levels plotted against BMI in obese siblings (n=156 ,r2= 0.012, 
p=0.17) . SIRT1 transcription was the DNA microarray signal value corrected for age, sex and 
relatedness.
3.2.4 Sequencing of  SIRT1  
Sequencing was carried out in order to find variants in LD with associated SNPs in an attempt to 
locate the causative mutation. Ten subjects were chosen that were homozygous for each of the 
four minor alleles associated with adult obesity.  A further nine subjects were sequenced that 
were  homozygous  for  the  minor  allele  of  rs2234975  (associated  with  obesity  in  children). 
Subjects that had the minor variant for adult associated SNPs were chosen such that they had 
the  common variant  for  the  child  associated  SNP and  vice  versa.   One sample  that was 
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homozygous for each minor allele associated with both adult and childhood obesity was also 
included. Eleven PCRs were carried out covering the nine exons in SIRT1 along with ten PCRs 
covering the 3kbp region upstream of the transcription start site. This was followed by direct  
sequencing.
One SNP was discovered  within  the  promoter  of  the samples that  carried the  minor  allele 
variant associated with obesity in the adult cohort. This was located 1348bp upstream of the 
SIRT1 transcription start site and identified as rs12778366. Four SNPs were discovered within 
the promoter  of  the samples  that  contained  the  minor  allele  of  the  variant  associated with 
obesity in the child smples. These were located 86bp, 210bp, 1085bp and 2473bp upstream of  
the  transcription  start  site  and  were  identified  as  rs2394443,  rs932658,  rs3758391  and 
rs12250285. One SNP was discovered within the promoters of all samples. This was located 
1759bp upstream of the transcription start  site and was identified as rs10740280. No SNPs 
were found within any of the SIRT1 exons (see Figure 3.7).
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Figure 3.7. SNPs discovered within the SIRT1 gene promoter region in samples that carried the 
minor allele variants associated with obesity. Positions are relative to the transcriptional start of  
SIRT1. 
3.2.5 Case-control genotyping in promoter
Genotyping  of  the  SIRT1 promoter  SNPs was  then  carried  out  in  the  French  case-control 
subjects. Each of the six SNPs discovered above were genotyped along with four additional  
SNPs, which were chosen from the four kilobase promoter region of  the gene in the NCBI 
database. Of these, five passed quality control, which included three of the six discovered SNPs 
including the one SNP that was found to be in LD with SNPs associated with adult obesity, 
rs12778366 (see Table 3.9).
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SNP Position on Chromosome 10 (bp)a Minor Allele Frequency
rs12246428 69640165 <0.01
rs12778366 69643079 0.12
rs3758391 69643342 0.31
rs35706870 69643617 0.13
rs3740051 69643959 0.06
rs932658 69644217 0.32
Table  3.9.  SIRT1  promoter  SNPs successfully  genotyped with  the  minor  allele  frequencies 
observed in the case-control subjects. a Positions in bp correspond to NCBI build 37.1 measured 
from the top of the p arm of the chromosome. 
No SNPs were associated with obesity in either adults or children. Association analysis was 
carried out together with the previous set of SNPs in order to obtain corrected p-values that  
reflect the additional statistical tests being used. These results are presented in Table 3.10. After 
this correction was applied, two SNPs remain significantly associated with obesity in adults, 
rs33957861 (corrected p=0.048) and rs11599176 (corrected p=0.026). LD analysis within the 
control samples revealed some LD between rs12778366 and the adult associated SNPs (r2  = 
0.42 – 0.69), however very little  LD was observed to any other promoter SNP. No LD was 
observed between the child associated SNP, rs2234975 and any promoter SNP (see Figure 
3.8).
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Genotype Counts
Controls Obese Adults
Obese 
Children Obese Adults Obese Children
SNP
Position Within 
SIRT1 Gene 1,1a 1,2 2,2 1,1 1,2 2,2 1,1 1,2 2,2
Odds ratio 
(95% CI)
Empirical 
P-value
Corrected 
P-value
Odds ratio 
(95% CI)
Empirical 
P-value
Corrected 
P-value
rs12778366 Promoter 14 161 697 20 261 912 9 116 468 0.84 (0.69-1.0) 0.080 0.52 0.89 (0.72 - 1.1) 0.32 0.96
rs3758391 Promoter 76 370 420 121 526 555 69 245 285 0.92 (0.8-1.1) 0.22 0.87 1.0 (0.87 - 1.2) 0.90 1.0
rs35706870 Promoter 9 197 662 20 270 908 14 119 466 0.95 (0.79-1.2) 0.60 1.0 0.93 (0.76 - 1.2) 0.54 1.0
rs3740051 Promoter 4 78 644 5 122 1068 4 67 520 1.1 (0.81-1.4) 0.60 1.0 1.19 (0.89 - 1.6) 0.25 0.91
rs932658 Promoter 77 372 418 122 523 541 66 241 280 0.91 (0.8-1.0) 0.17 0.79 0.98 (0.85 - 1.1) 0.82 1.0
rs33957861 Intron 1 874 254 21 663 133 14 482 121 8 0.75 (0.61-0.91) 0.0057 0.048b 0.87 (0.7 - 1.1) 0.21 0.86
rs737477 Intron 2 1051 132 6 449 56 1 504 69 5 0.94 (0.69-1.3) 0.72 1.0 1.14 (0.85 - 1.5) 0.40 0.99
rs2236318 Intron 2 319 568 223 249 388 146 176 282 124 0.91 (0.8-1.0) 0.17 0.79 0.99 (0.86 - 1.2) 0.93 1.0
rs10823103 Intron 3 503 475 111 378 311 66 286 223 62 0.88 (0.76-1.0) 0.086 0.53 0.93 (0.8 - 1.1) 0.39 0.99
rs12413112 Intron 4 876 238 22 671 149 7 457 119 7 0.77 (0.63-0.95) 0.013 0.12 0.92 (0.74 - 1.2) 0.48 1.0
rs11599176 Intron 4 886 261 25 684 156 8 463 122 9 0.74 (0.61-0.90) 0.0025 0.026b 0.89 (0.71 - 1.1) 0.28 0.93
rs10997865 Intron 4 480 511 129 354 323 81 249 264 71 0.90 (0.78-1.0) 0.135 0.71 1.0 (0.88 - 1.2) 0.75 1.0
rs11596401 Intron 4 468 520 123 339 329 70 254 255 72 0.89 (0.77-1.0) 0.083 0.55 1 (0.86 - 1.2) 0.96 1.0
rs35689145 Intron 4 948 187 9 693 107 1 526 80 4 0.74 (0.58-0.94) 0.015 0.14 0.79 (0.61 - 1.0) 0.076 0.51
rs33955981 Intron 4 518 456 115 389 333 76 280 243 60 0.95 (0.83-1.1) 0.47 1.0 0.99 (0.85 - 1.2) 0.94 1.0
rs2234975 3’ Untranslated Region 952 220 7 720 132 9 499 75 6 0.87 (0.7-1.1) 0.19 0.82 0.72 (0.56 - 0.94) 0.018 0.13
Table 3.10. Association analysis of SIRT1 promoter SNPs in French case-controls analysed together with the original genotyped SNPs in order to take into account  
the additional statistical tests being performed. a 1 denotes the common allele and 2 denotes the rare allele,b P-values that are statistically significant after correction 
using one million permutations.
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Figure 3.8. LD (r2) plot within the French control samples containing all SNPs genotyped and 
analysed within  SIRT1 and its promoter region.  Black squares indicate 100% LD and white 
squares indicate zero LD. The percentage LD level (r2) within grey squares are displayed.
3.2.6 Imputation
An alternative method for fine-mapping the association involves imputation of genotypes from a 
reference population. Using the 1000 genomes data265, genotypes were imputed 250kb either 
side of the SIRT1 gene using IMPUTE2 which generated 7786 imputed SNPs404. SNPTEST was 
used to test case-control associations to the imputed SNPs taking into account the genotype 
uncertainty  of  imputed  data.  414 SNPs out  of  7786 tested  were  nominally  associated  with 
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obesity in the adult case-control cohort and 24 had p-values <10-5. with the most significant SNP, 
rs12776134  p=1.9x10-6  (see  Figure  3.9). In  the  child  case-controls  249  were  nominally 
associated but none had p-values <10-5. None of the most significantly associated SNPs (those 
with p-values <10-4) were in SIRT1 exons.
Figure 3.9. LocusZoom445 plot of imputed SIRT1 SNPs tested for association in the French adult 
case-control  cohort.  LD  values  measured  using  r2 are  from  1000  genomes  data  and  are 
displayed relative to rs12776134, the most significantly associated imputed SNP.
3.2.7 Statistical power calculations
Using an odds ratio of  0.74 (as observed for  rs11599176, the most significantly associated 
SNP), a MAF of 0.13 (as observed for rs11599176) and a significance level of 0.0045 (0.05/11 
tests),  the power to detect an association was 25% in the adult  cohort.  In the child cohort,  
assuming  an  odds ratio  of  0.87,  power  was  2.6% (see  Table  3.11).  In  order  to  achieve a 
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statistical power of 95%, assuming an odds ration of 0.74, a MAF of 0.13 and a significance 
level of 0.0045, this study would need a sample size of 4332 cases and 4332 controls. With a  
significance level of 5.0x10-8 (genome-wide significance), this study would require 10842 cases 
and 10842 controls (see Figure 3.10). If the effect size was smaller (odds ratio greater than 
0.74) then the sample size required to reach a statistical power of 95% increases (see Figure 
3.11).
SNP
Significance 
level
MAF 
(controls)
OR 
(children) OR (adults) Power (children) Power (adults)
rs33957861 0.0045 0.13 0.85 0.75 0.036 0.21
rs737477 0.0045 0.061 1.1 0.94 0.017 0.07
rs2236318 0.0045 0.46 0.99 0.91 <0.01 0.038
rs10823103 0.0045 0.32 0.93 0.88 0.015 0.066
rs12413112 0.0045 0.12 0.91 0.77 0.013 0.16
rs11599176 0.0045 0.13 0.87 0.74 0.026 0.25
rs10997865 0.0045 0.34 1.0 0.90 <0.01 0.043
rs11596401 0.0045 0.35 0.99 0.89 <0.01 0.055
rs35689145 0.0045 0.090 0.79 0.74 0.055 0.15
rs33955981 0.0045 0.32 0.98 0.95 <0.01 0.011
rs2234975 0.0045 0.099 0.74 0.87 0.117 0.026
Table 3.11. Power calculations carried out using MAF and OR observed for each SNP in the 
SIRT1 gene investigated.
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Figure  3.10. Sample  size  plotted  with  statistical  power  for  a  SNP with  MAF=0.13 (as  was 
observed for rs11599176). α is the significance level: 0.0045 for 11 statistical tests and 5x10 -8 for 
genome-wide significance.
Figure 3.11. Sample size (number of cases, with number of controls=number of cases) required 
for varying odds ratios in order to achieve a statistical power of 95% for a SNP with MAF=0.13  
(as was observed for rs11599176). α is the significance level: 0.0045 for 11 statistical tests and 
5x10-8 for genome-wide significance.
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Statistical power for quantitative trait analysis in the French control samples was 43% to detect  
an association with an effect size of 0.5 BMI units assuming a MAF of 0.13, a SD of 2.1 and a  
significance level of 0.0045. At genome-wide significance level this falls to <1%. Smaller effect 
sizes would result in less power (see Figure 3.12).
Figure 3.12. Statistical power against effect size in French controls assuming a MAF of 0.13 
and SD of 2.1 BMI units and a significance level of 0.0045.
For the sequencing project, the probability of locating a common variant (MAF>5%) in high LD 
(r2>0.8) with the associated SNPs using 10 samples was calculated to be >99%, assuming such 
a variant exists. The probability of locating a variant with MAF = 1% in moderate LD (r2=0.5) was 
calculated to be 98%. The probability of locating a variant with MAF = 0.1% in moderate LD 
(r2=0.5) was calculated to be 70% (see Appendix A7 for calculations).
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3.2.8 Thesis-wide multiple testing correction
When SIRT1 SNPs are analysed together with all other gene SNPs investigated in this thesis, 
no variants remain significantly associated to obesity in either adults or children after correction 
using permutations (see Table 3.12). 
SNP
Empirical P-
value Children
Corrected P-
value Children
Empirical P-
value Adults
Corrected P-value 
Adults
rs12778366 0.081 1.0 0.080 1.0
rs3758391 0.22 1.0 0.22 1.0
rs35706870 0.60 1.0 0.60 1.0
rs3740051 0.60 1.0 0.60 1.0
rs932658 0.17 1.0 0.17 1.0
rs33957861 0.15 1.0 0.0057 0.36
rs737477 0.38 1.0 0.72 1.0
rs2236318 0.94 1.0 0.17 1.0
rs10823103 0.35 1.0 0.086 1.0
rs12413112 0.40 1.0 0.013 0.64
rs11599176 0.22 1.0 0.0025 0.20
rs10997865 0.80 1.0 0.14 1.0
rs11596401 0.94 1.0 0.083 0.99
rs35689145 0.076 0.98 0.015 0.56
rs33955981 0.83 1.0 0.47 1.0
rs2234975 0.018 0.51 0.19 1.0
Table  3.12 P-values after  correcting for  multiple  testing using permutations  and taking into 
account all SNPs investigated in this thesis.
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3.3 Discussion
These results suggest  that  the hypothesis that  SIRT gene variation influences obesity risk  merits 
further investigation in larger sample sizes.  The lack of  genome-wide significance and replication 
means  that  an  association  has  not  been  conclusively  proven.  However,  the  observation  of  
associations between SIRT1 SNPs and obesity in French case-controls and BMI in Swedish families 
provides evidence of a possible association.
The  p-values  reported  here  do  not  withstand  a  genome-wide  correction  for  multiple  testing. 
Furthermore, permutation analysis using all SNPs tested within this thesis results in non-significance 
of all tests, which means that the possibility of a false positive cannot be ruled out.  If this investigation 
is treated as an independent test assessing whether SIRT1 variation is associated with obesity and 
permutation testing used to correct for multiple tests397. then two SNPs are found to be significantly 
associated with obesity in adults supporting the candidacy of SIRT1 as an obesity gene.
At each SNP the minor allele was present at a higher frequency within the controls compared to the  
cases indicating a protective association. In the Swedish siblings the minor allele was associated with  
a  lower  BMI,  again  indicating  a  protective  association.  In  the  most  extreme  case  the  minor 
homozygote had a BMI of 2.8 kg/m2 lower than the common homozygote although the small numbers 
and large 95% confidence interval range means that the measurable effect may not be accurate. The 
same  four  SNPs  that  were  nominally  associated  with  severe  obesity  in  adults  were  nominally 
associated in the families, which is evidence that this is a real genetic association. The failure to find 
an association between SNPs and BMI in the French control groups is likely due to the low level of  
variance in these cohorts (standard deviation = 2.1 kg/m²), which results in a reduced power to detect 
association (43%). Alternatively it is possible that this is an association that effects obesity risk without  
modifying BMI in the non-obese population.
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These results  support and expand on the three previously reported SIRT1 association studies.  The 
first of  these  reported  a  protective  association  between  the  SIRT1 SNP rs7069102  (tagged  by 
rs11596401 in our study with r2=0.956 in HapMap) and obesity (p=0.007)442. In this thesis, rs11596401 
was not significantly associated with obesity in either French adults (p=0.083) or children (p=0.94).  
The second discovered an association between minor genotypes in rs2273773 (genotyped but failed 
QC in this study) and reduced BMI (p=0.001)443. The third reported a protective association of SIRT1 
SNPs rs1467568 (p=0.0009) and rs7895833 (p=0.007) and obesity444. Rs7895833 is located 21kb 
upstream of SIRT1 and was not tagged by any SNP investigated in this project. Rs1467568 is tagged 
by  rs11596401 in  this  study  (r2=1.0  in  HapMap)  but  this  SNP was  not  found  to  be  significantly 
associated with obesity in this study (p=0.073 in adults and p=1.000 in children).
Because  the  same  SNPs  are  not  associated  in  different  studies,  the  association  has  not  been 
replicated and so further work is required in order to exclude the possibility of a false-positive. Since 
each study reported the minor allele being associated with a reduced risk of obesity or a reduced BMI 
this  is  evidence  that  the  same  effect  is  being  detected.  However,  the  fact  that  the  reported  
associations are to different markers means that the association has not been properly replicated. 
This could be due to the likely fact that the causative variant has not been identified and the variability 
between  studies  introduced  by  different  recruitment  criteria.  Phenotype  measurements  and 
genotyping success rates may also add to the variation between studies. Again, the fact that none of  
these tests would be significant in a geneome-wide context  means that the possibility of  a false-
positive cannot be ruled out and thus replication is required in other, larger cohorts. It should also be 
noted that the SIRT1 gene appears to be in a region of low recombination (see Figure 3.1) so it is 
possible that any associated SNPs may be tagging variants in other nearby genes such as HERC4, 
DNAJC12 and CTNNA3.
The absence of a significant association between SIRT1 gene variation and obesity in any genome 
wide association study could be due to the stringent requirements to correct for multiple testing, which 
could result in associations with weak effect sizes being screened out. The most significant  SIRT1 
variant in the most recent GIANT GWAS233 was rs471962 with a p-value of 1.25x10-4..  Whilst this p-
114
value  does not  reach  genome-wide  significance,  it  does  reach  nominal  significance  which  might 
indicate an association that requires larger sample sizes in order to be detected. Rs471962 is located 
169 kb downstream of the gene and so was not typed in this study. However it is in high LD (r 2>0.8 in 
the HapMap CEU population) with a number of other variants within the gene including rs10997860 
which is tagged by rs10823103 (r2=1.0) in this study. This SNP was not significantly associated with 
obesity (p=0.083 before correction). This might reflect the lower statistical power in the French case-
controls  compared  to  the  GIANT  study  which  used  ~250,000  samples.  The  GIANT  GWAS 
investigating associations to WHR analysed 17 SNPs within the SIRT1 gene and found no nominal  
associations262.
Of the five nominally associated SNPs only rs12413112 and rs2234975 are present in the HapMap 
database.  This  means  that  other  nominally  associated  SNPs,  rs33957861,  rs11599176  and 
rs35689145 are not tagged by any SNP using HapMap data. However, data presented in this thesis 
indicates that rs12413112 tags both rs33957861 and rs11599176 very well (r2=0.95 and 0.95) and 
rs35689145 reasonably well (r2=0.63). As such it  is likely that coverage of common (>5%) SIRT1 
SNPs in GWAS is sufficient.
The significant increase in SIRT1 transcript in non-obese compared to obese (p=1.56x10-35) and the 
correlation of  SIRT1 (p=3.37x10-7) expression  to BMI in non-obese sib-pairs supports the findings 
reported by a Danish study in which SIRT1 transcription was significantly higher in lean compared to 
obese women337 and provides further evidence for a role of SIRT1 in obesity. The lack of correlation in 
the obese sib-pairs may be due to the lower numbers and the lower variation in transcript levels in 
that group (n=196, SD=4.1 in non-obese; n=156, SD=3.1 in obese). 
No significant association was found between SIRT1 SNPs and expression of the gene. This might be 
due to the fact that the causative SNP was not genotyped. Alternatively,  SIRT1 variants might be 
affecting obesity risk without altering its transcription level. Instead, variants within the gene could be 
altering the activity of the Sirtuin 1 enzyme via a change in amino acid sequence or by modifying a 
splice site. Another possibility is that a mutation within the untranslated region of the mRNA might alter 
the efficiency of translation, perhaps by modifying its secondary structure and such mechanisms have 
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been observed446. This wouldn’t affect levels of mRNA that were measured but would change the level  
of SIRT1 protein produced. SIRT1 protein then might influence susceptibility to obesity via its effects 
on the expression of genes important in lipid and glucose metabolism.  SIRT1 transcription levels 
might then be modified by BMI via other mechanisms. For example, expression of SIRT1 is known to 
be increased by fasting in mice and humans337,447 and more recently levels of SIRT1 protein have 
been demonstrated to be increased after fasting in mice448.
Statistical power calculations indicate that this study was not sufficiently powered to detect statistically 
significant associations with the effect sizes that were observed. In order to achieve p-values that are 
significant in a genome-wide context, larger samples sizes are required, at least 10,000 cases and 
10,000 controls assuming an odds ratio of 0.74 which was observed for rs11599176. If this odds ratio  
is actually lower, as might be expected of a variant with small effect size not detected in any large 
GWAS, then more samples are needed. Power was similarly low when analysing association to BMI 
in the French controls. This means that any attempt to replicate an association should be carried out  
in much larger cohorts. Another method of increasing the statistical power would be to meta-analyse 
these data together with previously published results.
Since only two of the three tag SNPs genotyped in this study passed QC, coverage of the SIRT1 gene 
was not complete. The SNP that failed QC, rs2273773, was previously reported to be associated with 
BMI in a Dutch population443 and as such it  would be useful to know whether this association is 
replicated  in  the  cohorts  investigated  in  this  thesis.  Also,  complete  coverage  was  of  course  not 
achieved in this study because rare variants (<5%) were not investigated.
All associated SNPs are located within introns or in the case of rs2234975, the 3’ untranslated region, 
which means they do not alter the amino acid sequence of the Sirtuin 1 protein. It is therefore unlikely  
that  these SNPs are causative.  That  the haplotype analysis  generated a lower p-value than any 
individual SNP could be evidence that these SNPs are tagging a more significantly associated variant, 
although the high LD between these SNPs (r2=0.96) means that this difference in p-values may not be 
significant. This variant would most likely be located within an exon where it could alter the amino acid  
structure of the protein or within the promoter region where it could affect the expression of the SIRT1 
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messenger RNA. Sequencing was unable to locate any exonic SNPs within the same LD block of the 
obesity associated SNPs and of  the five SNPs genotyped within the promoter region, none were 
found to be associated with obesity in either adults or children. Power to detect variants with MAF 
>1% and in high LD (r2>0.8) with the associated SNPs was sufficiently high (>98%), however as MAF 
and LD values drop (MAF=0.1%, r2=0.5) this power is reduced (70%) and if the causative SNP is even 
rarer (<0.1%) then this will drop further. Thus the possibility of a false-negative cannot be ruled out.  
Furthermore since only 3kb of the promoter region was sequenced, all regulatory regions have not  
been investigated.
An alternative method for searching for the causative mutation is by imputation. Using 1000 genomes 
data265, around 7000 imputed SNPs in the SIRT1 region were generated and tested for association to 
obesity in the French case-controls. 24 SNPs were found to be associated with obesity in the adults  
with p-values of <10-5  with the most significant marker at p=1.9x10-6. Each of these 24 markers had 
MAF in the range of 1-2% and each had a higher frequency in the controls compared to the cases.  
None of these markers are within SIRT1 exons so no clear candidates for functional mutations have 
been found. The fact that the most significant markers were not all in high LD with one-another is  
interesting  since  it  suggests  that  if  these  results  are  genuine  that  there  may  be  two  or  more  
independent associations to obesity within the SIRT1 gene.
It is possible that using 1000 genomes data may not give accurate imputed SNPs since the ancestry 
of the two sample sets will not match. The IMPUTE2 software is designed to choose samples with 
matching haplotypes in order to get  the most accurate imputation.  However the small  number of  
genotyped SNPs in this study might introduce errors into this process compared to using a GWAS 
dataset with many more variants. An alternative method would be to sequence a subset of the French 
case-controls and use this for imputation.  Nevertheless,  the fact  that  imputation resulted in more 
significantly associated SNPs could be evidence of a real genetic association and although these p-
values still do not reach genome-wide significance, they would survive correction for 7000 statistical 
tests (p<7x10-6). In order to validate this result, the most significant hits would need to be genotyped 
to confirm their accuracy.
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Therefore a mechanism by which SNPs could affect phenotype has not been established in this study. 
More sequencing of the  SIRT1 gene, including a substantial portion of the region upstream of the 
transcription start  site should be carried out in a larger number of samples in order to locate the  
causative variant. Any SNPs found to be highly significantly associated with obesity in the promoter 
region can then be assessed for their affect on expression of the  SIRT1 transcript using luciferase 
assays. If a non-synonymous SNP within an exon is found to be significantly associated with obesity 
then activity of the Sirtuin 1 enzyme can be measured and compared to the wild type using assays  
that measure Sirtuin enzyme activity449.
These results may have important clinical implications. An association between SIRT1 variation and 
obesity is concordant with evidence in mice that activators of SIRT1 decrease fat mass and thus may 
provide pharmacological uses as a treatment for obesity or other metabolic diseases. Their use as a 
therapeutic for T2D has been proposed previously334.
In conclusion, these results provide evidence of a possible association between variants of the SIRT1 
gene and the development of common obesity. This will  require replication in other populations in 
order to confirm the association as well as resequencing and functional work to locate the causative 
variant underlying this genetic association.
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Chapter 4
Investigation of genetic variants within the 
apelin gene for association to common 
polygenic obesity
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4.1 Introduction
Apelin  was  discovered  in  1998  as  the  endogenous  ligand  for  APJ450,  a  G protein  coupled 
receptor known to be localised to neurons in the brain451. The apelin gene (APLN) is located on 
the X chromosome at Xq25-26.1452.
APLN encodes a  77 amino  acid  pre-protein  that  is  expressed  in  a  wide  range of  tissues,  
including heart, lung, mammary gland and adipose453. The pre-protein is alternatively cleaved 
into one of four physiologically active signal peptides, apelin-36, apelin-17, apelin-13 and apelin-
12. Apelin-13 may also undergo pyroglutamylation at the N-terminal glutamine residue before 
being secreted into the blood stream453,454,455,456. These peptides are all ligands for APJ, with the 
pyroglutamated 13 amino acid apelin being the most potent457. 
4.1.1 Apelin is upregulated in obesity
Apelin is expressed in adipose tissue and is secreted by adipocytes458. In mice, its expression in 
adipocytes  is  upregulated  in  obese  animals  and  plasma  levels  of  the  apelin  protein  are  
significantly increased in obese compared to control mice458. APJ, the apelin receptor is also 
expressed in adipose tissue and is upregulated in obesity459. In humans, circulating apelin has 
also been shown to be increased in obese subjects showing that these phenomena are not 
isolated to rodents460.
In human adipocyte cell culture, apelin is upregulated in reponse to insulin458 suggesting that 
apelin expression in adipose is controlled by the hormone. In obese patients, plasma apelin and 
insulin levels  have been found to be correlated,  suggesting that  the regulation of  apelin by 
insulin could influence blood concentrations of apelin461.
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Other factors appear to regulate the expression of apelin in adipose. TNFa, an inflammatory 
cytokine that is upregulated in obesity has been shown to stimulate  APLN expression in both 
mouse and human adipocyte culture462. Over-expression of PGC1a, a key regulator of cellular 
energy homeostasis, has been shown to stimulate both expression and secretion of apelin463.
Apelin  expression  has  also  been  reported  to  be  upregulated  during  differentiation  of  pre-
adipocyte into adipocyte cell culture indicating a role in development of adipose tissue464,465.
4.1.2 Effects of apelin on energy regulation
Intracerebroventricular  injections  of  apelin  peptides  result  in  a  reduction  in  food  intake  in 
rats466,467. In mice, intravenous injections of apelin have been found to lower blood glucose and 
improve insulin sensitivity341,342. Daily apelin injection has also been shown to reduce adiposity in 
obese mice without influencing food intake468.  This study also showed a reduction in serum 
levels of triglycerides and an increased expression of UCP1 and UCP3 along with increased 
body temperature and oxygen consumption which suggests that apelin acts to stimulate energy 
expenditure via mitochondrial uncoupling468.
Apelin has also been found to stimulate angiogenesis and as such has been hypothesised to 
contribute to the development of new vasculature in the expanding adipose tissue469.
4.1.3 Apelin mouse models
Apelin-null mice are hyperinsulinemic and insulin resistant342. These mice also exhibit increased 
adiposity  and  increased  serum  concentrations  of  free  fatty  acids470.  Conversely,  mice 
engineered to  over-express  APLN are  resistant  to  diet-induced obesity and have increased 
oxygen consumption and body temperature without any difference in feeding behaviour471.
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These mouse models, therefore suggest a role of apelin in controlling body weight via glucose 
metabolism and regulation of energy expenditure and thus variation in the apelin gene may 
influence obesity risk.
4.1.4 Apelin genetic variation and obesity
No significant associations have been reported between variants in the apelin gene and obesity 
phenotypes to-date. A nominal association to fasting plasma glucose levels was discovered in a 
cohort of unrelated male Han Chinese but this study did not find any association to BMI or  
obesity472.
No associations have been reported in any GWAS to-date, however most of these studies do 
not analyse variants on the X chromosome. This means that it is possible that there are variants 
in the apelin gene that influence obesity risk that haven't been investigated
A Finnish genome-wide linkage study reported a linkage peak with obesity at Xq24, which in 
linkage terms is relatively close to the Apelin gene located around 8Mbp downstream at Xq25-
Xq26.3473.
Given its role in glucose and lipid metabolism and the linkage peak reported to obesity, apelin is 
a plausible candidate gene for genetic association to obesity and so this study was designed to 
investigate possible associations between variants in the  APLN gene and common polygenic 
obesity in French obese cases and non-obese controls (see Materials and Methods for details).
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4.2 Results
4.2.1 SNP Selection and Case-Control Genotyping
All fourteen common SNPs (MAF > 5%) within the Apelin gene that were in the NCBI database  
in July 2007 were genotyped in the French case-control subjects using Sequenom iPlex assays 
(see Figure 4.1). Out of thirteen, eleven SNPs had acceptable genotyping success rates (> 
85%, actual mean success rate = 94.5%) and were within HWE (p > 0.05). HWE was analysed 
in female controls only as APLN is located on the X chromosome and so males only have one 
allele at each SNP. Five SNPs had low minor allele frequencies (< 5%) so were not  taken 
forward for analysis (see Table 4.1).
Figure 4.1. Map of APLN gene with positions of SNPs genotyped in this project. █ APLN exons.
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SNP
Position  on  X 
Chromosomea
Position  within  APLN 
gene Minor Allele Frequency
rs3131264 128777626 Downstream 0.04
rs5975126 128780392 3' UTR <0.01
rs3115759 128781516 3' UTR 0.08
rs3115758 128781864 3' UTR 0.09
rs41334247 128782557 Intron 2 <0.01
rs2235306 128784098 Intron 1 0.02
rs2235307 128784832 Intron 1 0.05
rs2235308 128785212 Intron 1 0.08
rs2235312 128787095 Intron 1 0.08
rs2281068 128787773 Intron 1 0.08
rs3761581 128789721 Upstream 0.02
Table  4.1.  APLN SNPs  successfully  genotyped  with  minor  allele  frequencies  observed. 
aPositions in bp correspond to NCBI build 37.1  measured from the top of  the p arm of  the 
chromosome. 
Of the six remaining SNPs analysed for association to obesity, rs3115759 and rs2281068 were 
nominally associated with obesity in children (p = 0.043 and 0.005). No SNPs were nominally 
associated with adult obesity (See Table 4.2). After correcting the p-values using one million 
permutations, rs2281068 remained significantly associated with obesity in children (p = 0.017, 
OR = 1.53, 95% CI = 1.14-2.05). 
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Allele Counts
Controls Children Adults Odds Ratio Children 
(95% CI)
P-values Children Odds Ratio 
Adults (95% CI)
P-values Adults
1a 2 1 2 1 2 Empirical Corrected Empirical Corrected
rs3115759 1730 136 871 91 1404 133 1.3 (1.0-1.8) 0.043 0.14 1.2 (0.94-1.6) 0.15 0.36
rs3115758 1598 136 848 89 1392 132 1.2 (0.93-1.6) 0.14 0.37 1.1 (0.87-1.4) 0.40 0.77
rs2235307 1564 74 867 56 1421 86 1.4 (0.96-2.0) 0.088 0.24 1.3 (0.93-1.8) 0.14 0.34
rs2235308 1688 131 849 86 1359 132 1.3 (0.98-1.7) 0.065 0.19 1.3 (0.97-1.6) 0.083 0.23
rs2235312 1709 131 847 86 1373 134 1.3 (1.0-1.8) 0.051 0.16 1.3 (0.99-1.6) 0.061 0.17
rs2281068 1600 108 854 88 1388 123 1.5 (1.1-2.1) 0.0046 0.017 1.3 (1.0-1.7) 0.051 0.14
Table 4.2. Allelic association analysis of Apelin SNPs to obesity in children and adult French case-controls. Analysis was performed using PLINK. Empirical p-values 
result from a single chi-squared test, corrected p-values result from one million permutations. Allele numbers are presented instead of genotypes due to  APLNs 
position on the X chromosome. a 1 denotes the common allele, 2 denotes the minor allele.
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A high degree of LD was found throughout the gene with r2 values ranging from 0.61 to 1.0 (see 
Figure  4.2).  Haplotypes  constructed  from  the  two  nominally  associated  SNPs  were  significantly 
associated to obesity in children after correction using permutations (p = 0.016, OR = 1.48)(see Table  
4.3).
Figure 4.2.  Linkage disequilibrium (r2) plot of  APLN SNPs genotyped in the French female control 
samples.  Black squares indicate 100% LD. The percentage LD level  (r2)  within grey squares are 
displayed.
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SNP 1 SNP 2 Odds Ratio Empirical P-value Corrected P-value
rs2281068 rs3115759 1.48 8.0x10-3 0.016a
Table 4.3 Haplotype analysis in the child case-controls using the two SNPs nominally associated with 
obesity. a Statistically significant p-values. Corrected p-values result from one million permutations. 
APLN SNPs  were  analysed  for  association  to  BMI  within  the  controls  using  age  and  sex  as 
covariates, however no significant associations were discovered (see Table 4.4).
Mean BMI (95% CI) (kg/m2) P-Values
SNP 1,1a 1,2 2,2 Empirical Corrected
rs3115759 32.1 (31.6-32.6) 33.7 (32.1-35.3) 31.4 (29.2-33.5) 0.19 0.44
rs3115758 32.5 (31.9-33.0) 33.0 (31.5-34.5) 31.6 (29.3-34.0) 0.40 0.76
rs2235307 32.6 (32.1-33.1) 34.8 (32.8-36.9) 31.6 (28.9-34.3) 0.37 0.72
rs2235308 32.0 (31.5-32.5) 33.8 (32.2-35.4) 31.4 (29.0-33.7) 0.14 0.34
rs2235312 31.9 (31.5-32.4) 33.9 (32.3-35.5) 31.4 (29.0-33.7) 0.11 0.28
rs2281068 32.4 (31.9-32.9) 34.3 (32.6-36.0) 31.7 (29.4-34.0) 0.060 0.17
Table 4.4. Analysis of APLN SNPs for association with the quantitative trait of BMI in French controls 
using linear regression with age and sex as covariates. Corrected p-vales result  from one million 
permutations. a 1 denotes the common allele, 2 denotes the minor allele.
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4.2.2 Sequencing of  APLN   
In order to locate the genetic variant or variants that are responsible for this association, sequencing  
was carried out within the  APLN exons and promoter region. Ten subjects were chosen that  were 
homozygous for both minor alleles associated with obesity, in rs3115759 and rs2281068, and two 
subjects were chosen as controls that were homozygous for the common alleles of rs3115759 and 
rs2281068. Six PCR reactions were designed to cover the 1.5kbp region upstream of the transcription 
start site as well as the two translated APLN exons. The PCR products were then directly sequenced.
One SNP was discovered within the 5' untranslated region of exon 1. This was previously reported as 
rs2281069 (MAF < 0.01 in Sub-Saharan African population, no data for Caucasians). No SNPs were 
discovered within exon 2 or within the promoter region (see Figure 4.3). Because it is untranslated, it 
is unlikely to be causative and so was not taken forward for genotyping.
 Figure 4.3. Map of APLN gene showing positions of PCR products used to sequence the promoter region and the two translated exons. Positions in bp correspond 
to NCBI build 37.1. █ APLN exons.
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4.2.3 Thesis-wide multiple testing correction
When APLN SNPs were analysed together with all other SNPs investigated in this thesis, no 
significant associations remain after correction using permutations (see Table 4.5).
SNP
Epirical p-value 
children
Corrected p-value 
children
Epirical p-value 
adults
Corrected p-value 
adults
rs3115759 0.04 0.89 0.15 1.0
rs3115758 0.14 1.0 0.40 1.0
rs2235307 0.088 0.99 0.14 1.0
rs2235308 0.065 0.97 0.083 0.98
rs2235312 0.051 0.94 0.061 0.95
rs2281068 0.0046 0.22 0.051 0.90
Table  4.5. P-values  after  correcting  for  multiple  testing  using  permutations  and  taking  into 
account all SNPs investigated in this thesis.
4.2.4 Power calculations
Using an odds ratio of 1.53 (as observed in the most significantly associated SNP, rs2281068),  
a MAF of 0.063 (as observed in rs2281068 in the controls), and a significance level of 0.0083 
(0.05 divided by 6 tests), the power to detect an association was 40% in the child cohort and 
15% in the adult cohort (see Table 4.6).
SNP
Significance 
level
MAF in 
controls
Odds ratio 
in children
Odds ratio 
in adults
Power in 
children
Power in 
adults
rs3115759 0.0083 0.073 1.3 1.2 0.17 0.075
rs3115758 0.0083 0.078 1.2 1.1 0.08 0.025
rs2235307 0.0083 0.045 1.4 1.3 0.13 0.085
rs2235308 0.0083 0.072 1.3 1.3 0.14 0.11
rs2235312 0.0083 0.071 1.3 1.3 0.16 0.13
rs2281068 0.0083 0.063 1.5 1.3 0.40 0.15
Table  4.6. Power  calculations.  carried  out  using  MAF  and  OR  observed  for  each  SNP 
investigated in the APLN gene.
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To  achieve a statistical power of 95%, assuming a  significance level of 0.0083, odds ratio of 
1.53 and a MAF of 0.06, 5,748 samples would be required (2874 cases and 2874 controls).  
Assuming a  significance level of 5x10-8 (genome-wide significance) this rises to  16,532 (see 
Figure 4.4). If the real odds ratio is lower then the samples size requirements will be increased 
(see Figure 4.5).
Figure  4.4. Sample  size  plotted  with  statistical  power  for  a  SNP with  MAF=0.06  (as  was 
observed for rs2281068). α is the significance level: 0.0083 for 6 statistical tests and 5x10 -8  for 
genome-wide significance.
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Figure 4.5. Sample size required for varying odds ratios in order to achieve a statistical power 
of 95% for a SNP with MAF=0.06 (as was observed for rs2281068). α is the significance level: 
0.0083 for 6 statistical tests and 5x10-8  for genome-wide significance.
For the sequencing project, the probability of locating a common variant (MAF>5%) in high LD 
(r2>0.8) with the associated SNP (rs2281068, MAF=6.3%) using 10 samples was calculated to 
be >99%, assuming such a variant exists. The probability of locating a variant with MAF = 0.1% 
in moderate LD (r2=0.5) was calculated to be 84% (see Appendix A7 for calculations).
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4.3 Discussion
These results provide evidence of a possible association between one SNP in the Apelin gene 
and common polygenic obesity in French children. 
The p-values reported here do not withstand genome wide correction. Furthermore, permutation 
analysis using all  SNPs tested within this thesis results in non-significance of all  tests.  This, 
together with the fact that the association has not been replicated means that the possibility of a 
false-positive cannot be ruled out. SNPs were analysed using permutations to compensate for  
the six statistical tests being performed and this resulted in one putative association to obesity in 
children.
As noted in the introduction to this chapter, a nominal association of the Apelin SNP rs2235306 
was reported to be associated with fasting plasma glucose levels in Han Chinese (p = 0.04), 
however this study did not find an association to any obesity related phenotype472. In the results 
presented here,  rs2235306 had a low minor allele frequency (0.02) and since the previously 
reported association was not to obesity it was not analysed. More recently, an association was 
reported between an APLN SNP, rs3115757 and both BMI and WC in Chinese women but not 
men474. Rs3115757 was not genotyped in this study since it was not present in dbSNP at the 
time these assays were designed. It is not present in HapMap so there is no information on 
whether it is tagged by any genotyped SNP.
No associations  between apelin  SNPs and  obesity  phenotypes  have  been reported  in  any 
GWAS to-date.  This is due to the fact that most GWAS exclude X chromosome variants from 
analysis and highlights a current weakness in genome-wide studies.
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 Both nominally associated SNPs were found to have a higher frequency of the minor genotype  
within obese subjects compared to controls suggesting that the minor allele increases obesity 
risk. The putatively associated SNP, rs2281068 is located within intron 1 of the Apelin gene so is 
unlikely  to  be  causative  unless  it  affects  an  enhancer  element  located  within  the  intron. 
Therefore, if  this is a genuine association, it is probably in linkage disequilibrium with some 
other mutation responsible for modifying obesity risk. 
Sequencing was unable to locate any mutations in LD with the associated SNP that were either 
in the promoter (1.5kbp upstream of the start codon) or translated regions of the gene. One 
SNP, rs2281069 was discovered in the 5' UTR. Since this is untranslated and therefore unlikely 
to be functional it was not genotyped in the case-control subjects. Power to detect variants with 
MAF >5% and in  high  LD (r2>0.8)  with  the  associated SNPs was sufficiently  high  (>99%), 
however as MAF and LD values drop (MAF=0.1%, r2=0.5) this power is reduced (84%) and if 
the causative SNP is even rarer (<0.1%) then this will  drop further. Thus the possibility of a 
false-negative cannot be ruled out.  Furthermore since only 2kb of  the promoter region was 
sequenced, all regulatory regions have not been investigated.
Since no coding SNPs are currently known to exist in the human APLN gene and sequencing 
was not able to locate any variants in LD with the associated SNPs, it is likely that the causative 
variant is within the promoter region, upstream of the region sequenced in this study or within an 
enhancer or inhibitor element where it affects transcription of the gene. Using HapMap data the 
LD block containing APLN extends approximately 20kbp upstream of the gene and this region 
could contain variants that alter expression (see Figure 4.4).  Alternatively, the causative SNP 
could affect splicing of the mRNA and aberrantly spliced transcript may not translate into active 
apelin peptides. As apelin levels are correlated to adiposity353 and apelin injections have been 
shown  to  stumulate  weight  loss343,344,468 an  alteration  in  APLN expression  or  apelin  protein 
synthesis could lead to a malfunction in the control of body-weight thus influencing obesity risk. 
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Further work is required in order to replicate the association in other cohorts and ethnic groups.  
If  replication is successful  then sequencing will  be  required in order to locate the causative 
variant. This should be carried out by sequencing more of the promoter region (at least 20kb 
upstream of the transcription start site) in a larger number of samples. Novel variants will then  
be typed in the current sample sets and any association will  need to be replicated in other 
populations. After genotyping, any SNPs found to be significantly associated with obesity in the 
promoter region can then be assessed for their  effect on expression of the  APLN transcript 
using luciferase assays. An alternative to genotyping any discovered SNPs in all samples would 
be to impute genotypes from the sub-set of samples that have been sequenced. If this produced 
a significant  result  then genotypes could be validated afterwards which means the costs of 
genoytping are only incurred if a significant result is found. 
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Figure 4.4 LD plot (D') of APLN gene and the surrounding region. Bright red squares indicate D'=1 and LOD>2, shades of pink or red indicate D'<1 and LOD>2, blue 
indicate D'=1 and LOD<2 and white squares indicate D'<1 and LOD<2. 
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Chapter 5
Investigation of genetic variants within the 
Interleukin 11 gene for association to 
common polygenic obesity
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5.1 Introduction
Interleukin 11 (IL-11), also known as adipogenesis inhibitory factor, is a member of the IL-6 
family of anti-inflammatory cytokines and is expressed in a wide range of tissues including the 
CNS, bone, lung,  uterus, testis and adipose475.  IL-11  acts on a number of  tissues including 
central nervous system, testis, bone marrow, intestine and adipose354,475. 
IL-11 is an important regulator of hematopoiesis and in particular megakaryocyte formation475. It 
stimulates the proliferation and differentiation of blood stem cells into mature cells and has been 
demonstrated to promote platelet recovery in patients undergoing chemotherapy475. As well as 
blood cells it has also been reported to regulate development of bone marrow, epithelial cells 
and hippocampal neuronal progenitor cells and is thought to be important in the establishment 
of pregnancy475,476.
5.1.1 IL11 inhibits adipogenesis
IL11  inhibits  the  differentiation  of  pre-adipocytes  into  adipocytes  in  human  bone  marrow 
culture358. It also inhibits expression of lipoprotein lipase477 and in bone marrow culture it has 
been shown to  inhibit  fat  accumulation358.  In  fully  differentiated  adipocyte  cell-culture,  IL-11 
activates a number of signalling pathways355 and treatment of adipocyte cell culture with IL-11 
lowers transcription of  leptin  which is evidence of  an involvement  in  regulation of  adiposity  
levels357. It has also been shown to inhibit TNFa, a pro-inflammatory cytokine that is upregulated 
in obesity478. Given its role in controlling the expression of inflammatory cytokines in adipose 
tissue it  has been hypothesised that  IL-11 could regulate insulin  resistance associated with 
obesity355.
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5.1.2  IL11   variation and obesity 
To-date, no associations have been reported between IL-11 gene variants and obesity-related 
phenotypes. IL-11 does however, lie within the 1-LOD support interval of a linkage peak found to 
obesity, which means it is a candidate gene for this linkage479.
In the French GWAS, which used some of the same sample as this study 253, 16 SNPs within the 
IL11  region  were  found  to  have  a  p-value  <0.05,  with  the  most  significant  hit,  rs8101393 
(p=1.7x10-3)  a SNP 130,000bp downstream of  the gene.  In  the most  recent  GIANT GWAS 
investigating associations to BMI233, a SNP within the IL11 region, rs1042506, was found to be 
nominally associated however with a p-value of 4.16x10−2, however this is very unlikely to be a 
genuine genetic association (accessed online445, see Figure 5.1).
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Figure 5.1. SNPs analysed for association to BMI in IL11 region in the GIANT GWAS233.
Given the evidence that IL-11 is involved in the development of adipocytes and the obesity  
linkage peak reported near to the gene, it is a  plausible candidate for human polygenic obesity  
and  as  such  this  study  was  designed  to  investigate  the  possibility  of  genetic  associations 
between variants in the gene, its expression levels and obesity in French obese cases and non-
obese controls and Swedish sib-pairs (see Materials and Methods for details).
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5.2 Results
5.2.1 SNP selection and case-control genotyping
No tagging SNPs were identified in the IL-11 gene due to a lack of strong linkage disequilibrium 
(r2>0.8) in the HapMap genotype data. Seventeen SNPs were selected from the NCBI database 
(see Figure 5.1). After genotyping, sixteen SNPs survived quality control with a mean call rate of  
89%. Of these, ten had low minor allele frequencies (< 5%), leaving six SNPs that were taken  
forward for analysis (see Table 5.1).
Figure 5.1. Schematic diagram of the IL-11 gene showing the positions of SNPs successfully 
genotyped in this study. █ IL-11 exons.
141
SNP
Position on 
Chromosome 19a Position Within IL-11 Gene
Minor Allele 
Frequency
rs4252562 55876162 3' UTR <0.01
rs2298885 55876240 3' UTR 0.32
rs10425163 55876773 3' UTR <0.01
rs10402867 55876945 3' UTR <0.01
rs10402868 55876946 3' UTR <0.01
rs1042506 55877111 3' UTR 0.14
rs4806475 55877168 3' UTR <0.01
rs1042505 55877231 3' UTR 0.32
rs17850928 55877451
Non-synonymous Coding 
Exon 5 <0.01
rs7250912 55877874 Intron 4 <0.01
rs12975067 55878843 Intron 4 <0.01
rs4252576 55879685
Non-synonymous Coding 
Exon 4 <0.01
rs1126757 55879872 Synonymous Coding Exon 3 0.44
rs10407001 55881161 Intron 2 0.11
rs4252546 55882345 Upstream 0.48
rs7246652 55882807 Upstream <0.01
Table  5.1.  IL-11 SNPs  successfully  genotyped  with  minor  allele  frequencies  observed.  a 
Positions in  bp correspond to NCBI build 37.1 measured from the top of  the p arm of  the  
chromosome. 
Four SNPs were found to be nominally associated with obesity in the French adults (see Table 
5.2). These were rs2298885 (p = 0.024, OR = 1.2, CI =1.0-1.4), rs1042506 (p = 0.045, OR = 
0.82, CI = 0.68-1.0), rs1042505 (p = 0.003, OR = 1.2, CI = 1.1-1.4) and rs1126757 (p = 0.042,  
OR = 0.88, CI = 0.77-1.0). Of these, one SNP, rs1042505 was significantly associated with 
obesity after correction using permutations (p=0.016). None of  these SNPs were associated 
with obesity in the French children (see Table 5.2).
No associations were discovered between SNPs in IL-11 and the quantitative trait of BMI in the 
French controls (see Table 5.3).
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Genotype Numbers
Controls Children Adults Odds Ratio 
Children (95% CI)
P-values Children Odds Ratio Adults 
(95% CI)
P-values Adults
SNP 1,1a 1,2 2,2 1,1 1,2 2,2 1,1 1,2 2,2 Empirical Corrected Empirical Corrected
rs2298885 517 464 112 266 245 58 297 333 84 1.0 (0.87-1.2) 0.89 1.0 1.2 (1.0-1.4) 0.024 0.11
rs1042506 838 280 28 461 132 12 620 158 20 0.86 (0.7-1.1) 0.16 0.67 0.82 (0.68-1.0) 0.045 0.20
rs1042505 548 485 101 275 256 58 327 373 88 1.1 (0.91-1.2) 0.43 1.0 1.2 (1.1-1.4) 0.0027 0.016b
rs1126757 337 586 229 189 289 130 268 404 139 0.99 (0.86-1.1) 0.93 1.0 0.88 (0.77-1.0) 0.042 0.19
rs10407001 888 239 15 483 117 8 638 149 15 0.92 (0.74-1.2) 0.46 1.0 0.94 (0.77-1.2) 0.56 0.98
rs4252546 311 576 253 165 281 135 210 373 202 1 (0.87-1.2) 0.99 1.0 1.1 (0.95-1.2) 0.22 0.66
Table 5.2. Allelic association analysis of IL-11 SNPs to obesity in children and adult French case-controls. Analysis was performed using PLINK. Empirical p-values  
result from a single chi-squared test, corrected p-values result from one million permutations. a 1 denotes the common allele, 2 denotes the minor allele. b Statistically 
significant (p < 0.05) associations are shown in bold.
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Genotype Counts Mean BMI (95% CI) P-values
SNP 1,1a 1,2 2,2 1,1 1,2 2,2 Empirical Corrected
rs2298885 505 448 112 22.6 (22.5-22.8) 22.3 (22.1-22.4) 22.4 (22.3-22.5) 0.69 1.0
rs1042506 810 275 27 21.6 (21.5-21.8) 22.4 (22.3-22.5) 22.5 (22.3-22.6) 0.52 1.0
rs1042505 535 468 101 22.8 (22.7-22.9) 22.3 (22.2-22.4) 22.4 (22.3-22.5) 0.71 1.0
rs1126757 330 568 220 22.5 (22.4-22.7) 22.4 (22.3-22.5) 22.4 (22.3-22.5) 0.78 1.0
rs10407001 861 234 14 22.3 (22.2-22.4) 22.4 (22.3-22.6) 22.4 (22.3-22.6) 0.83 1.0
rs4252546 303 556 251 22.5 (22.4-22.6) 22.4 (22.2-22.5) 22.4 (22.2-22.5) 0.32 0.96
Table 5.3. Association analysis of  IL-11 SNPs to the quantitative trait of BMI within the French controls using linear regression and age and sex as covariates.  
Corrected p-values result from one million permutations. a 1 denotes the common allele, 2 denotes the minor allele.
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Two  SNPs  were  found  in  high  LD,  rs2298885  and  rs1042505  (r2=0.95),  though  LD  was 
otherwise very low (see Figure 5.2). Haplotype analysis was carried out using the four SNPs 
nominally  associated  with  obesity  in  adults.  All  haplotypes  were  nominally  associated  with 
obesity in adults, however only one haplotype survived correction (rs1126757 and rs1042505; 
p=0.025; OR=1.23) (see Table 5.4).
Figure  5.2. Linkage disequilibrium (r2)  plot  of  IL-11 SNPs genotyped in  the French control 
samples. Black squares indicate 100% LD and white squares indicate zero LD. The percentage 
LD level (r2) within grey squares are displayed.
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SNPs OR
Empirical 
P-value
Corrected 
P-value
rs2298885 rs1042506 rs1042505 rs1126757 1.2 0.011 0.13
rs2298885 rs1042506 rs1042505 1.2 0.0081 0.11
rs2298885 rs1042506 1.2 0.016 0.18
rs2298885 rs1042505 1.2 0.017 0.18
rs2298885 rs1126757 1.2 0.028 0.13
rs1042506 rs1042505 1.2 0.0057 0.066
rs1042506 rs1126757 0.81 0.033 0.32
rs1042505 rs1126757 1.2 0.0059 0.025a
Table 5.4. Haplotype association analysis with obesity in adults using the four SNPs found to be 
nominally associated with adult obesity.  a  Statistically significant p-values. Corrected p-values 
result from one million permutations. 
5.2.2 Genotyping within Swedish sib-pair cohort
Genotyping  was  carried  out  in  the  Swedish  sib-pair  cohort  using  the  same set  of  assays. 
Genotyping success rate  averaged 93% for  the four  SNPs nominally  associated within  the 
French case-control analysis. These four SNPs were analysed for association to BMI with the 
QFAM test using the within-families model of association. No associations were found with any 
IL-11 SNP (see Table 5.5).
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Genotype Counts Mean BMI (95% CI) P-Values
SNP 1,1a 1,2 2,2 1,1 1,2 2,2 Empirical Corrected
rs2298885 335 235 42 29.2 (28.4-29.9) 29.2 (28.3-30.1) 26.7 (25.2-28.3) 0.74 1.0
rs1042506 436 180 15 28.8 (28.2-29.4) 29.3 (28.3-30.3) 29.5 (25.7-33.2) 0.81 0.86
rs1042505 348 235 42 29.5 (28.8-30.2) 28.9 (28.1-29.8) 26.5 (25.0-28.0) 0.85 0.86
rs1126757 138 312 143 29.0 (27.8-30.3) 29.4 (28.6-30.1) 28.2 (27.1-29.2) 0.75 0.85
Table 5.5. Association analysis of IL-11 SNPs with BMI in the Swedish families using the QFAM test and the within-families model of association  correcting for age 
and sex as implemented by PLINK. Corrected p-values result from one million permutations. a 1 denotes the common allele and 2 denotes the rare allele.
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5.2.3 Analysis of   IL-11  transcription 
Microarray data was available that included measurements of IL-11 transcript levels in subcutaneous 
adipose tissue for each sibling within the Swedish sib-pair cohort. This was analysed for association 
with obesity, BMI and IL-11 genotype.
There was no association between SNPs in the IL-11 gene and its transcript after correcting for age, 
sex and BMI (see Table 5.6). When siblings were split into two groups of non-obese (BMI<30 kg/m2) 
and obese (BMI>30kg/m2) and the transcription levels corrected for age, sex and relatedness, the two 
groups  were  normally  distributed  as  assessed  using  a  normal  Q-Q  plot.  Using  an  independent 
samples t-test, a significant difference in the level of IL-11 transcription was found between the two 
groups (p=2.8x10-9,  see  Figure  5.3  and  Table  5.7).  When corrected,  IL-11 transcript  was  plotted 
against BMI and a weak correlation was observed in the non-obese group (r2=0.034, p=0.005, see 
Figure 5.4). There was no correlation in the obese group (r2= 0.002, p=0.42, see Figure 5.5).
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Genotype Counts Mean Transcript Level (95% CI) P-Values
SNP 1,1a 1,2 2,2 1,1 1,2 2,2 Empirical Corrected
rs2298885 174 128 24 5.8 (5.7-5.9) 5.7 (5.6-5.9) 5.9 (5.5-6.3) 0.64 0.63
rs1042506 235 101 6 5.8 (5.7-5.9) 5.8 (5.6-5.9) 5.7 (4.9-6.5) 0.38 0.29
rs1042505 184 131 24 5.8 (5.7-5.9) 5.8 (5.6-5.9) 5.9 (5.5-6.3) 0.36 0.32
rs1126757 74 170 80 5.8 (5.6-6.0) 5.7 (5.6-5.8) 5.9 (5.7-6.1) 0.63 0.62
Table 5.6. Association analysis of  IL-11 SNPs with  IL-11 transcript expression in subcutaneous adipose tissue, corrected for age, sex and BMI in the Swedish 
families using the QFAM test and the within-families model of association implemented by PLINK. a 1 denotes the common allele and 2 denotes the rare allele.
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Figure 5.3.  Box-plot of  IL-11 transcript levels in subcutaneous adipose tissue with obese and 
non-obese  subjects  from  Swedish  sib-pairs  displayed  separately.  IL-11 transcription  is  the 
microarray signal value corrected for age, sex and relatedness. Mean transcription ± standard 
deviation were 0.17 ± 0.60 in the non-obese and -0.22 ± 0.60 in the obese group.
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Number of 
Non-obese
Number of 
Obese
Mean Difference in IL-11 
transcription (95% CI) P-value
193 138 0.39 (0.27-0.52) 2.8x10-9
Table 5.7. T-test of subcutaneous adipose IL-11 transcription in obese and non-obese subjects 
from Swedish sib-pair families.  IL-11 transcription is the microarray signal value corrected for 
age, sex and relatedness.
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Figure 5.4. IL-11 transcription levels in subcutaneous adipose tissue plotted against BMI in non-
obese siblings (n = 193, r2 = 0.034, p = 0.005).  IL-11 transcription was the DNA microarray 
signal value corrected for age, sex and relatedness. 
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Figure 5.5.  IL-11 transcription levels  in subcutaneous adipose tissue plotted against BMI in 
obese siblings (n = 138 ,r2 = 0.002, p = 0.42) . IL-11 transcription was the DNA microarray signal 
value corrected for age, sex and relatedness. 
5.2.4 Thesis-wide multiple testing correction
When  IL11 SNPs were analysed together with all other SNPs investigated in this thesis, no 
significant associations remain after correction using permutations (see Table 5.8).
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SNP Empirical p-value 
children
Corrected p-
value children
Empirical p-value 
adults
Corrected p-value 
adults
rs2298885 0.89 1.0 0.024 0.76
rs1042506 0.16 1.0 0.045 0.82
rs1042505 0.43 1.0 0.0027 0.18
rs1126757 0.93 1.0 0.042 0.95
rs10407001 0.46 1.0 0.56 1.0
rs4252546 0.97 1.0 0.22 1.0
Table 5.8. Thesis-wide correction of p-values for muliple testing using 1 million permutations 
from association analysis of IL11 SNPs and obesity in French case-controls.
5.2.5 Power calculations
Using an odds ratio of 1.23 (as observed in the most significantly associated SNP, rs1042505),  
a MAF of 0.30 (as observed in rs1042505 in the controls), and a  significance level of 0.0083 
(0.05 divided by 6 tests), the power to detect an association was 68% in the adult cohort and 
13% in the child cohort (see Table 5.9).
SNP
Significance 
level
MAF in 
controls
Odds ratio 
in children
Odds ratio 
in adults
Power in 
children
Power in 
adults
rs2298885 0.0083 0.31 1.0 1.2 0.084 0.52
rs1042506 0.0083 0.15 0.86 0.82 0.25 0.42
rs1042505 0.0083 0.30 1.1 1.2 0.13 0.68
rs1126757 0.0083 0.45 0.99 0.88 0.085 0.39
rs10407001 0.0083 0.12 0.92 0.94 0.13 0.11
rs4252546 0.0083 0.47 1.0 1.1 0.083 0.23
Table  5.9. Power  calculations  carried  out  using  MAF  and  OR  observed  for  each  SNP 
investigated in the IL-11 gene.
To  achieve 95% power assuming a  significance level of 0.0083, an odds ratio of 1.18 and a 
MAF  of  0.31  would  require  12316  samples  (6158  cases  and  6158  controls).  Assuming  a 
significance level of 5x10-8 (genome-wide significance) this rises to 33,386 (see figure 5.6). If 
the real odds ratio is lower then the sample size requirements go up (see Figure 5.7).
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Figure  5.6.  Sample size  plotted  with  statistical  power  for  a  SNP with  MAF=  0.30 (as was 
observed for rs1042505). α is the significance level: 0.0083 for 6 statistical tests and 5x10 -8  for 
genome-wide significance.
Figure 5.7. Sample size required for varying odds ratios in order to achieve a statistical power 
of 95% for a SNP with MAF= 0.30 (as was observed for rs1042505). α is the significance level: 
0.0083 for 6 statistical tests and 5x10-8 for genome-wide significance.
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5.3 Discussion
These results demonstrate a possible association between one SNP in the IL-11 gene and 
common polygenic obesity in French adults. Replication in other cohorts is necessary in order to 
confirm this association. No previous associations of variants in this gene to human obesity or 
obesity-related  phenotypes  have  been  reported  to  date,  which  would  make  this  a  novel 
discovery if it were to become validated.
The association does not withstand genome-wide correction for multiple testing, which means 
that  the  possibility  of  a  false-positive  cannot  be ruled out..  For  the purposes of  this  study, 
genome-wide correction was not considered necessary as IL-11 is a strong biological candidate 
gene with well-established functional links to adipose tissue and hence obesity. Rs1042505 was 
found to be significantly associated to obesity after correction using one million permutations. 
However, future replication will need to reach genome-wide significance in order to confirm the 
association.
LD between SNPs genotyped in IL-11 was low, which confirms the HapMap data in which LD 
was too low to generate tag SNPs. Haplotypes were still  analysed in order to test whether 
associated SNPs formed part of a haplotype group that could contain a more significant SNP 
not typed in this project. All haplotypes constructed from the nominally associated SNPs were  
found  to  be  nominally  associated  with  obesity  in  adults,  however  only  one  haplotype  was 
significantly associated after correction for multiple tests. This haplotype had a less significant p-
value than the single significant SNP. This is not surprising given the low LD found within the 
gene. Therefore no conclusions can be drawn as to whether there is a more significant SNP in  
the region causing the association to obesity reported here.
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The failure to find an association in the child case-control cohort could be because of the low 
statistical power. It is possible, however that this is a genetic variant that influences obesity risk 
in adults but not in children. Alternatively this could be evidence that this is not a real genetic 
association and merely a statistical artefact. The failure to find an association between SNPs 
and BMI in the French control  groups could be  because, if  this is a genuine association, it 
affects disease risk and does not modify BMI in the normal-weight population. The failure to find 
an  association  between  SNPs  and  BMI  in  the  Swedish  families  might  be  due  to  the  low 
statistical power in this dataset due to lower sample numbers (n = 661 individuals with BMI  
data) and the fact that subjects are related which means there is much less genetic variation. 
Alternatively it might be that this result is a false-positive.
The lack of a significant association to IL-11 variants in any GWAS to-date might be evidence 
that this is not a real association. Another explanation is that coverage of IL-11 SNPs is not 
complete in genome-wide studies. In the recent GIANT BMI publication233, three SNPs within IL-
11 were genotyped: rs1042506 (p=0.042), rs4252552 (p=0.37) and rs1126757 (p=0.20). Only 
two  of  these  SNPs  were  genotyped  in  the  GIANT WHR paper262 (rs1042506,  p=0.86  and 
rs4252552, p=0.40). In this thesis, two of these SNPs were nominally associated with obesity in 
adults  (rs1042506,  p=0.0045,  rs1126757  p=0.042).  These  were  not  the  most  significantly 
associated SNPs, however. Given the low LD within the gene, this means that coverage of IL-11 
variation in GWAS is not complete. The most significantly associated SNP in the French adult  
case-controls,  rs1042505  is  poorly  correlated  with  these  two  SNPs  (r2=0.07  and  0.31 
respectively)  which means that  if  this is a genuine association,  it  will  be missed by current 
GWAS, highlighting a weakness of current genome-wide investigations. 
157
The significant  difference observed in  IL-11 transcript  levels  between obese and non-obese 
siblings may be further evidence for a role of IL-11 in the development of obesity. However it is  
also possible that IL-11 transcription is being modified in some way by an individual's BMI. Since 
IL-11 has an immunological role its expression could be regulated differently in obesity, which is  
associated  with  chronic  inflammation  and  activation  of  the  immune  system480.  The  lack  of 
association between IL-11 SNPs and its expression could again be due to the low number of 
samples in the Swedish sib-pair cohort (n=359 individuals with IL-11 transcript data). However, 
since  the transcript  data  is  quantitative,  statistical  power  should  be  sufficient  to  detect  any 
association so it is more likely that the IL-11 SNP variation investigated is not associated with 
transcription of the gene. 
The associated SNP, rs1042505 is located within the 3' UTR, therefore it  does not alter the 
amino-acid sequence of the IL-11 protein. If this association is genuine then it is likely that this  
SNP is within LD with another variant that is causative. This could be a non-synonymous coding  
SNP,  a  variant  within  the  promoter  region  or  within  an  enhancer  element  that  influences 
transcription. Alternatively, it could be a mutation that alters a splice site. Given the low level of  
LD found within the region this is less likely, however sequencing of the exons and promoter  
region should be carried out in order to locate any potentially causative mutations.
In summary, these results demonstrate a possible association between an IL-11 gene variant  
and  obesity  in  a  French  Caucasian  cohort.  This  will  require  further  investigation  in  other 
populations in order to confirm the associations and sequencing and functional work to locate 
the causative variant.
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Chapter 6
Investigation of genetic variants within the 
adiponutrin gene for association to common 
polygenic obesity
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6.1 Introduction
Adiponutrin  is  a  cell  membrane protein  encoded by the  patatin-like  phospholipase domain-
containing  protein  3  (PNPLA3)  gene  in  humans,  which  is  located  on  the  long  arm  of 
chromosome  twenty  two  and  is  comprised  of  eight  exons.  It  belongs  to  a  family  of  
phospholipases that include patatin-like phospholipase 1 (PNPLA1), adipose triglyceride lipase 
(ATGL/PNPLA2),  adiponutrin  (ADPN/PNPLA3),  gene  sequence  2  (PNPLA4)  and  GS2-like 
(PNPLA5)481. All of these enzymes are highly expressed in adipose tissue481.
6.1.1 Adiponutrin has a role in lipid metabolism
Adiponutrin is expressed in WAT and BAT and was originally reported to be a triacylglycerol 
lipase360.  Lipase  activity  was  subsequently  confirmed  in  a  study  that  also  demonstrated 
acylglycerol  transacylase  activity  (transfers  fatty  acids  to  mono-  and  di-acylglycerol)482. 
Overexpression  of  adiponutrin  in  vitro does  not  result  in  a  decrease  in  intracellular  tri-
acylglyceride  concentration483.This  suggests  that  adiponutrin  may  have  a  role  in  both  lipid 
hydrolysis and lipogenesis.
6.1.2 Adiponutrin i  s regulated by  metabolic factors  
In  vitro adiponutrin  expression  is  increased  during  differentiation  of  pre-adipocytes  and  is 
induced by glucose and insulin treatment360,484. Expression in WAT of rodents is downregulated 
during fasting360,485 and upregulated after re-feeding484,485. Additionally, expression is decreased 
in  insulin-deficient  mice  and  insulin-receptor  knockout  mice484.  Expression  is  normalised  in 
insulin-deficient mice when administered with insulin. 
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Zucker (fa/fa) rats that do not have a functional leptin receptor and over-express leptin have 
increased adiponutrin expression360. Conversely, expression of adiponutrin in  ob/ob mice, that 
lack  a  functional  leptin  gene,  is  downregulated483.  These  results  suggest  that  adiponutrin 
expression is controlled by leptin.
Similar results have been found in humans. Expression of adiponutrin in WAT is significantly 
increased  during  a  hyperinsulinemic  euglycemic  clamp486.  Expression  of  adiponutrin  is 
increased  in  obese  compared  to  non-obese  subjects  probably  because  of  the  association 
between high circulating insulin levels and obesity369.
6.1.3 Adiponutrin gene variation and non-alcoholic fatty liver disease
A GWAS of  nonsynonymous  coding  SNPs reported  an  association  between rs738409  and 
hepatic fat levels and hepatic inflammation in a multiethnic population (p=5.9×10−10)487.  This 
result was replicated in a Finnish cohort (p = 0.002) which also found an association between 
liver PNPLA3 transcription and BMI (r2=0.62,  p<10-4)364 in a European-American cohort488. The 
same SNP was  also  reported  to  be  associated  with  various  phenotypes  that  relate  to  the 
histological  severity  of  the  disease489.  Another  study  in  children  and  adolescents  with 
nonalcoholic  fatty  liver  disease  reported  an  association  between  rs738409  and  the  same 
histological markers (p<10-4)490.  As nonalcoholic fatty liver disease is associated with obesity 
and metabolic syndrome, this supports a possible link between adiponutrin and obesity491.
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6.1.4 Adipon  utrin gene variation and obesity  
Expression of Adiponutrin in subcutaneous and visceral adipose tissue has been reported to be 
increased in obese compared to non-obese subjects in a Swedish study369.  This study also 
reported an association between two SNPs, rs2072907 and rs1010022, in the Adiponutrin gene 
and obesity (p-values = 0.015 and 0.021), however these associations become non-significant  
after correcting for age.  This association was subsequently replicated in a second Swedish 
cohort which survived the correction for age effects492.
No  significant  associations  between  PNPLA3 variants  and  obesity  phenotypes  have  been 
reported in any GWAS to-date.  In the French GWAS, which used some of the same sample as 
this study253, 44 SNPs within the PNPLA3 region were found to have a p-value <0.05, with the  
most significant SNP, rs5764455 having a p-value of 3.5x10 -4. However, this SNP is located 
55,000 bp downstream of the gene and lies within another gene,  PPARVB.  The most recent 
GIANT publication233 found a nominally significant p-value of 2.19x10-3 with one SNP, rs5764317 
within the  gene region in which  PNPLA3  is located, however at least three other genes are 
located closer to this SNP than  PNPLA3 (data acessed online445, see Figure 6.1). No SNPs 
located in the PNPLA3 gene were nominally associated.
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Figure 6.1. SNPs analysed for association to BMI in the PNPLA3 region in the GIANT GWAS233.
Given its links to lipid metabolism and the genetic association previously reported, adiponutrin is  
a plausible candidate gene for obesity and so this study was designed to investigate possible  
genetic associations between variants in the gene and common polygenic obesity in French 
obese cases and non-obese controls (see Materials and Methods for details).
163
6.2 Results
6.2.1  SNP Selection and Case-Control Genotyping  
Twenty-five SNPs were genotyped within the adiponutrin gene including twenty tag SNPs which 
covered all thirty-nine common adiponutrin SNPs (MAF>5%) in the HapMap database with a 
mean r2 of 0.985 (see Figure 6.1). After genotyping, seventeen SNPs passed quality control with 
a mean call rate of 94%. Three of these had low minor allele frequencies (<5%) so were not 
analysed (see Table 6.1). Of the six tag SNPs genotyped, five passed QC. Rs11090617 failed 
due to low genotyping success rate.
Figure 6.1. Map of adiponutrin gene with positions of SNPs genotyped in this project. * Tag 
SNPs. █ Adiponutrin exons.
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SNP
Position on 
Chromosome 22a
Position Within Adiponutrin 
Gene
Minor Allele 
Frequency
rs4823104 44321149 Intron 1 0.21
rs2076212 44322970 Non-Synonymous Coding Exon 2 0.23
rs139047 44323074 Intron 2 0.48
rs734561* 44324104 Intron 2 0.34
rs139051 44324676 Intron 2 0.44
rs738408* 44324730 Synonymous Coding Exon 3 0.35
rs12483959 44325996 Intron 3 0.28
rs9626056 44327075 Intron 3 0.14
rs35764214 44328819 Non-Synonymous Coding Exon 4 <0.01
rs34179073 44328832 Synonymous Coding Exon 4 0.15
rs35726887 44328917 Non-Synonymous Coding Exon 4 <0.01
rs9625964 44337610 Intron 7 0.14
rs2294916* 44340922 Intron 8 0.27
rs2294917 44341986 Intron 8 0.41
rs2294918* 44342116 Non-Synonymous Coding Exon 9 0.48
rs6006460 44342174 Non-Synonymous Coding Exon 9 <0.01
rs2294919* 44342325 3' UTR 0.32
Table 6.1. SNPs successfully genotyped with minor allele frequencies observed.  aPositions in 
bp correspond to NCBI build 37.1 measured from the top of the p arm of the chromosome.
One SNP, rs4823104, was nominally associated with obesity in children (p=0.043, OR=0.80,  
CI=0.64-0.99) but this was not significantly associated after adjusting for false positives using 
permutations  (p=0.391).  Another  SNP,  rs738408,  was  nominally  associated  with  obesity  in 
adults (p=0.045, OR=1.17, CI=1.01-1.36) but this did not survive correction using permutations 
(p=0.386) (see Table 6.2). 
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Genotype Numbers
Controls Children Adults
Odds Ratio 
Children (95% CI)
P-values Children
Odds Ratio 
Adults (95% CI)
P-values Adults
SNP 1,1a 1,2 2,2 1,1 1,2 2,2 1,1 1,2 2,2 Empirical Corrected Empirical Corrected
rs4823104 932 267 21 505 121 4 656 166 8 0.80 (0.64-0.99) 0.043 0.39 0.86 (0.71-1.1) 0.14 0.78
rs2076212 890 298 12 476 137 14 658 195 18 0.98 (0.80-1.2) 0.81 1.0 0.99 (0.82-1.2) 0.87 1.0
rs139047 399 589 217 205 302 103 299 392 160 0.98 (0.85-1.1) 0.74 1.0 0.98 (0.87-1.1) 0.81 1.0
rs734561 731 391 52 380 195 22 487 288 33 0.92 (0.78-1.1) 0.36 0.99 1.0 (0.89-1.2) 0.67 1.0
rs139051 517 492 154 254 280 84 364 380 121 1.1 (0.94-1.3) 0.29 0.96 1.1 (0.94-1.2) 0.33 0.98
rs738408 660 328 65 345 201 28 483 329 47 1.0 (0.87-1.2) 0.72 1.0 1.2 (1.0-1.4) 0.045 0.39
rs12483959 852 333 30 439 174 16 598 245 29 1.0 (0.84-1.2) 0.91 1.0 1.1 (0.92-1.3) 0.34 0.98
rs9626056 1019 184 9 522 82 3 734 108 14 0.86 (0.67-1.1) 0.28 0.96 0.95 (0.76-1.2) 0.70 1.0
rs34179073 1031 186 14 504 99 2 729 129 6 0.98 (0.76-1.3) 0.84 1.0 0.93 (0.74-1.2) 0.54 1.0
rs9625964 934 148 12 517 90 4 736 126 7 1.0 (0.79-1.3) 0.86 1.0 1.0 (0.81-1.3) 0.82 1.0
rs2294916 792 296 51 421 169 25 586 237 29 1.0 (0.85-1.2) 0.85 1.0 0.99 (0.83-1.2) 0.86 1.0
rs2294917 556 491 116 305 248 64 417 343 88 0.97 (0.84-1.1) 0.71 1.0 0.98 (0.85-1.1) 0.75 1.0
rs2294918 414 581 232 205 293 104 298 409 145 0.96 (0.84-1.1) 0.61 1.0 0.94 (0.83-1.2) 0.35 0.98
rs2294919 762 402 58 383 197 30 552 266 40 1.0 (0.84-1.2) 0.97 1.0 0.94 (0.81-1.1) 0.46 1.0
Table 6.2. Allelic association analysis of Adiponutrin SNPs to obesity in children and adult French case-controls. Analysis was performed using PLINK. Empirical p-
values result from a single chi-squared test, corrected p-values result from one million permutations. a 1 denotes the common allele, 2 denotes the minor allele.
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LD analysed within the controls was low throughout the gene; no pair of SNPs had an r2 value 
greater than 0.85 (see Figure 6.2). This reflects the fact  that thirteen out of  fourteen SNPs 
analysed were tag SNPs. 
Figure 6.2. Linkage disequilibrium (r2) plot of Adiponutrin SNPs genotyped in the French control 
samples. Black squares indicate 100% LD and white squares indicate zero LD. The percentage 
LD level (r2) within grey squares are displayed.
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One SNP, rs9626056 was found to be associated with BMI in the French controls (p=0.02), 
however this does not survive correction using permutations (p=0.19) (see Table 6.3).
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Genotype Numbers Mean BMI (95% CI) P-values
SNP 1,1a 1,2 2,2 1,1 1,2 2,2 Empirical Corrected
rs4823104 908 256 20 22.4 (22.2-22.5) 22.5 (22.3-22.8) 22.4 (21.5-23.3) 0.28 0.96
rs2076212 864 289 12 22.4 (22.2-22.5) 22.6 (22.3-22.8) 21.7 (20.7-22.7) 0.40 0.99
rs139047 389 573 207 22.5 (22.3-22.7) 22.3 (22.1-22.4) 22.3 (22.0-22.6) 0.22 0.92
rs734561 705 385 51 22.4 (22.2-22.6) 22.2 (22.0-22.4) 23.0 (22.3-23.6) 1.0 1.0
rs139051 502 478 150 22.4 (22.2-22.6) 22.4 (22.2-22.6) 22.2 (21.9-22.5) 0.36 0.99
rs738408 640 321 63 22.4 (22.2-22.5) 22.5 (22.3-22.8) 22.4 (21.9-22.8) 0.37 0.99
rs12483959 825 325 29 22.4 (22.2-22.6) 22.4 (22.2-22.6) 22.6 (21.8-23.3) 0.96 1.0
rs9626056 989 179 8 22.3 (22.2-22.4) 22.7 (22.4-23.0) 22.7 (21.9-23.6) 0.019 0.19
rs34179073 1000 180 14 22.4 (22.2-22.5) 22.4 (22.1-22.7) 22.6 (21.7-23.5) 0.57 1.0
rs9625964 908 145 11 22.3 (22.2-22.5) 22.6 (22.2-22.9) 23.3 (22.4-24.2) 0.060 0.48
rs2294916 766 289 49 22.4 (22.2-22.5) 22.4 (22.2-22.6) 22.6 (22.1-23.1) 0.60 1.0
rs2294917 541 474 114 22.5 (22.3-22.6) 22.3 (22.1-22.5) 22.4 (22.0-22.8) 0.29 0.97
rs2294918 405 558 227 22.4 (22.2-22.6) 22.3 (22.2-22.5) 22.5 (22.2-22.7) 0.70 1.0
rs2294919 741 389 56 22.5 (22.3-22.6) 22.3 (22.1-22.5) 22.2 (21.7-22.8) 0.16 0.82
Table 6.3. Association analysis of Adiponutrin SNPs to BMI in the French controls using linear regression with age and sex as covariates. Corrected p-values result  
from 1 million permutations. a 1 denotes the common allele, 2 denotes the minor allele.
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6.2.2 Power calculations
Using an odds ratio of 1.17 (as observed in the most significantly associated SNP, rs738408), a 
MAF of 0.22 (as observed in rs738408 in the controls), and a significance level of 0.0036 (0.05 
divided by 14 tests), the power to detect an association was 28% in the adult cohort and 4% 
in the child cohort (see Table 6.5).
SNP
Significance 
level
MAF in 
controls
Odds ratio 
in children
Odds ratio 
in adults
Power in 
children
Power in 
adults
rs4823104 0.0036 0.13 0.80 0.86 0.25 0.16
rs2076212 0.0036 0.13 0.98 0.99 0.037 0.036
rs139047 0.0036 0.42 0.98 0.98 0.040 0.041
rs734561 0.0036 0.21 0.92 1.0 0.080 0.043
rs139051 0.0036 0.34 1.1 1.1 0.093 0.089
rs738408 0.0036 0.22 1.0 1.2 0.042 0.28
rs12483959 0.0036 0.16 1.0 1.1 0.037 0.079
rs9626056 0.0036 0.083 0.86 0.95 0.097 0.045
rs34179073 0.0036 0.087 0.98 0.93 0.037 0.055
rs9625964 0.0036 0.079 1.0 1.0 0.038 0.039
rs2294916 0.0036 0.17 1.0 0.99 0.039 0.037
rs2294917 0.0036 0.31 0.97 0.98 0.043 0.040
rs2294918 0.0036 0.43 0.96 0.94 0.052 0.083
rs2294919 0.0036 0.21 1.0 0.94 0.036 0.067
Table  6.5. Power  calculations  carried  out  using  MAF  and  OR  observed  for  each  SNP 
investigated in the adiponutrin gene.
In order to achieve a statistical power of 95%, assuming a significance level of 0.0036, an odds 
ratio  of  1.2  and a MAF of  0.22,  a sample size of  18,822 samples (9,411 cases and 9,411 
controls) would be required. Assuming a significance level of 5x10-8 (genome-wide significance), 
45,654 samples would be required.
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6.3 Discussion
No  evidence  was  found  for  an  association  between  variants  in  the  adiponutrin  gene  and 
common obesity in either adults or children after correcting for multiple testing. The association  
that  was  reported  by  Johansson  et  al.369 between  three  adiponutrin  SNPs  (rs2072907, 
rs12483959 and rs139051) and obesity in Swedish Caucasians was not replicated. In this study 
rs2072907  is  tagged by  rs2294916  (r2=1.0  using  HapMap  data),  rs12483959  is  tagged by 
rs11090617 (r2=1.0 using HapMap data)  and rs139051 was genotyped directly.  rs11090617 
failed QC and rs139051 was not significanlty associated, either before or after correcting for 
multiple tests.  The reason that  these data do not  agree may be due to the relatively weak 
associations originally reported. P-values were greater than 0.01 and became non-significant 
after correcting for age. It is also possible that there was not sufficient statistical power to detect  
an  association  using  the  French  case-control  cohorts.  Using  the  minor  allele  frequencies 
observed,  statistical  power  is  estimated  at  a  maximum  probability  of  70%  to  detect  an 
association assuming an odds ratio of 0.79 as was reported369. Furthermore, tag-SNP coverage 
of the adiponutrin gene was not complete in this study since rs11090617 did not pass QC. This 
combined with the limited statistical power means that the possibility of a false-negative cannot 
be ruled out.
No associations have  been reported  between  PNPLA3 variants  and obesity  or  BMI  in  any 
GWAS  to-date.  The  most  recent  GIANT  BMI  publication  genotyped  42  SNPs  within  the 
adiponutrin gene and found no SNPs to be even nominally associated. This is therefore more 
evidence that adiponutrin gene variation is not likely to influence obesity risk.
In summary, these results suggest that variants in the adiponutrin gene do not contribute to the 
development of obesity in French Caucasians.
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Chapter 7
Investigation of genetic variants within the 
Nesfatin gene for association to common 
polygenic obesity
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7.1 Introduction
Nesfatin-1 is an 82 amino acid peptide derived from nucleobindin2 (NUCB2), a protein encoded 
by the gene NUCB2372. In rats, NUCB2 is widely expressed in the CNS as well as liver, adipose 
and the ghrelin-producing cells of the stomach, which are known to be involved in regulating 
food  intake372,493. Cleavage  of  the  NUCB2  preprotein  is  catalysed  by  PCSK1  which  also 
produces nesfatin-2 and nesfatin-3 and variants in the PCSK1 gene have been found to cause a 
form of monogenic obesity198. 
7.1.1 Central action of nesfatin-1 to reduce food intake
Injection  of  nesfatin-1  into  the  brains  of  both  rats  and  mice  has  been  shown  to  reduce 
feeding372,377. This effect is not observed for nesfatin-2 or nesfatin-3372. Additional studies in rats 
have consistently demonstrated a suppression of feeding when nesfatin-1 was injected into the 
lateral494,495,  3rd372,377,  or  4th  brain  ventricle494,  cisterna  magna494,  and  the  paraventricular 
nucleus377. Reduction in food intake is also observed in leptin-receptor deficient rats indicating 
that Nesfatin-1's action is independent of leptin372. Furthermore, knockdown of NUCB2 in the rat 
hypothalamus using an antisense oligonucleotide increases food intake372. 
In addition to the effects on feeding, continuous central infusion of nesfatin-1 into rats resulted in 
reduced body weight and administration of a NUCB2 antisense oligonucleotide increased body 
weight372. Acute injection of nesfatin-1 has also been shown to decrease body weight without 
altering food intake in a 24 hour cumulative period suggesting a  role  in  controllling energy 
expenditure494. Nesfatin-1 has been shown to directly inhibit NPY neurons in the ARC496.
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7.1.2  NUCB2   expression is regulated by metabolic factors 
Hypothalamic expression of the nesfatin gene has been found to vary under different metabolic 
conditions, which supports a role as a regulator of energy metabolism. NUCB2 transcription in 
the rat hypothalamus is significantly reduced after twenty-four hours fasting and this is restored 
after  re-feeding372,373.  Re-feeding  after  a  24  hour  fast  was  found  to  activate  nesfatin-1 
immunopositive neurons in the supraoptic nucleus as assessed by double staining for Fos and 
nesfatin-1 immunoreactivity494. In addition, intraperitoneal injections of CCK activated nesfatin-1 
immunopositive cells in the PVN and the nucleus of the solitary tract of rats pointing towards a  
role for central nesfatin-1 in the mediation of gut hormone satiety signalling494,497.
7.1.3 Peripheral nesfatin-1
The nesfatin-1 protein  has been shown to  be able  to  cross the blood-brain  barrier  in  both 
directions498,499.  NUCB2  is expressed in the stomach and using immunoreactive staining, the 
nesfatin-1 protein is co-located with ghrelin500. These results suggest that nesfatin-1 may act as 
a gut-brain hormone to influence food intake. Similar to the results of CNS administration of 
nesfatin-1, intraperitoneal injections have been shown to reduce feeding in mice501.
In humans, fasting levels of plasma nesfatin-1 have been reported to be significantly reduced in 
male obese subjects compared to non-obese male controls and were negatively correlated with 
BMI  in  the  non-obese  group381.  A recent  study  using  female  anorexic  patients  reported  a 
significant increase in circulating nesfatin-1 compared to age-matched healthy controls382.
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7.1.4 Nesfatin-1 as a pharmacological target for the treatment of obesity
Because  leptin  resistance  is  normally  associated  with  obesity  and  peripheral  and  central  
injection of nesfatin-1 exerts an anorexigenic effect independent of leptin action372, targeting the 
nesfatin-1 pathway may provide a viable approach for pharmacological interventions of obesity.
7.1.5  NUCB2   variation and obesity 
In 2007 when this gene was selected for study in this project, no reported associations between 
NUCB2 variation and obesity were found in the literature. In 2011, an association was reported 
between 3  NUCB2 SNPs (rs1330, rs214101 and rs757081) and obesity (p=0.016, 0.015 and 
0.034)  and  three  SNPs (rs214086,  rs214101 and rs757081)  and BMI (p=0.023,  0.002 and 
0.008) in male but not female Belgian Caucasians502.
No significant associations between NUCB2 variation and obesity or BMI have been reported in 
any GWAS to-date. In the French GWAS253,18 SNPs within the region were nominally significant 
with  the  most  significant  result,  rs7129639,  p-value  of  1.8x10-3.  The most  recent  GIANT 
GWAS233 found  a  p-value  of  5.4x10-4 to  rs542274,  a  SNP within  the  NUCB2 region  (data 
acessed online445)(see Figure 7.1).
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Figure 7.1. SNPs analysed for association to BMI in NUCB2 region in the GIANT GWAS233.
Due to its role in regulating appetite, the Nesfatin gene is a plausible candidate for common 
polygenic obesity in humans. Genetic variants within the NUCB2 gene and the surrounding LD 
block were genotyped and investigated for associations to common polygenic obesity using 
French obese cases and non-obese controls (see Materials and Methods for details).
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7.2 Results
7.2.1 SNP Selection and Case-Control Genotyping
Thirty-six SNPs were genotyped within the LD block containing the NUCB2 gene, including 33 
SNPs  tagging  all  HapMap  SNPs  within  the  region  (mean  r2=0.965,  see  Figure  7.2).  This 
included  125kb  upstream  of  the  gene  and  69kb  downstream  and  the  downstream  region 
contains the diabetes gene, KCNJ11. After genotyping quality control, thirty-two SNPs remained 
with a mean success rate of 94%. Of these, twenty-seven had minor allele frequencies above 
the required five percent and were taken forward for analysis (see Table 7.1). Of the twenty-one  
tag SNPs genotyped within the region, seventeen passed QC and were analysed.
Figure 7.2. Map of NUCB2 gene and surrounding region with positions of SNPs genotyped in 
this project. *Tag SNPs. █ NUCB2 exons.
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SNP
Position on 
Chromosome 
11a
Position Relative to 
NUCB2 Gene
Minor Allele 
Frequency
rs2302510* 17168986 Upstream <0.01
rs16933873* 17172737 Upstream 0.38
rs11826763 17191534 Upstream 0.05
rs214935* 17193122 Upstream 0.48
rs17647408* 17229466 Upstream 0.24
rs2354863 17230389 Upstream 0.10
rs2079293 17238051 Upstream 0.02
rs12295879 17244473 Upstream 0.03
rs7108861* 17255001 Upstream 0.08
rs10832749* 17260867 Upstream 0.20
rs10832750* 17260918 Upstream 0.48
rs214083* 17298859 Intron 1 0.46
rs7127347 17300844 Intron 1 0.25
rs214106* 17311811 Intron 2 0.50
rs10832756* 17314345 Intron 2 0.09
rs1330 17316029 Intron 2 0.45
rs34405111 17351721 Downstream <0.01
rs12292418 17351748 Downstream <0.01
rs12365375 17356826 Downstream 0.08
rs10832767 17359017 Downstream 0.08
rs6486364* 17386257 Downstream <0.01
rs7937091* 17392300 Downstream 0.32
rs10832782* 17397273 Downstream 0.48
rs10832783 17401134 Downstream 0.13
rs7110094 17401519 Downstream 0.25
rs3741203* 17403163 Downstream 0.37
rs2285676* 17408025 Downstream 0.45
rs11024273* 17412717 Downstream (KCNJ11) 0.39
rs8192690 17414570 Downstream (KCNJ11) 0.13
rs757110* 17418477 Downstream 0.46
rs1799859 17419279 Downstream 0.40
rs12422139 17422397 Downstream 0.14
Table  7.1.  NUCB2 SNPs  successfully  genotyped  with  observed  minor  allele  frequencies. 
aPositions in bp correspond to NCBI build 37.1 measured from the top of the p arm of the 
chromosome.
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One SNP, rs10832756 was associated with obesity in children (p=0.02, OR=0.6, CI=0.38-0.93), 
however this does not survive correction using permutations (p=0.33, see Table 7.2). Analysis 
was  repeated  excluding  subjects  with  T2D,  impaired  fasting  glucose  or  impaired  glucose 
tolerance  (any  patient  with  fasting  blood  glucose  >5.6  mmol/l)  in  order  to  filter  out  any 
association that may be present between SNPs in LD with KCNJ11 and diabetes, which might 
be masking associations to obesity. After removing these subjects, two SNPs, rs10832756 and 
rs757110 were nominally associated with obesity in children (p-values: 0.042, 0.039; OR: 0.61, 
0.83;  CI:  0.38-0.99,  0.70-0.99),  however  these associations  do not  withstand correction for 
multiple testing using permutations (see Table 7.3). 
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Genotype Numbers
Controls Children Adults
Odds Ratio Children (95% 
CI)
P-values Children
Odds Ratio Adults 
(95% CI)
P-values Adults
SNP 1,1a 1,2 2,2 1,1 1,2 2,2 1,1 1,2 2,2 Empirical Corrected Empirical Corrected
rs16933873 679 461 65 334 227 42 468 322 55 1.1 (0.91-1.3) 0.41 1.0 1.1 (0.92-1.2) 0.44 1.0
rs11826763 1171 61 0 587 27 0 772 44 0 0.89 (0.56-1.4) 0.62 1.0 1.1 (0.74-1.6) 0.66 1.0
rs214935 377 599 248 195 295 119 269 385 165 0.96 (0.84-1.1) 0.58 1.0 0.96 (0.84-1.1) 0.50 1.0
rs17647408 914 296 18 448 139 18 576 201 22 1.1 (0.89-1.3) 0.44 1.0 1.2 (0.97-1.4) 0.11 0.84
rs2354863 1097 116 8 562 58 4 759 84 2 0.98 (0.72-1.3) 0.89 1.0 0.96 (0.73-1.3) 0.78 1.0
rs12295879 1163 39 0 596 17 0 816 26 0 0.85 (0.48-1.5) 0.57 1.0 0.95 (0.58-1.6) 0.87 1.0
rs7108861 1074 90 5 361 28 0 752 67 0 0.84 (0.55-1.3) 0.42 1.0 0.95 (0.70-1.3) 0.78 1.0
rs10832749 965 261 16 477 123 12 657 151 11 1.0 (0.83-1.3) 0.85 1.0 0.88 (0.72-1.1) 0.22 0.98
rs10832750 414 597 213 218 302 107 295 368 137 0.97 (0.85-1.1) 0.71 1.0 0.93 (0.82-1.1) 0.30 1.0
rs214083 414 507 168 200 257 92 335 355 119 1.1 (0.92-1.2) 0.43 1.0 0.92 (0.80-1.1) 0.20 0.97
rs7127347 871 322 35 465 142 13 608 223 18 0.83 (0.68-1.0) 0.053 0.62 0.95 (0.80-1.1) 0.54 1.0
rs214106 329 612 297 170 307 136 225 413 183 0.94 (0.82-1.1) 0.39 1.0 0.95 (0.84-1.1) 0.43 1.0
rs10832756 1067 117 7 335 22 1 737 83 2 0.60 (0.38-0.93) 0.021 0.33 0.96 (0.73-1.3) 0.78 1.0
rs1330 507 543 152 266 273 74 340 381 108 0.96 (0.83-1.1) 0.60 1.0 1.0 (0.91-1.2) 0.62 1.0
rs12365375 1128 104 6 559 57 0 769 59 1 0.99 (0.71-1.4) 0.94 1.0 0.78 (0.57-1.1) 0.13 0.87
rs10832767 1124 107 6 554 58 0 756 59 1 0.98 (0.71-1.4) 0.93 1.0 0.77 (0.56-1.1) 0.11 0.83
rs7937091 810 380 48 388 196 27 513 272 34 1.1 (0.91-1.3) 0.38 1.0 1.1 (0.94-1.3) 0.23 0.98
rs10832782 432 575 234 200 304 104 280 397 134 1 .0(0.87-1.2) 0.96 1.0 0.96 (0.84-1.1) 0.52 1.0
rs10832783 1065 159 6 545 78 3 735 107 4 0.96 (0.73-1.3) 0.78 1.0 0.98 (0.76-1.3) 0.85 1.0
rs7110094 892 308 28 443 156 15 595 206 19 1.0 (0.85-1.2) 0.80 1.0 1.0 (0.84-1.2) 0.96 1.0
rs3741203 665 469 89 324 234 45 467 283 71 1.0 (0.87-1.2) 0.79 1.0 0.97 (0.84-1.1) 0.69 1.0
rs2285676 509 549 163 254 285 85 360 366 119 1.0 (0.89-1.2) 0.71 1.0 1.0 (0.88-1.1) 0.96 1.0
rs11024273 600 479 98 298 245 53 456 304 74 1.0 (0.89-1.2) 0.63 1.0 0.92 (0.80-1.1) 0.28 0.99
rs8192690 1063 172 6 529 81 4 725 94 5 0.98 (0.75-1.3) 0.86 1.0 0.84 (0.66-1.1) 0.17 0.95
rs757110 480 561 177 260 286 78 328 400 118 0.91 (0.79-1.1) 0.20 0.97 1.0 (0.88-1.1) 0.98 1.0
rs1799859 627 477 74 315 250 43 424 328 72 1.1 (0.91-1.2) 0.47 1.0 1.1 (0.97-1.3) 0.14 0.91
rs12422139 1052 170 6 528 87 3 716 120 8 1.0 (0.78-1.3) 0.90 1.0 1.1 (0.87-1.4) 0.44 1.0
Table 7.2. Allelic association analysis of NUCB2 SNPs to obesity in children and adult French case-controls. Analysis was performed using PLINK. Empirical p-values result from a  
single chi-squared test, corrected p-values result from one million permutations. a 1 denotes the common allele, 2 denotes the minor allele.
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Controls Obese Children Obese Adults
1,1a 1,2 2,2 1,1 1,2 2,2 1,1 1,2 2,2 Odds Ratio Children (95% 
CI)
P-values Children
Empirical Corrected Odds Ratio Adults 
(95% CI)
P-values Adults
Empirical Corrected
rs16933873 304 211 30 304 206 40 205 142 28 1.1 (0.88-1.3) 0.54 1.0 1.1 (0.88-1.3) 0.46 1.0
rs11826763 508 33 0 533 27 0 344 19 0 0.79 (0.47-1.3) 0.36 1.0 0.85 (0.48-1.5) 0.59 1.0
rs214935 181 250 103 179 270 106 130 158 78 1.0 (0.87-1.2) 0.73 1.0 1.0 (0.83-1.2) 0.93 1.0
rs17647408 400 130 6 410 125 17 253 92 12 1.1 (0.86-1.4) 0.44 1.0 1.3 (0.97-1.7) 0.077 0.74
rs2354863 496 48 1 516 51 3 331 43 0 1.1 (0.74-1.6) 0.65 1.0 1.3 (0.83-1.9) 0.26 0.99
rs12295879 515 18 0 545 15 0 361 12 0 0.79 (0.40-1.6) 0.50 1.0 0.95 (0.46-2.0) 0.90 1.0
rs7108861 467 34 2 324 24 0 333 31 0 0.91 (0.54-1.5) 0.72 1.0 1.1 (0.70-1.8) 0.61 1.0
rs10832749 411 128 7 432 115 11 292 67 5 0.94 (0.73-1.2) 0.61 1.0 0.79 (0.59-1.1) 0.12 0.88
rs10832750 170 264 108 194 280 100 132 161 62 0.9 (0.76-1.1) 0.24 1.0 0.84 (0.70-1.0) 0.083 0.76
rs214083 194 215 73 182 233 85 152 158 52 1.1 (0.94-1.4) 0.20 0.97 0.95 (0.78-1.2) 0.60 1.0
rs7127347 386 143 15 422 134 12 264 107 5 0.85 (0.68-1.1) 0.19 0.96 0.97 (0.75-1.3) 0.84 1.0
rs214106 142 256 143 152 284 123 106 173 87 0.90 (0.76-1.1) 0.21 0.98 0.90 (0.74-1.1) 0.26 0.99
rs10832756 454 52 5 294 22 1 321 44 1 0.61 (0.38-0.99) 0.042 0.53 1.0 (0.70-1.5) 0.85 1.0
rs1330 228 227 78 242 254 64 153 167 48 0.92 (0.77-1.1) 0.37 1.0 0.99 (0.82-1.2) 0.93 1.0
rs12365375 509 38 2 512 50 0 345 26 0 1.2 (0.77-1.8) 0.46 1.0 0.91 (0.55-1.5) 0.72 1.0
rs10832767 504 41 2 507 51 0 339 26 0 1.1 (0.74-1.7) 0.60 1.0 0.86 (0.53-1.4) 0.55 1.0
rs7937091 363 156 23 353 181 23 226 124 13 1.1 (0.90-1.4) 0.30 1.0 1.1 (0.90-1.4) 0.29 1.0
rs10832782 189 256 100 180 277 98 130 173 61 1.0 (0.87-1.2) 0.71 1.0 0.95 (0.78-1.2) 0.58 1.0
rs10832783 474 69 3 496 73 3 327 47 1 1.0 (0.73-1.4) 0.97 1.0 0.95 (0.65-1.4) 0.78 1.0
rs7110094 386 137 10 403 144 13 261 96 8 1.0 (0.82-1.3) 0.77 1.0 1.1 (0.81-1.4) 0.72 1.0
rs3741203 293 205 35 293 213 44 218 114 34 1.1 (0.90-1.3) 0.41 1.0 0.95 (0.77-1.2) 0.66 1.0
rs2285676 231 242 65 231 260 79 167 157 51 1.1 (0.92-1.3) 0.30 1.0 1.0 (0.82-1.2) 0.99 1.0
rs11024273 267 219 35 270 223 50 221 118 35 1.1 (0.91-1.3) 0.31 1.0 0.87 (0.71-1.1) 0.22 0.98
rs8192690 463 78 3 481 76 3 324 42 1 0.94 (0.69-1.3) 0.72 1.0 0.76 (0.52-1.1) 0.16 0.94
rs757110 204 245 90 236 267 67 145 169 60 0.83 (0.70-0.99) 0.039 0.50 0.97 (0.8-1.2) 0.73 1.0
rs1799859 293 200 33 287 231 37 188 144 36 1.1 (0.92-1.4) 0.25 0.99 1.2 (0.99-1.5) 0.060 0.63
rs12422139 472 69 4 483 80 1 314 57 4 1.0 (0.75-1.4) 0.85 1.0 1.3 (0.88-1.8) 0.21 0.98
Table 7.3. Allelic association analysis of NUCB2 SNPs to obesity in non-diabetic children and adult French case-controls. Analysis was performed using PLINK. Empirical p-values 
result from a single chi-squared test, corrected p-values result from one million permutations. a 1 denotes the common allele, 2 denotes the minor allele.
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Genotype Counts Mean BMI (95% CI) P-values
SNP 1,1a 1,2 2,2 1,1 1,2 2,2 Empirical Corrected
rs16933873 665 445 63 22.4 (22.3-22.6) 22.4 (22.2-22.6) 22.4 (21.9-22.9) 0.96 1.0
rs11826763 1139 59 0 22.4 (22.2-22.5) 22.7 (22.1-23.2) - 0.28 0.99
rs214935 370 583 239 22.4 (22.2-22.6) 22.4 (22.3-22.6) 22.2 (21.9-22.4) 0.21 0.97
rs17647408 892 285 16 22.4 (22.3-22.5) 22.4 (22.1-22.6) 22.3 (21.2-23.4) 0.79 1.0
rs2354863 1067 113 8 22.4 (22.3-22.5) 22.7 (22.3-23.0) 22.3 (21.1-23.5) 0.33 1.0
rs12295879 1130 39 0 22.4 (22.3-22.5) 22.9 (22.2-23.5) - 0.15 0.92
rs7108861 1047 84 5 22.4 (22.3-22.5) 22.3 (21.9-22.8) 21.2 (19.3-23.2) 0.46 1.0
rs10832749 936 255 16 22.4 (22.2-22.5) 22.5 (22.2-22.7) 21.8 (20.7-22.9) 0.82 1.0
rs10832750 400 580 212 22.3 (22.1-22.5) 22.5 (22.3-22.7) 22.4 (22.1-22.7) 0.31 1.0
rs214083 403 492 166 22.4 (22.2-22.6) 22.5 (22.3-22.6) 22.3 (22.0-22.6) 0.63 1.0
rs7127347 846 314 34 22.4 (22.3-22.6) 22.4 (22.2-22.6) 22.0 (21.3-22.8) 0.57 1.0
rs214106 318 592 293 22.2 (22.0-22.4) 22.5 (22.3-22.6) 22.4 (22.2-22.7) 0.18 0.95
rs10832756 1038 114 7 22.4 (22.2-22.5) 22.4 (22.0-22.8) 22.1 (21.4-22.8) 0.89 1.0
rs1330 492 527 149 22.3 (22.1-22.5) 22.5 (22.3-22.7) 22.4 (22.1-22.8) 0.15 0.91
rs12365375 1099 98 6 22.4 (22.3-22.5) 22.3 (21.9-22.8) 21.9 (19.6-24.2) 0.55 1.0
rs10832767 1096 101 6 22.4 (22.3-22.5) 22.3 (21.9-22.7) 21.9 (19.6-24.2) 0.54 1.0
rs7937091 790 366 47 22.4 (22.3-22.6) 22.3 (22.1-22.5) 22.5 (21.9-23.1) 0.56 1.0
rs10832782 418 562 226 22.4 (22.2-22.6) 22.4 (22.2-22.6) 22.4 (22.1-22.7) 0.86 1.0
rs10832783 1035 154 6 22.4 (22.2-22.5) 22.7 (22.4-23.1) 22.7 (20.4-24.9) 0.042 0.53
rs7110094 868 298 27 22.4 (22.2-22.5) 22.4 (22.1-22.6) 22.2 (21.5-23.0) 0.88 1.0
rs3741203 644 459 86 22.4 (22.2-22.5) 22.4 (22.2-22.6) 22.1 (21.7-22.6) 0.63 1.0
rs2285676 491 535 160 22.4 (22.2-22.6) 22.4 (22.3-22.6) 22.2 (21.9-22.6) 0.38 1.0
rs11024273 582 468 96 22.4 (22.3-22.6) 22.5 (22.3-22.6) 21.9 (21.4-22.3) 0.11 0.85
rs8192690 1033 167 6 22.4 (22.3-22.5) 22.4 (22.1-22.7) 22.4 (21.7-23.0) 0.99 1.0
rs757110 467 545 171 22.3 (22.1-22.5) 22.5 (22.3-22.7) 22.6 (22.2-22.9) 0.076 0.73
rs1799859 613 460 73 22.5 (22.3-22.6) 22.4 (22.2-22.6) 22.4 (21.9-22.9) 0.56 1.0
rs12422139 1020 167 6 22.4 (22.3-22.5) 22.4 (22.1-22.7) 21.9 (20.7-23.2) 0.83 1.0
Table  7.4. Association  analysis  of  NUCB2 SNPs  to  BMI  using  linear  regression  with  age  and  sex  as  covariates.  Corrected  p-values  result  from 1  million 
permutations. a1 denotes the common allele, 2 denotes the minor allele.
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One SNP, rs10832783, was nominally associated with BMI in the French controls (p=0.042), 
however this association was not significant after correction using permutations (see Table 7.4).
Linkage disequilibrium within the region was analysed within the controls (see Figure 7.3). No 
LD blocks were identified and LD was low within the region, however, NUCB2 SNP, rs214083 
was in high LD with KCNJ11 SNP, rs11024273 (r2 = 0.71).
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Figure 7.3. Linkage disequilibrium (r2) plot of SNPs genotyped in  NUCB2 and the surrounding region in the French control samples.  ●NUCB2 SNPs, ■ KCNJ11 
SNPs. Back squares indicate 100% LD and white squares indicate zero LD. The percentage LD level (r2) within grey squares are displayed.
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7.2.2 Power calculations
Using an odds ratio of 0.6 (as observed in the most significantly associated SNP, rs10832756),  
a MAF of 0.06 (as observed in rs10832756 in the controls), and a significance level of 0.0019 
(0.05 divided by 27 tests), the power to detect an association was <1% in the adult cohort and 
13% in the child cohort.
SNP
Significance 
level
MAF in 
controls
Odds ratio 
in children
Odds ratio 
in adults
Power in 
children
Power in 
adults
rs16933873 0.0019 0.25 1.1 1.1 <0.01 <0.01
rs11826763 0.0019 0.025 0.89 1.1 <0.01 <0.01
rs214935 0.0019 0.45 0.96 0.96 <0.01 <0.01
rs17647408 0.0019 0.14 1.1 1.2 <0.01 0.029
rs2354863 0.0019 0.054 0.98 0.96 <0.01 <0.01
rs12295879 0.0019 0.016 0.85 0.95 <0.01 <0.01
rs7108861 0.0019 0.043 0.84 0.95 <0.01 <0.01
rs10832749 0.0019 0.12 1.0 0.88 <0.01 0.014
rs10832750 0.0019 0.42 0.97 0.93 <0.01 0.011
rs214083 0.0019 0.39 1.1 0.92 <0.01 0.014
rs7127347 0.0019 0.16 0.83 0.95 0.036 <0.01
rs214106 0.0019 0.49 0.94 0.95 <0.01 <0.01
rs10832756 0.0019 0.055 0.60 0.96 0.13 <0.01
rs1330 0.0019 0.35 0.96 1.0 <0.01 <0.01
rs12365375 0.0019 0.047 0.99 0.78 <0.01 0.022
rs10832767 0.0019 0.048 0.98 0.77 <0.01 0.025
rs7937091 0.0019 0.19 1.1 1.1 <0.01 0.013
rs10832782 0.0019 0.42 1.0 0.96 <0.01 <0.01
rs10832783 0.0019 0.070 0.96 0.98 <0.01 <0.01
rs7110094 0.0019 0.15 1.0 1.0 <0.01 <0.01
rs3741203 0.0019 0.26 1.0 0.97 <0.01 <0.01
rs2285676 0.0019 0.36 1.0 1.0 <0.01 <0.01
rs11024273 0.0019 0.29 1.0 0.92 <0.01 0.012
rs8192690 0.0019 0.074 0.98 0.84 <0.01 0.016
rs757110 0.0019 0.38 0.91 1.0 0.014 <0.01
rs1799859 0.0019 0.27 1.1 1.1 <0.01 0.021
rs12422139 0.0019 0.074 1.0 1.1 <0.01 <0.01
Table  7.6. Power  calculations  carried  out  using  MAF  and  OR  observed  for  each  SNP 
investigated in the NUCB2 gene region.
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To achieve a statistical power of 95%, assuming a significance level of 0.0019, a MAF of 0.06 
and  an odds ratio  of  0.6,  3,891  cases  and  3,891  controls  would  be  required.  Assuming a 
significance level of 5x10-8, this rises to 8,683 cases and 8,683 controls (see Figure 7.4). If the 
real odds ratio is greater than 0.6 then this figure will rise (see Figure 7.5).
Figure  7.4. Sample  size  plotted  with  statistical  power  for  a  SNP with  MAF=0.0.6  (as  was 
observed for rs10832756). α is the significance level: 0.0019 for 26 statistical tests and 5x10 -8 
for genome-wide significance.
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Figure 7.5. Sample size (number of cases, with number of controls=number of cases) required 
for varying odds ratios in order to achieve a statistical power of 95% for a SNP with MAF=0.06  
(as was observed for rs10832756). α is the significance level: 0.0019 for 26 statistical tests and 
5x10-8 for genome-wide significance.
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7.3 Discussion
This  study  was  carried  out  to  test  the  hypothesis  that  variants  in  NUCB2  influenced 
susceptibility to obesity. This was plausible because nesfatin-1, a product of the NUCB2 gene is  
expressed in appetite controlling regions of the brain and injection of recombinant nesfatin-1 into 
the brains of rodents suppresses feeding, suggesting a role of the gene in controlling satiety372. 
During the practical stage of this PhD, no studies had been published which investigate such an 
association.
No significant associations were discovered between SNPs in and near the NUCB2 gene and 
obesity  in  either  adults  or  children.  Rs10832756  was  nominally  associated  with  obesity  in  
children  (p=0.02)  however  this  association  became  non-significant  after  correction  using 
permutations, which suggests that this is a false positive rather than a genuine association. 
When  diabetic  patients  were  removed  from  the  analysis  the  same  SNP  was  nominally 
significant but at a greater p-value (p=0.042). 
No significant associations between NUCB2 gene variation and obesity phenotypes have been 
reported in any GWAS to date. The most recent GIANT BMI233 and WHR262 studies investigated 
25 SNPs within  the  NUCB2 region and found no significant  associations although nominal 
associations  to  BMI  were  found  including  to  rs542274  (p=5.4x10-4).  This  is  tagged  by 
rs10832750 in this study (p=0.30 in adults and 0.71 in children).
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Out of thirty-six SNPs genotyped in this study, twenty-seven were analysed for associations to 
obesity. Nine SNPs failed QC or had low minor allele frequencies. Furthermore, rare variants 
(<5%) were not investigated and so coverage of the gene was not complete.  Statistical power 
calculations indicate that this study was underpowered to detect associations with the effect  
sizes observed. These two points mean that the possibility of a false-negative cannot be ruled 
out.
In summary, these results suggest that variants in the NUCB2 gene are not likely to contribute 
to the development of obesity in a French Caucasian population.
.
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Chapter 8
Investigation of genetic variation within the IRS-
1 gene and transcription levels for 
association to BMI
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8.1 Introduction
Insulin receptor  substrate 1 (IRS-1) is a signalling molecule encoded by the IRS-1 gene in 
humans which is located on the long arm of chromosome 2 and contains two exons. IRS-1 is  
crucial for transmitting signals from insulin and IGF-1 receptors to intracellular pathways that  
control metabolism384.
8.1.1 IRS-1 and glucose metabolism
IRS-1  knockout  mice  have  mild  diabetic  phenotypes  as  well  as  a  50%  reduction  in  body 
weight384,386. A number of variants within the IRS-1 gene have been found to influence T2D risk,  
including  a  non-synonymous  coding  SNP,  rs1801278  which  has  been  reported  by  several 
studies224,387,504. A variant within the IRS-1 gene was recently found to be significantly associated 
with T2D, insulin resistance and hyperinsulinemia in a GWA study carried out by collaborators in 
France388. Genotyping of the associated SNP, rs2943641 in Swedish families was carried out 
during this study but the results were not published.
8.1.2 IRS-1 and obesity
Adipocytes from IRS-1 knockout mice have reduced differentiation and lipid accumulation386. 
Associations to obesity phenotypes have also been reported including BMI and WHR in a Dutch 
study505,  BMI  in  African  Americans506 and  blood-leptin  concentrations  in  obese  subjects507 
although these associations have not been replicated.
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No SNPs within the IRS1 region were found to be nominally significant in the French GWAS253 
or any of the GIANT publications263,233. A more recent GWAS that investigated associations to 
body fat percentage, however reported a significant association to a SNP near the IRS1 gene255. 
This finding was published after the completion of the practical work in this thesis.
Given its important role in the insulin signalling pathway, the IRS-1 gene is a plausible candidate 
gene  for  obesity  and  this  study  was  designed  to  investigate  the  possibility  of  genetic  
associations  between rs2943641,  its  expression  levels  and obesity  in  the  Swedish  sib-pair 
cohort (see Materials and Methods for details). Analysing transcript expression data is also an 
opportunity to explore the possibility that the association to T2D reported by Rung  et al.388 is 
mediated via altering levels of transcription.
193
8.2 Results
Genotyping of the  IRS-1 SNP, rs2943641 in the Swedish families cohort was carried out by 
collaborators in France388. No association was found between rs2943641 and BMI (corrected 
p=0.5, see Table 8.1). 
Genotype 
Counts Mean BMI (95% CI) P-Values
1,1a 1,2 2,2 1,1 1,2 2,2 Empirical Corrected
214 259 106 29.0 (28.1-29.9) 28.9 (28.1-29.7) 28.4 (27.0-29.7) 0.49 0.50
Table 8.1. Association analysis of IRS-1 SNP, rs2943641 with BMI corrected for age and sex in 
the Swedish families using the QFAM test  implemented by PLINK.  a1 denotes the common 
allele and 2 denotes the rare allele. Corrected p-values result from one million permutations.
Microarray  data  was  available,  which  included  measurements  of  IRS-1 transcript  levels  in 
subcutaneous adipose tissue for each sibling within the Swedish sib-pair cohort.  A significant 
association  was  found  between rs2943641  and  IRS-1 transcript  (corrected  p=1.0x10-5,  see 
Table 8.2). 
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Genotype 
Counts Mean transcription level (95% CI) P-values
1a,1 1,2 2,2 1,1 1,2 2,2 Empirical Corrected
89 133 42 46.7 (43.2-50.2) 35.9 (34.1-37.7) 33.8 (31.8-35.8) 2.8x10-9 1.0 x 10-5
Table 8.2. Association analysis of IRS-1 SNP, rs2943641 with IRS-1 transcript level corrected for age, 
sex and BMI in the Swedish families using the QFAM test implemented by PLINK.  a1 denotes the 
common allele and 2 denotes the rare allele. Corrected p-values result from one million permutations.
IRS-1 expression was analysed for association with obesity. Between obese and non-obese groups, a 
significant difference was found in IRS-1 transcript levels after correcting for relatedness, age and sex 
(p=1.0x10-15, see Figure 8.1 and Table 8.3). 
195
Figure 8.1.  Box-plot of  IRS-1 transcript levels in subcutaneous adipose tissue with obese and non-
obese subjects from Swedish sib-pairs displayed separately.  IRS-1 transcription is  the microarray 
signal value corrected for age, sex and relatedness. 
Number  of  Non-
obese
Number  of 
Obese
Mean  Difference  in  IRS-1 
transcription (95% CI) P-value
190 151 11.1 (8.33-13.9) 1.0x10-15
Table 8.3. T-test of subcutaneous adipose IRS-1 transcription in obese and non-obese subjects from 
Swedish  sib-pairs.  IRS-1 transcription  is  the  microarray  signal  value  corrected  for  age,  sex  and 
relatedness.
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8.3 Discussion
These results demonstrate a significant  association between IRS-1 variant,  rs2943641 and IRS-1 
transcription levels in the subcutaneous adipose tissue of Swedish sib-pairs. The p-value reported 
here does remain significant in a genome-wide context, however replication of this result is needed 
before a genuine association is established. Therefore variation in the  IRS-1 gene is likely to be 
responsible for modifying its expression in adipose tissue and if this is true in other tissues as well  
then  this  may  explain  the  associations  reported  between  the  gene  and  T2D388.  No  significant 
association was observed between IRS-1 variation and BMI. Rs2943641 is located 500kbp upstream 
of the transcription start point of the IRS-1 gene. This means it could lie within an enhancer element 
where it affects binding of a transcription factor. Alternatively it might be in LD with some other variant  
that is responsible for modifying expression of the gene, either in the promoter or some enhancer  
region. Further work is required in order to locate the causative variant. 
A significant reduction in transcription levels was found in obese compared to non-obese siblings. This 
difference might be an indication that IRS-1 expression levels influence BMI or it might be the case  
that the disease state of obesity is responsible for altering expression of the gene. The lack of an 
association between IRS-1 genetic variation and BMI makes it more likely that an individual's body 
weight is causing the observed association.
A recent GWAS discovered a significant association between rs2943650, a SNP near IRS-1 and body 
fat percentage255. Rs2943650 is in high LD with rs2943641 (r2=1.0 in the HapMap CEU population). 
The  failure  to  replicate  this  association  is  likely  due  to  the  reduced  statistical  power  in  this 
investigation. Alternatively it may the case that this SNP modifies body fat percentage but not BMI.  
Since no IRS-1 variants are significantly associated to BMI in any GWAS to-date this is a plausible 
explanation.
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In summary, no evidence was found for an association between IRS-1 gene variation and BMI in a 
Swedish family cohort, however a significant association between gene variation and expression in 
subcutaneous adipose tissue was discovered.
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Chapter 9
Investigation of DNA methylation for 
associations with human polygenic obesity
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9.1 Introduction
DNA methylation is an epigenetic modification of DNA in which the 5 position of  a cytosine 
residue within a CpG dinucleotide is methylated. CpG dinucleotides are under-represented in 
the human genome (observed/expected ratio of 0.2), however certain regions exist that contain 
a high density of CpG sites (observed/expected ratio of 0.6). These are called CpG islands and  
are  found  in  the  promoter  regions  of  approximately  three  quarters  of  all  known  genes 508. 
Elevated methylation in gene promoters is correlated with a reduction in gene expression509.
There is evidence that DNA methylation patterns can be heritable. In mice CpG methylation at 
loci affecting expression of the  agouti gene, which controls fur colour, have been found to be 
resistant to demethylation during reprogramming510. This means that a phenotype of yellow fur, 
obesity,  diabetes  and  increased  susceptibility  to  cancer  can  be  inherited  over  multiple 
generations278,511. In humans, inherited methylation of CpG sites within MLH1 and MSH2 gene 
promoters have been found to cause some cases of familial colorectal cancer512,513.  A recent 
twin study revealed a significant difference in the DNA methylation patterns between dizygotic 
twins  compared  to  monozygotic  twins  which  cannot  be  explained  by  underlying  genetic 
differences309.  This  demonstrates  that  DNA methylation  is  at  least  partially  heritable,  which 
opens the possibility  that  it  may contribute to complex diseases such as obesity.  The most 
established example of altered DNA methylation that results in obesity is Prader-Willi Syndrome 
which can be caused by deficiencies in the imprinting of the paternal copy of  chromosome 
15514,515. Genomic imprinting has also been reported to influence common obesity at three loci 
spread across the genome314. Overfeeding of rats has been demonstrated to lead to changes in 
the methylation pattern of  the  POMC gene291 and methylation of  the  TNFa gene has been 
shown to predict response to weight loss in humans315.
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The satiety signal leptin is a key protein involved in the control of appetite and mutations in the  
gene are responsible  for  a Mendelian form of  obesity.  Additionally,  variants  in  its  gene are 
associated with both obesity and levels of leptin hormone in circulating blood, although these 
associations have not been replicated in any GWAS to date516,517,518. The leptin CpG island is 
differentially methylated across tissues, which points to a possible role of methylation in the 
regulation of this gene391. Methylation of one CpG site in the leptin promoter has been shown to 
be increased in diet-induced obesity in rats393.
Methylation at a single CpG site can vary within a single tissue type in a single individual and so  
a suitable experimental method for quantifying methylation levels was required. At the time a 
method  was chosen,  methods used  for  quantification of  CpG methylation included  cloning-
based  sequencing519,520 and  pyrosequencing521,522. The  cloning  method  is  somewhat  labour 
intensive  and  therefore  time  consuming  when  dealing  with  the  large  numbers  of  samples 
required for association studies. It requires cloning of the PCR product before sequencing and 
typically at least ten clones (and preferably more) need to be sequenced in order to determine 
the  quantitative  level  of  methylation  at  each  CpG  site  from  a  mixture  of  PCR  products. 
Pyrosequencing can be used to quickly and accurately measure quantitative methylation status 
at single CpG sites in large numbers of samples but its short read lengths (typically 30bp) mean 
that it cannot be used to measure more than a few CpG sites at a time.
More  recently  Sequenom  have  offered  a  method  that  uses  their  matrix-assisted  laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry technology to distinguish 
between methylated and unmethylated residues after PCR and primer extensions carried out on 
bisulfite treated DNA. This has the advantage of being both high-throughput and accurate for 
measurements of  quantitative  methylation at  single  residues.  However it  is  limited in  that  it 
cannot be used to analyse every residue within a CpG island in a single assay523. Ilumina have 
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also developed an array based method that can measure methylation at large numbers of CpG 
residues across the genome. Typically though, these arrays only investigate a small number of 
CpG sites per  gene promoter  and as such are not  suitable  for  investigation of  entire  CpG 
islands in candidate genes524.
Therefore  a  method  that  uses  direct  sequencing  was  needed  in  order  to  provide  quick,  
inexpensive and accurate measurements of quantitative DNA methylation at multiple CpG sites 
within a CpG island, suitable for investigation of methylation in candidate genes in large sample 
numbers.
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9.2 Results
9.2.1 Developing a Protocol for Measuring CpG Methylation
Firstly,  bisulfite  sequencing  within  a  stock  sample  of  human genomic  DNA (Promega)  was 
carried out to verify that the protocol was effective at detecting methylation states at CpG sites 
within  the  POMC  promoter  region  CpG  island  in  genomic  DNA derived  from  blood  (see 
Materials and Methods). This gene was chosen as methylation is well established525. Two sets 
of PCR primers were designed to amplify two regions of 418bp and 369bp within the POMC 
promoter (see Appendix for primer sequences). PCR of both primer sets was successful but the 
sequencing reactions were only successfully completed in the first PCR product. This gave a 
clean read for the first 270bp which provided enough information to determine that nine out of 
twenty-one  CpG  sites  within  the  sequenced  region  were  methylated  as  indicated  by 
unconverted C residues. At each of the nine loci where C residues were observed, smaller T 
peaks were also present indicating that the DNA samples contained a mixture of methylated and 
unmethylated DNA. At ten CpG sites that were converted, smaller C peaks were observed,  
again indicating a mixture of methylated and unmethylated DNA. In two cases a CpG site had 
both C and T peaks of similar size and these were counted as being methylated (see Figure 1).  
It  is unlikely that the mixed bases observed could be due to incomplete conversion of non-
methylated C residues because all non-CpG C residues (that would have appeared in the DNA 
sequence not  treated with  bisulfite)  had been completely converted to A residues with  only 
background C peaks observed (90.8% and 100% converted in two residues measured).
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Bisulfite sequencing was then carried out in a further 9 obese subjects and variation in the 
methylation status at three loci was observed (see Figure 2.)
Figure 9.1. Electropherogram showing the sequencing of  the CpG island within  the POMC 
promoter. CpG sites are highlighted. Control 1 and Control 2 are non-CpG C-residues that were 
expected to be fully converted to T residues.
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Figure 9.2. Bisulfite sequencing of POMC CpG island in two samples. CpG sites are highlighted 
and differences in methylation status can be observed at CpG 3.
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9.2.2 Locating CpG Islands within Obesity-Associated Genes
Using CpGPlot software305, putative CpG islands were found in the promoter regions of obesity 
associated genes: leptin (LEP),  FTO,  and peroxisome proliferator–activated receptor gamma 
(PPARγ) (see Figures 9.3-9.5). Putative CpG islands were also found in the obesity candidate 
gene Adiponutrin (see Figure 9.6). 
Figure 9.3. CpG plots of the region covering the promoter region and start of the leptin gene. 
The top graph displays the ratio of observed to expected CpG dinucleotides. The middle graph 
displays the percentage of C or G nucleotides and the bottom graph displays the position of any 
putative CpG islands. CpG islands are defined as regions greater than 100bp that contain a 
ratio of observed to expected CpGs greater than 0.6 and a GC content of greater than 50%. The 
start of the gene is indicated by an arrow.
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Figure 9.4. CpG plots of the region covering the promoter region and start of the  FTO gene. 
The top graph displays the ratio of observed to expected CpG dinucleotides. The middle graph 
displays the percentage of C or G nucleotides and the bottom graph displays the position of any 
putative CpG islands. CpG islands are defined as regions greater than 100bp that contain a 
ratio of observed to expected CpGs greater than 0.6 and a GC content of greater than 50%. The 
start of the gene is indicated by an arrow.
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Figure 9.5. CpG plots of the region covering the promoter region and start of the PPARγ gene. 
The top graph displays the ratio of observed to expected CpG dinucleotides. The middle graph 
displays the percentage of C or G nucleotides and the bottom graph displays the position of any 
putative CpG islands. CpG islands are defined as regions greater than 100bp that contain a 
ratio of observed to expected CpGs greater than 0.6 and a GC content of greater than 50%. The 
start of the gene is indicated by an arrow.
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Figure 9.6. CpG plots of the region covering the promoter region and start of the Adiponutrin 
gene. The top graph displays the ratio of observed to expected CpG dinucleotides. The middle 
graph displays the percentage of C or G nucleotides and the bottom graph displays the position 
of  any  putative  CpG islands.  CpG islands  are  defined  as  regions  greater  than  100bp that 
contain a ratio of observed to expected CpGs greater than 0.6 and a GC content of greater than  
50%. The start of the gene is indicated by an arrow.
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9.2.3 Investigation of DNA methylation in leptin gene
Methylation levels of CpG sites within the leptin gene promoter were investigated for potential  
associations with human polygenic obesity. Leptin was chosen as its involvement in energy 
regulation and obesity is well  established224 and it has a clear putative CpG island within its 
promoter region (see Figure 9.3 above).
PCR primers were designed to amplify a 294bp region within the Leptin CpG island, which was 
followed by direct sequencing (See Figure 9.7 for PCR product location and Appendix for primer 
sequences).  Using  stock  gDNA,  methylation  was  observed  at  all  6  CpG  sites  within  the 
sequenced region. A small amount of variation between subjects was observed at each CpG 
site with the highest  variation observed at CpG 6 (mean methylation level  of  39.2% with  a 
standard deviation of 18.7%, see Table 9.1 and Figure 9.8).
Figure  9.7 The  region  of  the  leptin  gene  analysed  by  bisulfite sequencing  with  CpG 
dinucleotides numbered and shown in bold. Base-pair positions are relative to the transcription 
start of the Leptin gene. The position of the sequencing primer is also indicated by an arrow. 
CpG 0 was not within the sequencing read.
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 Figure 9.8. Electropherograms showing differing levels of methylation at CpG site 6 from the 
bisulfite sequencing of Leptin within three obese individuals. Control 1 and Control 2 are non-
CpG loci that are expected to be fully converted.
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DNA CpG 1 CpG 2 CpG 3 CpG 4 CpG 5 CpG 6
Control 79.1 76.2 66.3 68.9 84.5 44.8
Obese 1 88.5 80.0 84.4 70.3 87.0 39.1
Obese 2 82.3 81.8 73.6 63.5 84.5 46.4
Obese 3 85.3 85.5 82.4 61.7 60.1 36.0
Obese 4 88.3 82.3 82.7 40.2 63.8 63.3
Obese 5 91.2 89.7 82.5 67.8 81.1 36.6
Obese 6 92.3 85.6 70.4 76.7 72.0 2.6
Obese 7 77.3 91.2 93.5 55.5 76.0 68.5
Obese 8 90.6 91.0 87.6 62.2 46.3 27.7
Obese 9 79.2 83.6 80.2 52.1 83.0 26.9
Mean Methylation Level 85.4 84.7 80.4 61.9 73.8 39.2
Standard Deviation 5.6 4.9 8.2 10.5 13.3 18.7
Table 9.1. Variation in levels  of  DNA methylation at  six CpG sites sequenced in the Leptin 
promoter CpG island between different DNA samples. Methylation level is measured as peak 
height of the G residue divided by the sum of the peak heights of the G and C residues at that  
site as read from DNA sequencing data from that sample.
9.2.3.1 Low volume bisulfite sequencing protocol
The method used above was modified in order to test whether it could be used with smaller  
quantities  of  DNA such  that  a  case-control  study  could  be  carried  out.  The  protocol  was 
modified from the method presented in the Materials and Methods chapter as follows: 10ng 
DNA was mixed with 0.7µl Hydroquinone and 12µl Conversion Buffer made up to 14µl with 
dH2O. This was placed in a thermocycler for three minutes at 94°C followed by nine hours at  
50°C. 50 µl DNA Binding Buffer was mixed with the conversion reaction and pipetted into a DNA 
purification column. This was span at 10,000 rpm for 30 seconds in a microcentrifuge and the 
collection tube emptied. 200µl DNA Wash Buffer was added to the column which was then span 
at  10,000  rpm for  30  seconds.  200µl  Desulfonation  Buffer  was  added  to  the  column  and 
incubated at room temperature for 20 minutes before spinning at 10,000 rpm for 30 seconds. 
200µl of DNA Wash Buffer was then added and the column was spun at 10,000rpm for 30  
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seconds. The column was then placed in a new 1.5ml microcentrifuge tube and 50µl of DNA 
Elution buffer was pipetted onto the surface of the column filter. This was incubated at room 
temperature for  3  minutes  before spinning down at  10,000rpm for  30 seconds.  The eluted 
solution was purified, converted DNA ready for PCR.
This protocol was used to measure leptin CpG methylation in four out of ten samples used 
above. Peak height ratios were compared and found to differ by an average of 7.4% ±7.0%.
9.2.4 Investigation of leptin gene DNA methylation levels for possible association to 
human polygenic obesity
DNA methylation in the leptin gene CpG island was measured in 92 morbidly obese French 
adults and 92 non-obese controls from the D.E.S.I.R cohort. (see Materials and Methods for 
details of subjects). Out of 184 samples treated with bisulfite and sequenced, eighty-two cases 
and seventy-five controls  met quality control  standards  (i.e.  two non-CpG cytosine residues 
were >95% converted) and were analysed for association. Because the first three CpG sites  
were  found  to  be  over  90% methylated  in  the majority  (>95%) of  samples,  they were  not 
analysed.  Using  the  quantitative  measure  of  percent  methylation,  CpG 5  was  found  to  be 
nominally associated with both obesity (p=0.013) and age- and sex-corrected BMI (p=0.032) 
(see Table 9.2). No statistically significant result was observed for any phenotype for the other 
two variably methylated CpG dinucleotides.
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CpG Site
Mean Methylation in 
Obese 
(Standard Deviation)
Mean Methylation in 
Controls 
(Standard Deviation)
Obesity 
(P-value)
BMI* 
(P-value)
CpG 4 73.3% (5.7%) 74.0% (5.1%) 0.86 0.77
CpG 5 79.0% (6.0%) 88.0% (3.6%) 0.013 0.032
CpG 6 46.5% (7.6%) 49.0% (7.3%) 0.65 0.54
Table 9.2. Association of obesity and BMI with the percentage methylation at the three variably-
methylated CpG sites in the Leptin gene CpG island. *Age and sex corrected BMI.
Thirty-two SNPs located within a 200kb region containing the Leptin gene were analysed for 
association with BMI in the 92 control subjects. This genotyping data was made available by 
collaborators  in  France526.  Four  SNPs  were  nominally  associated  with  BMI  (rs2167289, 
rs791600, rs10249476, rs4731429), however none survive correction using permutations (see 
Table 9.3). These SNPs were then analysed for association to CpG 5 methylation. One of the 
SNPs  nominally  associated  with  BMI,  rs4731429  was  nominally  associated  with  CpG  5 
methylation (p=0.017, see Table 9.4). This does not survive correction using permutations.
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Genotype Counts Mean BMI (95% CI) P-values
SNP 1a,1 1,2 2,2 1,1 1,2 2,2 Empirical Corrected
rs17151739 24 24 2 22.4 (21.8-22.9) 22.5 (21.9-23.1) 21.8 (18.5-25.00) 0.76 1.0
rs6960004 34 14 2 22.5 (22.0-23.0) 22.2 (21.5-23.0) 22.2 (19.5-24.8) 0.44 1.0
rs6953698 32 17 1 22.6 (22.1-23.1) 22.0 (21.3-22.6) - 0.32 1.0
rs322812 11 31 8 22.6 (21.8-23.3) 22.4 (21.9-23.0) 22.05 (21.24-22.86) 0.56 1.0
rs322760 13 30 7 22.6 (21.9-23.3) 22.3 (21.8-22.9) 22.3 (21.1-23.4) 0.57 1.0
rs4731401 40 10 0 22.4 (21.9-22.8) 22.6 (21.6-23.6) - 0.55 1.0
rs322737 13 28 9 22.6 (21.7-23.4) 22.3 (21.8-22.8) 22.5 (21.7-23.3) 0.91 1.0
rs1421309 35 14 1 22.5 (22.0-23.0) 22.0 (21.2-22.8) - 0.61 1.0
rs10447854 26 22 2 22.3 (21.8-22.8) 22.4 (21.8-23.1) 23.8 (23.4-24.2) 0.25 1.0
rs1017607 16 26 8 22.2 (21.5-22.9) 22.2 (21.6-22.7) 23.5 (22.7-24.4) 0.11 0.92
rs12706827 41 8 1 22.5 (22.0-22.9) 21.8 (20.8-22.9) - 0.41 1.0
rs6976221 29 17 4 22.3 (21.7-22.8) 22.7 (22.1-23.2) 22.4 (20.2-24.5) 0.34 1.0
rs12538332 30 17 3 22.3 (21.8-22.8) 22.5 (21.8-23.2) 23.1 (211-25.2) 0.85 1.0
rs6956123 36 14 0 22.4 (22.0-22.9) 22.3 (21.5-23.1) - 0.50 1.0
rs6467165 40 9 1 22.5 (22.0-22.9) 22.1 (21.1-23.0) - 0.64 1.0
rs4731416 40 10 0 22.3 (21.9-22.7) 22.8 (21.7-23.9) - 0.50 1.0
rs11981584 40 8 2 22.4 (21.9-22.8) 22.4 (21.2-23.6) 23.4 (20.7-26.1) 0.66 1.0
rs2167289 14 25 11 23.2 (22.4-24.0) 22.3 (21.7-22.8) 21.7 (21.0-22.3) 0.0069 0.17
rs791595 35 12 3 22.2 (21.7-22.7) 22.8 (21.9-23.7) 23.1 (22.1-24.0) 0.11 0.93
rs791600 14 25 11 23.2 (22.4-24.0) 22.3 (21.7-22.8) 21.6 (21.0-22.3) 0.0069 0.17
rs2021808 44 6 0 22.3 (21.9-22.8) 22.8 (21.6-24.1) - 0.57 1.0
rs791608 44 6 0 22.5 (22.0-22.9) 22.0 (20.8-23.3) - 0.35 1.0
rs10249476 20 26 4 22.0 (21.4-22.6) 22.6 (22.0-23.1) 23.5 (22.4-24.6) 0.04 0.58
rs10487506 13 29 8 22.8 (22.0-23.6) 22.4 (21.9-23.0) 21.6 (20.8-22.4) 0.13 0.95
rs4731429 17 25 8 21.6 (21.0-22.1) 22.7 (22.1-23.2) 23.3 (22.4-24.2) 0.0055 0.13
rs4731437 35 14 1 22.3 (21.8-22.8) 22.7 (22.0-23.3) - 0.57 1.0
rs1466146 35 14 1 22.4 (21.9-22.9) 22.6 (21.9-23.3) - 0.72 1.0
rs6979784 31 15 4 22.4 (21.9-22.9) 22.4 (21.7-23.2) 22.18 (20.3-24.0) 0.67 1.0
rs7811892 22 22 6 22.6 (21.9-23.2) 22.3 (21.7-22.9) 22.1 (20.9-23.3) 0.23 1.0
rs1545444 15 29 6 22.3 (21.5-23.0) 22.3 (21.7-22.8) 23.4 (22.3-24.5) 0.33 1.0
rs12532999 13 30 7 22.3 (21.5-23.0) 22.2 (21.7-22.7) 23.5 (22.6-24.4) 0.17 0.98
rs6964936 20 27 3 22.4 (21.7-23.0) 22.5 (21.9-23.0) 21.8 (20.2-23.4) 0.90 1.0
Table 9.3. Association analysis of SNPs in the Leptin gene region with BMI in French controls using linear regression and age and sex as covariates. Corrected p-
values result from one million permutations. a 1 denotes the common allele, 2 denotes the minor allele.
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Genotype Counts Mean CpG 5 Methylation (95% CI) P-values
SNP 1a,1 1,2 2,2 1,1 1,2 2,2 Empirical Corrected
rs17151739 24 24 2 0.85 (0.77-0.94) 0.91 (0.86-0.95) 0.98 (0.94-1.02) 0.18 0.99
rs6960004 34 14 2 0.89 (0.85-0.94) 0.86 (0.73-0.99) 0.95 (0.92-0.97) 0.86 1.0
rs6953698 32 17 1 0.91 (0.88-0.95) 0.84 (0.72-0.96) - 0.081 0.84
rs322812 11 31 8 0.85 (0.75-0.95) 0.88 (0.82-0.95) 0.92 (0.88-0.96) 0.40 1.0
rs322760 13 30 7 0.84 (0.76-0.93) 0.89 (0.82-0.96) 0.93 (0.89-0.97) 0.28 1.0
rs4731401 40 10 0 0.9 (0.87-0.93) 0.82 (0.61-1.03) - 0.19 0.99
rs322737 13 28 9 0.87 (0.73-1.02) 0.9 (0.85-0.95) 0.84 (0.77-0.9) 0.70 1.0
rs1421309 35 14 1 0.91 (0.88-0.94) 0.82 (0.67-0.97) - 0.25 1.0
rs10447854 26 22 2 0.85 (0.77-0.93) 0.93 (0.91-0.96) 0.75 (0.26-1.24) 0.43 1.0
rs1017607 16 26 8 0.92 (0.89-0.94) 0.87 (0.78-0.95) 0.88 (0.75-1) 0.48 1.0
rs12706827 41 8 1 0.87 (0.81-0.93) 0.94 (0.9-0.98) - 0.27 1.0
rs6976221 29 17 4 0.86 (0.79-0.93) 0.95 (0.91-0.98) 0.78 (0.57-0.99) 0.78 1.0
rs12538332 30 17 3 0.9 (0.86-0.94) 0.85 (0.73-0.97) 0.94 (0.89-1) 0.80 1.0
rs6956123 36 14 0 0.87 (0.81-0.93) 0.92 (0.84-1) - 0.36 1.0
rs6467165 40 9 1 0.9 (0.84-0.95) 0.82 (0.71-0.93) - 0.52 1.0
rs4731416 40 10 0 0.86 (0.81-0.92) 0.96 (0.93-0.99) - 0.11 0.92
rs11981584 40 8 2 0.87 (0.81-0.92) 0.97 (0.95-0.99) 0.9 (0.79-1) 0.24 1.0
rs2167289 14 25 11 0.85 (0.71-0.99) 0.9 (0.85-0.95) 0.89 (0.84-0.94) 0.57 1.0
rs791595 35 12 3 0.88 (0.82-0.94) 0.92 (0.86-0.97) 0.8 (0.51-1.09) 0.85 1.0
rs791600 14 25 11 0.85 (0.71-0.99) 0.9 (0.85-0.95) 0.89 (0.84-0.94) 0.57 1.0
rs2021808 44 6 0 0.87 (0.82-0.93) 0.95 (0.93-0.97) - 0.31 1.0
rs791608 44 6 0 0.87 (0.82-0.93) 0.96 (0.94-0.99) - 0.23 1.0
rs10249476 20 26 4 0.87 (0.77-0.96) 0.91 (0.86-0.95) 0.84 (0.62-1.05) 0.81 1.0
rs10487506 13 29 8 0.91 (0.84-0.98) 0.91 (0.86-0.95) 0.75 (0.53-0.97) 0.063 0.76
rs4731429 17 25 8 0.8 (0.68-0.92) 0.92 (0.88-0.96) 0.95 (0.94-0.96) 0.017 0.35
rs4731437 35 14 1 0.9 (0.86-0.94) 0.84 (0.7-0.98) - 0.39 1.0
rs1466146 35 14 1 0.9 (0.86-0.94) 0.84 (0.7-0.97) - 0.34 1.0
rs6979784 31 15 4 0.89 (0.85-0.94) 0.91 (0.86-0.95) 0.71 (0.24-1.17) 0.18 0.99
rs7811892 22 22 6 0.87 (0.79-0.96) 0.89 (0.82-0.95) 0.91 (0.85-0.98) 0.64 1.0
rs1545444 15 29 6 0.86 (0.74-0.99) 0.88 (0.83-0.94) 0.94 (0.92-0.97) 0.39 1.0
rs12532999 13 30 7 0.86 (0.78-0.95) 0.88 (0.81-0.95) 0.95 (0.92-0.98) 0.35 1.0
rs6964936 20 27 3 0.85 (0.75-0.95) 0.92 (0.87-0.96) 0.83 (0.67-0.99) 0.40 1.0
Table 9.4. Association analysis of SNPs in the Leptin gene region with CpG 5 methylation in French controls using linear regression and age and sex as covariates. 
Corrected p-values result from one million permutations. a 1 denotes the common allele, 2 denotes the minor allele.
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9.2.5 Analysis of  LEP   transcript levels 
Leptin transcription data from the Swedish sib-pair cohort was analysed in order to ascertain 
whether or not expression of the gene is altered in subcutaneous adipose tissue. When siblings 
were split  into two groups of non-obese (BMI<30 kg/m2)  and obese (BMI>30kg/m2)  and the 
transcription  levels  corrected  for  age,  sex  and  relatedness,  the  two  groups  were  normally  
distributed. Using an independent samples t-test,  a significant difference in the level of  LEP 
transcription was found between the two groups (p=2.2x10-16, see Figure 9.9 and Table 9.5). 
217
Figure 9.9. Box-plot of  LEP transcript levels in obese and non-obese subjects from Swedish 
sib-pairs.  SIRT1  transcription  is  the  microarray  signal  value  corrected  for  age,  sex  and 
relatedness. Mean transcription ± standard deviation were -3.57 ± 3.56 in the non-obese and 
6.09 ± 4.19 in the obese group.
Number of 
Non-obese
Number of 
Obese
Mean Difference 
in SIRT1 
transcription 
(95% CI) P-value
190 156 9.66 (8.92-10.41) 2.20x10-16
Table 9.5. T-test of LEP transcription in obese and non-obese subjects from Swedish families. 
LEP transcription is the microarray signal value corrected for age, sex and relatedness.
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9.3 Discussion
These results demonstrate an effective method for measuring quantitative methylation status at  
a single CpG site using direct bisulfite-PCR sequencing and low quantities of genomic DNA 
(~10ng per sample). It should be noted that during the course of this project, the same method 
was independently developed and published by Jiang et al.527. The relative speed and simplicity 
of this method compared to cloning and pyrosequencing techniques make it ideally suited to 
screening larger numbers of samples for use in case-control association studies.
These results demonstrate a nominal association that does not survive correction for multiple 
testing between leptin promoter methylation and obesity in humans. This study provides a good 
example  of  the  utility  of  analysing  DNA methylation  as  a  quantitative  trait,  as  it  is  both  a 
statistically powerful approach and it provides information at the single base level. At the time 
the practical work in this thesis was completed, no associations had been reported between 
DNA methylation measured as a quantitative trait and polygenic human obesity. Since then, a 
study that reported an association between promoter methylation of serotonin transporter gene 
in blood leukocytes and obesity in monozygotic twins has been published528.
Methylation of CpG 5 was found to be decreased in obese subjects compared to non-obese. As 
increased methylation of a CpG island typically leads to a reduction in expression of a gene529, 
this suggests that, in the obese subjects, expression of leptin is upregulated, possibly as part of 
the feedback mechanism to lower food intake through leptin’s action on the brain530.  This is 
supported by the evidence that expression of the gene was found to be significantly increased in 
obese  compared  to  non-obese  siblings  in  the  Swedish  family  cohort,  an  established 
phenomenon that  might  be  expected since  leptin  secretion  is  increased  in  obese  subjects 
531,532.Exploration of leptin CpG methylation levels in this cohort would be a crucial next step in  
order to acquire evidence that methylation levels in this gene are effecting its expression.
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This study examined methylation levels in DNA samples obtained from whole blood and while it  
may be the case that methylation levels in blood are highly correlated with those in adipose 
tissue, this has not been proven and so needs to be investigated in the future. Equally, there 
may be additional environmental signals that are affecting methylation in blood-derived DNA 
that  are  driving  the  changes  in  leptin  methylation  or  it  might  be  that  obesity  is  modifying 
methylation patterns as seen in a recent study in rats393.
The association of rs4731429 with percentage methylation at CpG 5 could indicate a possible 
link between DNA methylation and the primary DNA sequence, if it were statistically significant. 
An association between a SNP and percentage methylation at a single CpG could suggest that 
in this case, epigenetic changes at this site are both heritable and in linkage disequilibrium (LD) 
with variation in the primary sequence. Such an association has been previously reported in the 
cancer predisposition gene MGMT529. It is not clear what the basis of the association is between 
the SNP and methylation at the single CpG as there is no evidence whether it is functional or  
simply  in  LD  with  another  functional  variant.  While  the  significance  of  the  associations  of  
rs4731429 to obesity and BMI do not withstand correction for multiple testing, they underline the  
possibility  that  the two types of  variation are statistically associated because they are both 
associated with the same phenotype, either statistically or functionally.
This result will need to be replicated in larger numbers and in other populations to confirm the 
associations reported here, as it is very clear that this study is underpowered, especially for the 
SNP association work. Confirming high correlation between methylation levels of these CpG 
sites in adipose tissue and blood is also desirable. Comparison of percentage methylation and 
leptin  transcript  expression  levels  would  be  very  useful  in  determining  whether  differential 
methylation of the leptin promoter is associated with BMI because of altered leptin transcription. 
The heritability of the CpG methylation also needs to be investigated in families to confirm the 
possibility that the methylation and SNP association reported here is highlighting a novel inter-
relationship between two types of genomic variation. 
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In conclusion the results reported here highlight the potential importance of DNA methylation in 
either  the development of obesity or in response to the obese state. It also demonstrates the 
utility of single-base resolution measurement of methylation within candidate genes.
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Chapter 10
Discussion
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10.1 Summary of thesis results
The work presented in this thesis used a candidate gene approach to attempt to identify genetic  
variation contributing to the risk of developing common polygenic obesity. These studies were 
conducted over a period of rapid development in the field of complex disease genetics. At the 
start  of  this  project,  genome-wide  association  studies  had  recently  become  feasible  and 
numerous reproducibly associated markers to common obesity have been discovered using 
these methods over the last few years. The first of these were two reports of a novel association  
to FTO246,247 and the most recent brings the total validated genetic associations to BMI or obesity 
to 34233,256.  However, only an estimated 1.5% of the heritability of BMI is currently explained in  
GWAS association. Due to the hypothesis-free strategy and large numbers of variants being 
screened, very stringent corrections are required in order to minimize the chances of a false-
positive, which unfortunately results in an inflation of the false-negative rate. This means that 
some variants with small effect sizes will be screened out. .This project was designed in order to 
investigate the possibility  of  genetic associations between common variants  (MAF>5%) and 
coding  SNPs  in  candidate  genes  and  human  polygenic  obesity. Out  of  67  successfully 
genotyped markers, 12 were not present in HapMap and a further  six are located on the X 
chromosome which makes 18 SNPs not likely to be included in GWAS and demonstrates the 
advantage of this approach.
Chapter 3 described an investigation of the SIRT1 gene, which was chosen on the basis of its 
transcriptional  regulation of  genes involved in lipid  metabolism418 and  SIRT1 knockout mice 
having increased body weight421. Putative associations between variants in the SIRT1 gene and 
common obesity were found in both an adult French case-control cohort and a Swedish family 
cohort.  When  starting  this  project,  no  associations  between  SIRT1 SNPs  and  obesity 
phenotypes  had  been  published,  however  three  studies  have  since  reported  significant 
associations442,443,444. This means that the association between SIRT1 variants and obesity has 
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been found across a number of populations which is some evidence that it is genuine and not a 
false positive.  All  reported associations found a correlation between the minor  allele  and a 
reduced BMI or obesity risk which is evidence that the same association is being detected and 
therefore more likely that it is genuine. No associations to  SIRT1 have been reported in any 
GWAS, however nominally significant SNP associations have been detected in the region (e.g. 
rs471962  with  a  p-value  of  1.25x10-4)  indicating  the  possibility  of  an  association  that  was 
screened out by multiple testing correction. The association between adipose SIRT1 transcript 
expression and obesity produced more convincing p-values (1.56x10-35) and is further evidence 
of the influence of SIRT1 on obesity risk. The results of this chapter have been published533.
In Chapter 4, the apelin gene was selected due to its plasma concentration correlating with 
BMI460 and studies that reported reduced food intake in rats injected with apelin peptides 466,467. 
One SNP within the gene was found to be nominally associated with obesity in a French child 
case-control cohort. However, this association does not reach genome-wide significance and 
has not been replicated so could be a false-positive. No previous associations between APLN 
variation and obesity were found in the literature which means this is a  potentially interesting 
discovery which will require further investigation in order to confirm it's validity. The lack of X 
chromosome variants reported in GWAS makes this an interesting result.
Chapter 5 detailed the investigation of IL-11, an anti-inflammatory cytokine with inhibitory effects 
on adipogenesis and lipase activity354,355,356. A nominal association between  IL11  variation and 
obesity  was  found  in  the  French  adult  case-control  cohort.  The  lack  of  genome-wide 
significance and replication means that the possibility of a false-positive has not been ruled out.  
No associations between obese phenotypes and IL-11 variation have been reported to-date.  
The limited coverage of  IL-11 variants in HapMap makes this a particularly interesting result 
since it is likely that current GWAS do not include any SNPs that tag the most associated SNP.
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Chapter  6  reported  an  investigation  into  adiponutrin,  a  lipase  that  is  expressed  in 
adipocytes483,360. A study in Swedish subjects reported an association between adiponutrin gene 
SNPs and obesity369. No significant associations were found to any SNP genotyped, including 
those that had previously been reported. This highlights the importance of replication studies to 
establish true associations. However, the limited statistical power means that a false-negative 
cannot be ruled out and this highlights a weakness of using small cohorts in association studies.
The nesfatin gene was chosen in Chapter 7 due to its expression in appetite controlling neurons 
in  the  hypothalamus371,372 and  its  anorexigenic  effect  when  injected  into  rodent  brains372. 
Unfortunately,  there was no evidence of  any associations between SNPs in the region and 
obesity  that  were  statistically  significant  after  permutations.  Again,  limited  statistical  power 
means that the possibility of a false-negative cannot be ruled out.
In Chapter 8, the IRS1 gene was investigated having recently been reported to be associated 
with T2D by collaborators in France. Genotype and transcript data from the Swedish sib-pair  
cohort was analysed and a significant association between  IRS-1 variation and transcription 
levels of the gene was discovered that could explain the mechanism of the association to T2D.  
However,  IRS1 variation was not  found to be associated with BMI.  There was a significant 
association between IRS1 transcript levels and obesity but it might be more likely that obesity is 
altering transcription of the gene rather than the gene causing obesity.
The  putative  associations  described  above  all  survive  correction  for  multiple  testing  using 
permutations  when  each  gene  is  analysed  individually,  which  reduces  the  chance  of  false 
positives. The p-values would not be significant in the context of a genome-wide investigation 
and  do  not  survive  thesis-wide  corrections  which  means  that  the  possibility  that  these 
associations are false-positives cannot be ruled out. This, along with replication are neccessary 
in order to consider a genetic association to be real. 
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Because there is a large gap between the variation in BMI that can be attributed to published 
GWAS and the heritability estimates for common obesity, there remain many more associations 
yet to be discovered. These will most likely come from rare or common variants not investigated 
in  current  GWAS or  common variants  with  small  effect  sizes.  This  highlights  the continued 
relevance of candidate gene studies which can be used to investigate a much greater proportion 
of  the variation within a single gene region. Candidate gene studies can therefore act as a 
complementary approach to GWAS by following up on signals that do not survive the genome-
wide corrections but are at least nominally significant. 
None of the associations reported in this thesis have been found to be significantly associated 
to BMI or obesity in any GWAS to date. This raises the question of whether or not these are  
genuine genetic associations and if so why are they not showing up in the GWAS. One possible 
reason is that they are being screened out by multiple testing corrections. GWAS routinely reject  
p-values >5x10-8 as statistical noise. In order to control the false-positive rate though the false-
negative rate is increased and so many real associations may be missed, particularly if effect  
sizes  are  small.  Another  explanation  is  that  the  associations  are  to  variants  that  are  not  
sufficiently tagged by SNPs in current genotyping arrays due to incomplete coverage in the 
HapMap database or location within the sex chromosomes. Two of the associations reported in 
this thesis are not likely to be covered in GWAS. Firstly, the apelin SNP, rs2281068, which was 
putatively  associated with  obesity in  children has not  been analysed for  association to any 
obese phenotype in GWAS due to its location on the X chromosome. Secondly, the putatively 
associated IL-11 SNP, rs1042505, may not be sufficiently tagged in any GWAS since it is not 
present in HapMap and is not well correlated with any other SNP within the region (maximum 
r2=0.31).
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Another possibility is that some of this missing heritability is caused by epigenetic variation. This  
was  explored  in  Chapter  9  where  DNA methylation  in  the  leptin  gene  was  measured  and 
analysed  for  association  to  common  obesity.  Initially,  a  method  to  measure  quantitative 
methylation in large numbers of samples was developed since CpG methylation can vary within 
a single tissue type. When using DNA extracted from blood, which contains multiple cell types 
this was even more important. Direct bisulfite sequencing was used and DNA methylation at the 
individual base level was analysed by measuring peak height ratios from the electropherogram. 
Methylation levels were measured at six sites in the leptin promoter CpG island in a subset of  
French obesity case-controls. A nominal association was discovered between one CpG site and 
obesity.  This  is  a  potentially  interesting  result  since  no  associations  between  quantitative 
methylation in the leptin gene and obesity have been reported to date. However, the p-values 
obtained are not genome-wide significant and this, together with the fact that the association 
has not been replicated, means that the possibiity of a false-positive cannot be ruled out so no 
definitive  conclusions  can  be  drawn  at  present.  It  is  essential  that  further  samples  are 
investigated and with the high-throughput method that was developed here it should be possible  
to routinely investigate as many as 500 cases and 500 controls.
10.2 Future work
The first objective of any future work will be to replicate the associations discovered here in 
other populations to establish whether or not they are genuine. Larger cohorts should be used in 
order to increase the statistical power such that associations that are significant in a genome-
wide  context  can  be  detected,  ideally  in  line  with  the  numbers  suggested  by  the  power 
calculations.  Using  the  GIANT  approach  it  may  be  possible  to  impute  the  relevant  SNP 
genotypes in sufficient samples to reach the required numbers without further  laboratory work 
being required. 
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The second objective  is  discovering the DNA sequences that  are  directly  implicated  in  the 
pathophysiology  of  obesity.  SNPs  that  have  been  found  to  be  associated  with  common 
polygenic obesity may not be causative but simply inherited together with a causative variant 
that alters the amino acid sequence of the encoded protein or expression levels of a gene. Fine-
mapping of associated genes is required in order to discover these causative variants. The 1000 
Genomes project may provide the necessary fine mapping information but it is notable that this  
project is not sequencing subjects chosen on  the basis of disease status, in the case of this 
project, high BMI or morbid obesity. This means that those functional variants underlying obesity 
may  not  be  being  sequenced.  Identification  of  functional  variants  is  important  since  an 
understanding of how variation in the gene effects phenotype will lead to a better understanding 
of the aetiology of the disease which could aid in the development of therapeutics that target the 
disease. Additionally finding the functional mutations will  lead to better estimations of  effect 
sizes and thus how much the currently known associations explain the total heritability of the  
disease. This is particularly helpful if multiple variants within a gene each affect the phenotype 
independently. In the future, genetic information could be used to predict disease risk and aid 
prognosis and so the accuracy of such information will be improved by mapping the functional 
variants. 
The strategy for locating functional mutations will involve fine-mapping of the associated genes 
by sequencing in a subset of samples followed by association analysis of any SNPs discovered. 
This is a potentially onerous task since LD blocks can span regions that can be hundreds of  
kilobases in length and transcription factors can affect gene expression via enhancer elements 
located similarly long distances away from a gene. This difficulty is illustrated by Chapters 3 and  
4 where sequencing was carried out in the exons and promoter regions of SIRT1 and APLN but 
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no significantly associated SNPs were discovered. Next generation sequencing technologies 
will  aid  in  this  process  by  reducing  costs  and  increasing  speed.  Follow  up  genotyping  in 
populations with  different  LD structures would also be useful  to  help  differentiate  functional 
SNPs from those that are associated due to being in high LD with the functional SNP.
Any  SNPs  found  within  exons  that  are  significantly  associated  with  obesity  are  strong 
candidates for functional mutations and there are a number of strategies to test this hypothesis.  
Firstly,  software  such  as  Polyphen534 can  be  used  to  evaluate  whether  a  non-synonymous 
mutation could be damaging to the protein. Other mutations might affect transcription factor 
binding or splicing and this can be assessed computationally too. However, molecular validation 
will  be  necessary. Levels of  mRNA expression can be measured using reverse-transcriptase 
PCR or RNA sequencing in the tissue of interest, to see if the mutant allele alters transcription 
levels. A mutation may effect phenotype by altering protein expression by altering RNA stability 
or  introducing  splice  defects.  Protein  expression  can  be  assessed  by  Western  blotting, 
assuming that a suitable specific antibody is available. Enzyme activity assays can be used if  
the protein's has an enzymatic activity that  is  well  understood. For  example,  sirtuin  activity 
assays are available449 that could be used to compare mutant versions of SIRT1 with wild type.
Alternatively, if the associated variants are not coding SNPs then the possibility that they affect  
expression levels of the gene in question can be looked at. This was investigated in Chapter 3  
which  examined  SIRT1  expression  in  adipose  tissue,  although  no  association  was  found 
between gene variation and transcript expression levels. In Chapter 8 association was detected 
between IRS1 gene variation and its transcript expression levels in adipose tissue. Whilst these 
methods can suggest a mechanism by which gene variation alters mRNA expression, they do 
not pinpoint the exact mutation that is responsible. Reporter gene assays such as luciferease 
could be used instead to measure which variants effect transcription. 
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The association between CpG methylation in the leptin gene and obesity will need replicating in  
other populations. It is also necessary to confirm the association in DNA extracted from adipose 
tissue where leptin is expressed as there is no clear mechanism by which altered methylation of 
the  gene  in  blood  cells  could  influence  BMI,  assuming  the  association  is  genuine.  The 
presumption is that the methylation status in blood simply reflects the methylation status in the  
adipose tissue.  The next  step will  be to  confirm whether  this  assumption is  true and then, 
ideally, go on to measure transcript levels of the gene to establish whether or not they correlate 
with CpG methylation. Ultimately, these techniques can then be used to explore the possibility 
that  DNA methylation  is  associated  with  obesity  in  other  candidate  genes  using  the  same 
technique or across the genome using techniques such as the Illumina methylation microarrays.
A major challenge in the field of complex genetics is the discovery of the remaining variants that  
contribute towards the heritability of traits and diseases such as BMI and obesity. There are a 
number of possibilities for where this missing heritability will be found. It may be a consequence 
of common variants with small effect sizes that are not currently picked up by GWAS due to the 
stringent multiple testing corrections. Given that the lower the odds ratio, the larger the study 
needed to reach statistical significance, studying these variants will  require larger and larger 
cohorts and using current GWAS approaches they will have to be in the millions of samples as 
the GIANT meta-analysis using approximately 250,000 subjects was unable to account for more 
than a few percent of the genetic variation.
The missing heritability could also be explained by rare variants that are not adequately tagged 
in current  GWAS. A recent paper reported that  rare variants are more likely to be found in  
functional  regions  of  the  genome  than  common  variants  suggesting  that  the  majority  of  
phenotypic variation could come from rare alleles535.  Novel associations to rare variants will 
require much denser genotyping arrays or, alternatively, as sequencing cost continue to fall,  
exome or whole genome sequencing. This can be carried out in a subset of samples with the 
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biggest hits followed up with genotyping in larger sample sets. When sequencing costs drop 
even further, whole genome sequencing can be carried out in large cohorts. Exome sequencing 
may not be the best approach when searching for variants that influence complex traits since it  
is likely that many causative mutations lie outside of exons, however its cost effectiveness will 
make it an attractive first choice compared to whole genome sequencing.
It is obviously possible that common variants associated with obesity in GWAS may be tagging 
functional  variants  that  have  much  lower  minor  allele  frequencies.  These  rare,  functional 
mutations could be expected to have effect sizes that are larger than those currently reported 
since some of the statistical association between genetic variant and disease will be lost by the 
imperfect tagging of the marker variant to the functional variant. Associations to rare variants  
tend to have larger effect sizes than those to common variants536 so this is a possibility. Fine 
mapping  of  GWAS  results  will  help  to  pinpoint  functional  mutations  and  with  the  recent 
technological  developments in DNA sequencing,  this process will  become cheaper and less 
time-consuming. A simple strategy would involve sequencing in a subset of subjects used in the 
original GWAS followed by imputation in the remainder.
It  might  be the  case  that  within  each  gene that  influences disease  risk,  there are  multiple  
independent variants that each exert effects on phenotype. Current methods might miss this 
since GWAS are designed to identify the top hit within an associated region and replicate only 
this single variant. For example, the major histocompatibility complex (MHC) region has been 
shown to have multiple independent effects in autoimmune diseases, such as type 1 diabetes537 
and rheumatoid arthritis538. These effects will be more properly understood after fine-mapping of 
associations is undertaken.
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Another possibility is that the genetic variation that is contributing to the heritability is not related  
to SNPs at all. CNVs are likely to contribute too. Between any two individuals the genetic base-
pair  differences  due  to  CNVs  is  at  least  100  times  higher  than  that  due  to  SNPs 539.  The 
association  between  BMI  and  NEGR1 reported  in  the  first  GIANT  publication  has  been 
hypothesised to be caused by a 45kb deletion upstream of the gene263. Rare deletions have 
been  successfully  demonstrated  to  be  associated  with  obesity271,540 and  subsequently  a 
duplication in the same region was associated with low BMI270. A better understanding of the 
effects of CNVs will come from genome sequencing as they are currently relatively difficult to 
characterise.
One area that has yet to be addressed within the field is epistasis, that is interactions between  
genetic variants. A recent paper suggests that epistasis could be causing an overestimation of 
the  heritability  of  complex  traits  which  means  that  the  proportion  of  heritability  currently 
explained  is  larger  than  is  thought541.  Statistical  power  to  detect  interactions  between  two 
variants are currently very low which means that they are unlikely to be detected in the current 
GWAS  and  will  either  need  larger  cohorts  in  order  to  be  explored  successfully  or  novel 
analytical  techniques  will  need  to  be  developed  to  avoid  the  exponential  increase  in  the 
numbers of statistical tests as gene-gene interactions are examined. The same will be true of 
gene-environment  effects  which  have  the  added  difficulty  of  accurately  assessing  the 
environmental variables.
Lastly, some portion of heritability may come from epigenetic variation such as DNA methylation 
and  histone  modifications.  DNA methylation  is  becoming  amenable  to  examination  using 
genome-wide methylation platforms in the same cohorts used for genetic association studies. 
Whole  methylome  sequencing  by  bisulphite  (Bis-seq)  or  using  methylated  DNA 
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immunoprecipitation (MeDIP-seq) can be used initially to discover candidate variants which can 
then be followed up in larger sample sets using the same method of  bisulphite sequencing 
employed in this thesis. Further technological  developments will  be needed before  the wide 
range of histone modifications can be screened for routinely.
Another point to consider is phenotyping. There are likely to be several different pathways that 
can go wrong that result in obesity and therefore there may be several separate phenotypes 
that are currently grouped together as one disease, with each one having different associated 
genetics. That is, common diseases are currently classified according to a common effect rather 
than a common cause. Furthermore, the use of BMI as a phenotype has its limitations. In the  
non-obese population, from which most GWAS for BMI are sampled (for example the mean BMI 
of samples in the discovery phase of the first GIANT publication was between 25.1 and 27.5 
with less than 20% of subjects >30kg/m2 263), the variation in BMI depends on lean mass as well 
as fat mass542,543. This means that variants affecting fat mass and susceptibility to obesity are 
not directly assessed. Better phenotyping of samples, to obtain more detailed information on 
body size and fat distribution, could therefore improve the accuracy of genetic studies.
The next  challenge in human disease genetics, after the functional variants that control the 
heritable  portion  of  disease  risk  have  been  identified,  will  be  clinical  application  of  this 
knowledge. An increased understanding of the pathways involved in controlling BMI and obesity  
risk has the potential to lead to the development of drugs that target proteins in these pathways. 
In the future, genome sequencing could be used as a standard tool for diagnosis and prognosis 
of genetic disease so a more complete understanding of all the variants that effect obesity risk  
will be important.
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In conclusion, this thesis reports the possibility of novel associations between two genes, IL-11 
and APLN and common polygenic obesity as well as another gene, SIRT1 for which previous 
associations  have  been  published.  Additionally,  the  possibility  of  a  novel  association  was 
discovered between CpG methylation in the leptin gene and obesity. These findings add to the 
body of knowledge of obesity genetics, which in the future could aid in developing therapeutics 
for this widespread and serious disease. It is also clear that there is much still to be discovered  
in the field of obesity genetics in order to complete our understanding of the heritability of this 
disease.
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A  1. Tagging SNPs genotyped and the corresponding captured SNPs  
Gene
Tagging 
SNP SNPs Captured
SIRT1 rs11596401 rs10997868,  rs1467568,  rs2224573,  rs11596401, 
rs10997866,  rs10997875,  rs7069102,  rs10823111, 
rs10997870,  rs1885472,  rs3758391,  rs7091896, 
rs10997860
SIRT1 rs3818292 rs10823108,  rs10823112,  rs3740051,  rs3818292, 
rs2236319, rs7096385
SIRT1 rs12413112 rs12778366, rs12413112
Nesfatin rs214935 rs4356203,rs618331,rs214910,rs10832733,rs214935,r
s214940,rs7123301,rs7125607,rs214901,rs7478986,rs
620241,rs7342262,rs11024158,rs7107283,rs7946010,r
s603618,rs10766381,rs214921,rs11024204,rs1747288
6,rs12280930,rs11024159,rs7936310,rs11024208,rs12
286505,rs214925,rs214900,rs7925692,rs214914,rs214
939,rs512852
Nesfatin rs3741203 rs11024251,rs9645621,rs10766388,rs3741203,rs1083
2757,rs10832769,rs10832768,rs10766393,rs10766384
,rs10766391,rs9633836,rs10832770,rs10466382,rs108
32779,rs10766383,rs1002227
Nesfatin rs1987694 rs17561348,rs586785,rs17473243,rs12577418,rs2149
33,rs3950680,rs17560341,rs12577525,rs1987694
Nesfatin rs10832750 rs10832752,rs542274,rs7108315,rs214076,rs1488933,
rs214071,rs10832750,rs214101
Nesfatin rs16933873 rs11605718,rs1974527,rs16933827,rs16933873,rs169
24899,rs16933823,rs11603765,rs2040859
Nesfatin rs10832775 rs10832781,rs11024262,rs2354867,rs10832763,rs108
32775,rs11024263,rs10832772
Nesfatin rs7108861 rs7108861,rs10832738,rs10832741,rs12285874,rs110
24165,rs10832742
Nesfatin rs7937091 rs7121987,rs12791318,rs7110037,rs7937091,rs16933
984,rs4451707
Nesfatin rs757110 rs2051772,rs1557765,rs5215,rs757110,rs7928810,rs1
0832778
Nesfatin rs2051773 rs214105,rs2051773,rs214070,rs757081,rs214091,rs2
521999
Nesfatin rs17647408 rs11604470,rs11604561,rs17647408,rs1979602,rs1160
7974
Nesfatin rs16933837 rs16933829,rs11024218,rs16924900,rs16933837
Nesfatin rs214083 rs214083,rs214097,rs214092,rs214093
Nesfatin rs10832749 rs10832749,rs10832753,rs7111505,rs12226898
Nesfatin rs11024273 rs4148638,rs2074312,rs11024273
263
Nesfatin rs10832782 rs7395484,rs7395484,rs11024272
Nesfatin rs6486364 rs2214285,rs8192691,rs6486364
Nesfatin rs10832756 rs10832756,rs16933952,rs12419530
Nesfatin rs214106 rs10741725,rs214106
Nesfatin rs2302510 rs3802962,rs2302510
Nesfatin rs2285676 rs2285676,rs886288
Adiponutrin rs2294916 rs4823179,rs1883349,rs2072905,rs1010023,rs229491
6,rs2073081,rs2072907,rs926633,rs1010022,rs289601
9,rs2281135
Adiponutrin rs2294918 rs4823174,rs2294918,rs2076210,rs5764034
Adiponutrin rs11090617 rs11090617,rs2076211,rs4823173,rs12483959
Adiponutrin rs734561 rs734561,rs2006943
Adiponutrin rs738408 rs738409,rs738408
Adiponutrin rs2294919 rs2076208,rs2294919
264
A2. Primer Sequences Used in Sequenom Genotyping Assays
SNP Gene PCR Primer 1 PCR Primer 2 iPlex Extension Primer
rs34122272 SIRT1 ACGTTGGATGACAATGTATAGCCA
GGCACG
ACGTTGGATGAACTCCTGACCTTG
TGATCC
ATCCTGGCACTTTGG
rs35689145 SIRT1 ACGTTGGATGTAGTCCCAGCTGTT
CGGAAG
ACGTTGGATGGCAGCATATTATTGG
CTCAC
GGAGAATCGCTTGAACTC
rs33957861 SIRT1 ACGTTGGATGCTTTAGGAATTCTG
CTCACTC
ACGTTGGATGGCTCCCGGCTATCT
TTTCTG
TTCTGCTCACTCAGTTTCA
rs10997871 SIRT1 ACGTTGGATGAGGGTAGCTTTATG
TAGTTG
ACGTTGGATGCTTCCTTCTCCATAT
CATGT
CAGTTCGTAATCAGAAAGG
rs41274092 SIRT1 ACGTTGGATGACTACTTCGCAACT
ATACCC
ACGTTGGATGACCATGACACTGAAT
TATCC
CCTCACATAGACACGCTGGA
rs7073231 SIRT1 ACGTTGGATGCTCTGCCTTCTAAA
GTGCTG
ACGTTGGATGACACAACAAGACCT
CATCTC
CTTCTAAAGTGCTGGGATTA
rs33955981 SIRT1 ACGTTGGATGAGGGTCTCTGTCAT
ATGTTC
ACGTTGGATGCCTCTTTATTATGCT
ACAGAC
CGAACAAATTAAAAAACCCAGTC
rs11594238 SIRT1 ACGTTGGATGCCATGCCAGGCTAA
TTTTTG
ACGTTGGATGGGTCGATCATTTGA
GGTCAG
CCAGGCTAATTTTTGTATTTTTA
rs7904945 SIRT1 ACGTTGGATGTAAGTGCCGGGATA
CATGTG
ACGTTGGATGGATAGATGCAGCAA
ACCACC
GGAGTGATACATGTGCAGAATGC
rs10997865 SIRT1 ACGTTGGATGTGAGTCAGTGTACT
AGGCAG
ACGTTGGATGCCAATATTTCCTTTT
CATGGC
TGTCCTAGGCAGAAAGTTCACTAA
rs11596401 SIRT1 ACGTTGGATGGAGAACTTGACTCT
ACAAAG
ACGTTGGATGCTCCTGAGTAGCTG
AGACCA
AACATTTAGCTAGGTATATGGTAC
rs34414573 SIRT1 ACGTTGGATGGCTGTTAATGAAGA
AATGTG
ACGTTGGATGCATTTCTGAATCTCT
GAATCC
GGACTAAAAGAACTGGATAGTTGA
rs2894057 SIRT1 ACGTTGGATGCCAGGTTCAAGTGA
TTCTGC
ACGTTGGATGAAAAATAGCCAGAC
GTGGTG
CCCCCTCCCGAGTAGCTGGAATTA
C
rs2236318 SIRT1 ACGTTGGATGGGGAAAAGGCTTA
AAGTCAAC
ACGTTGGATGCAAAAAACCCTCAC
AGAATGC
TCAAAATCTCATTTATTTTCTGAAGT
rs3818292 SIRT1 ACGTTGGATGAGAAGTATTGGCCT
TGACAG
ACGTTGGATGATGCATGCAACTGC
AGCATC
GAAGTTAATTATAGAAAACCTCAGA
T
rs10823103 SIRT1 ACGTTGGATGCCTTATCTGTGTTA
AAGATGG
ACGTTGGATGCAACCCTACCCTTAT
TTCAG
TGTGTTAAAGATGGAATATGAGGTA
T
rs2394443 SIRT1 ACGTTGGATGTTAAACCCCATCAC
GTGACC
ACGTTGGATGACCCGTAGTGTTGT
GGTCTG
GGCCGCCCCCGCCCTCT
rs11599176 SIRT1 ACGTTGGATGCCGGAGTTCAAGA
GATCTTC
ACGTTGGATGGATTTTTTGGATGCA
GTAGC
CCAAAGCACTGGGATTA
rs35224060 SIRT1 ACGTTGGATGGTTCATGTCTGTTA
CTTCCTG
ACGTTGGATGTGGATTTGGGACTG
ATGGAG
TACTTCCTGTTTCACAGATA
rs2273773 SIRT1 ACGTTGGATGATTCCAGCCATCTC
TCTGTC
ACGTTGGATGTCCAGCGTGTCTAT
GTTCTG
CTCTGTCACAAATTCATAGCC
rs35592342 SIRT1 ACGTTGGATGACTTTCTGACTTCT
GCCACG
ACGTTGGATGAAGAGCAGACGTGT
TCACAG
GGACTGCCACGATTTGCAAAC
rs12413112 SIRT1 ACGTTGGATGATGTGGCTGTTGAG
TACTTG
ACGTTGGATGCCATACTGGATCTCT
AAAATC
AGTACTTGAAATGTATTGATATGT
rs737477 SIRT1 ACGTTGGATGAAAAGGGGACAAG
TGAGGTG
ACGTTGGATGTCTTGAACTCCCGA
CCTCAG
GGGGCACATGCCTGTAA
rs36067477 SIRT1 ACGTTGGATGACCATGACACTGAA
TTATCC
ACGTTGGATGACTACTTCGCAACTA
TACCC
TGAATTATCCTTTGGATTCC
rs2234975 SIRT1 ACGTTGGATGGACTTTAAAACAGT
GTACAAG
ACGTTGGATGGTAGACTGTTTAATG
ACTGG
AGTGTACAAGTAAAAAACACT
rs1126757 IL11 ACGTTGGATGTCCCTTGCCCTTAC
CTGTAG
ACGTTGGATGACCACAACCTGGAT
TCCCTG
AGCTCCCAGTGCCCC
rs10407001 IL11 ACGTTGGATGGGAGGAGAGAGAC
TGGGCG
ACGTTGGATGCCGCCAGCCGTCG
GTCTGT
AGATGCGGCCGACGGA
rs12975067 IL11 ACGTTGGATGCTGGGCAACAAGA
GCAAAAC
ACGTTGGATGGGTCCATGGTTTTC
TTTTCC
GCAAAACTCCCTCTCTC
rs17850928 IL11 ACGTTGGATGCAGTCAAGTGTCA
GGTGCAG
ACGTTGGATGTGGCGCCCCCCTCC
TCAG
GCCCCCCCAGGATGGCG
rs1042506 IL11 ACGTTGGATGTATGTTCCTGCCCA
GGCCTA
ACGTTGGATGTCCCGGATTCTTGG
GTCTC
GAGGGCAGAAGTCTGTGG
rs10425163 IL11 ACGTTGGATGTCGGTCACCCAGA
CAGCTCT
ACGTTGGATGACAAACAAAAGGCC
CTATGC
GGGGACAGCTCTGTGGAGGC
rs2298885 IL11 ACGTTGGATGAAGCAAGCCTCTCT
CCTTAG
ACGTTGGATGAGCAACATGGTGCA
TCTGTG
GGGTACGGGCGGCTGGGTGG
rs8104023 IL11 ACGTTGGATGAGGGACGCAGGGA
CTGGTG
ACGTTGGATGAATCCCAGGGAGTC
TCCCG
CGCGGGAGGTGACCCCCATCG
rs10402868 IL11 ACGTTGGATGAAGGGAAGCCTGG
GTTTTTG
ACGTTGGATGATCGCCCTCAAGTG
GATATG
GGTGAGACAGAGAACAGGGAA
rs10402867 IL11 ACGTTGGATGATCGCCCTCAAGTG
GATATG
ACGTTGGATGAAGGGAAGCCTGG
GTTTTTG
AGTGGATATGTATGACACATTT
rs4252557 IL11 ACGTTGGATGCGGTGAAACCCTG
TGTCTAC
ACGTTGGATGTCCTGAGTAGCTGG
GACTTC
TGTGTCTACTAAAATACAAAAAAATT
AT
rs4252576 IL11 ACGTTGGATGAGCGGACCTACTG
TCCTAC
ACGTTGGATGCAGGGTCTTCAGGG
AAGAG
TCCTACCTGCGGCAC
rs4806475 IL11 ACGTTGGATGTATTTCAGGAGCAG
GGGTGG
ACGTTGGATGCTTGGAGACCCAAG
AATCCG
GGCAGGTGGACTCCT
rs7246652 IL11 ACGTTGGATGTAATCCCAGCTACT
TGGGAG
ACGTTGGATGAATGGCGCGATCAA
TGGCAC
GGAGGTTGCAGTGAG
rs4252546 IL11 ACGTTGGATGTTCTCTGGTGTGTC
TCTCTG
ACGTTGGATGCACACAGAGTGAAG
GACAG
CATCTCTGTGGATCTCC
rs7250912 IL11 ACGTTGGATGCAAAGCGCTGGGA
TAACAGG
ACGTTGGATGATCTCAGAGCTGGG
TTTTTG
AATTGTTCTAACAGCAGC
rs4252553 IL11 ACGTTGGATGAGCCTGGGCAGCA
TAGCAA
ACGTTGGATGTCTAGCCTGGGCAA
CAGAG
GGCAGCATAGCAAGACTCT
rs1042505 IL11 ACGTTGGATGCCACCCCTGCTCC
TGAAATA
ACGTTGGATGCATTATCTCCCCCTA
GTTAG
AGTATAAATAAGGCACAGATG
rs4252562 IL11 ACGTTGGATGGAGGCTTGCTTGG
GATATAG
ACGTTGGATGCCAAAGTGCCAGGA
TTACAG
CTGCTTGGGATATAGAAAGATAT
rs10832783 Nesfatin ACGTTGGATGTCTAATGGTGCTGG
GAGAAG
ACGTTGGATGGAGCAACAAGGATG
TGGTAG
GCCAGCATCTCTCAT
rs12422139 Nesfatin ACGTTGGATGTGTGGCGATTCGTA
CCTATG
ACGTTGGATGACTTACTGTATGCCA
GGCAC
GGCACCGTGCTAAGT
rs757110 Nesfatin ACGTTGGATGTGTCCTGCAGCATT
GGGTTG
ACGTTGGATGGGTGCTGAAGCACG
TCAATG
CGTCAATGCCCTCATC
rs11024273 Nesfatin ACGTTGGATGTTTGCTCCATCCTG
CACTTG
ACGTTGGATGGGAGAAGGGTTTTG
AGCAAG
TTGAGCAAGAAAGCGA
rs2285676 Nesfatin ACGTTGGATGACACCCTCTCTCAT
CAACTG
ACGTTGGATGGCTCTACTTGGTCC
CTGAAA
GTCCCTGAAAAAGCACC
rs2354863 Nesfatin ACGTTGGATGCCCCTTCTCCTACT
GCTTAA
ACGTTGGATGGGGCACAAAGATGT
TAAGGG
AAGGGGAGAGGAACGAT
rs7484027 Nesfatin ACGTTGGATGGCAAATTTTGCCAG
TTATCC
ACGTTGGATGAATGCAATGTGTGAT
CCCAG
GATCTTAGCGCAGAAAAA
rs16933837 Nesfatin ACGTTGGATGGAGTAGCTGGGATT
ACAGGC
ACGTTGGATGCTGTTATCTTCCAGA
GAGTC
AGAGAGTCTAGAAAAGCAA
rs2079293 Nesfatin ACGTTGGATGATGATGAGGGGAT
GGGAAAG
ACGTTGGATGCTGTCTACCTCATTT
GGATG
AGAACTCTCAATTTATCACC
rs10832750 Nesfatin ACGTTGGATGACCCCTTCTCAATG
ACACTG
ACGTTGGATGGGAGACTAAAGGTT
TCCCAG
CACTATGGATTGCATTAAGGT
rs7127347 Nesfatin ACGTTGGATGCAAGGAAAAACTTC
AATCAC
ACGTTGGATGGTACTGGAATCTGG
CCATGA
TAAGTATACTTTTCACCACATC
rs16933873 Nesfatin ACGTTGGATGACAGTGCTACAAG
GCCTTTC
ACGTTGGATGCCTTCACAGGCAGT
TCTTTC
TCAATTCCCTAAGTTTTAGAAA
rs34405111 Nesfatin ACGTTGGATGGTTTCTGAAGCTCA
TCTGCC
ACGTTGGATGGCAACAGTTCTTCA
CAGAGG
CAGAGGAAGAACTAAAAGAATA
rs2051773 Nesfatin ACGTTGGATGTCTGTTCTTGGTGT
GACAAC
ACGTTGGATGAAGGACATAGTAAAT
ATGC
TGCTTTAAAAAGGAAATCATCTA
rs2521998 Nesfatin ACGTTGGATGAAGGCTTAGAATGA
GGGAAC
ACGTTGGATGCCATCTTAAAGATTT
ATTGC
CTTAAACTTTTAAAACATACCTCA
rs1330 Nesfatin ACGTTGGATGTTACAGAGCATTGT
CTTGCC
ACGTTGGATGTGGGTGAATTTTATG
ACGTG
TCAATAAAGATGCTAAAAAATTGG
rs12295879 Nesfatin ACGTTGGATGCCTTCAAGTAATCC
CCAATG
ACGTTGGATGACTTCAAACTTTCTC
TGCAC
TTATCAAAAGCTCAAGTGAAAAAAA
rs1799859 Nesfatin ACGTTGGATGACCATTAGGGCGTA
GGTAAG
ACGTTGGATGGTGACCTCCATCTC
CAACTC
GACCTCCATCTCCAACTCCCTGCA
CAG
rs11024249 Nesfatin ACGTTGGATGGGGTGATTAACTTT
AGGGTG
ACGTTGGATGGATGAAGGAACATG
AAAGGAG
ATGAAGGAACATGAAAGGAGAGAA
TA
rs12796879 Nesfatin ACGTTGGATGGGGCCAAATATTAG
TGTGC
ACGTTGGATGAACTTGTCACTCCT
CTGCAC
CAGAGAAAAGGTACAATCTTTACAA
TG
rs214083 Nesfatin ACGTTGGATGAACCAAAAGGGTT
CATCTCG
ACGTTGGATGCAGCAACCTCTGAC
ACTTAG
GGAGAAAGTTAGTGTAAGTCGTGAT
AT
rs10832775 Nesfatin ACGTTGGATGTGCGACCTCCTGA
AGCAAAC
ACGTTGGATGTTGGGTTCTGAACT
TTGCGG
TTGCGGTTAAATTGATTTAAAAACT
GGT
rs1987694 Nesfatin ACGTTGGATGTGTGAGCCCTTAAA
AGGGAC
ACGTTGGATGATTGGCAAGACTCC
TGTCTC
TGTCTCGAGCCGAGC
rs17647408 Nesfatin ACGTTGGATGTCTACCACAACCTG
AGCCG
ACGTTGGATGTGGAGTCGGCCGAA
GCTTTC
TGAGCCAGCTGAGGG
rs7110094 Nesfatin ACGTTGGATGTACAGATCTCAGGG
ATCTGC
ACGTTGGATGTGCTCAGTCAGTGG
CAGAAG
CTGGCACCAGCTGGAA
rs8192690 Nesfatin ACGTTGGATGCCTTGAGTTCGATA
AGCCAG
ACGTTGGATGACTTGTCTGCACGG
ACGAAG
GCGAAGGAGGCGAAGA
rs11826763 Nesfatin ACGTTGGATGCAGTTGTGTCAGG
AAATGGG
ACGTTGGATGGTGAAGGAACACTT
AACACC
ACCTTATACACTGTTGGG
rs2634462 Nesfatin ACGTTGGATGCTCTTCTCCAATCT
CTAGAC
ACGTTGGATGTGATTGTTTCAGATG
GAAGG
TCAGATGGAAGGAGACTA
rs10832767 Nesfatin ACGTTGGATGAACCTGCTAGAGAA
GTCCAC
ACGTTGGATGCACCTTAGTATCCCA
ATTCC
GGAGTTGAGGCACCAGTGG
rs214106 Nesfatin ACGTTGGATGTTGCATTGTTGGTG
CTTGTC
ACGTTGGATGCAGCTGCTTTGTTT
CTGTGC
ATGCCAAATCATAGCTTAAT
rs10832749 Nesfatin ACGTTGGATGCCCCAACCTGAGA
AAATGAG
ACGTTGGATGGTCAGCATATTACCA
ACCTG
GGGCAACCTGGGAAACCTTT
rs10832782 Nesfatin ACGTTGGATGCTGCTGACTTAGCT
CTTTGG
ACGTTGGATGATTGCAGAGGGCAT
CAGAAG
GAAGCGGGTAGATGAAATAGC
rs12365375 Nesfatin ACGTTGGATGTGATGACTACTATC
TGTGAC
ACGTTGGATGCGATTTAACCACAGT
TTACC
TAACCACAGTTTACCATCTAAA
rs10832756 Nesfatin ACGTTGGATGTTGACTTCACAGAG
TCATTG
ACGTTGGATGGTTTACTATGTACCA
AGCAG
CCAAGCAGTATGCTAAACTTTT
rs214935 Nesfatin ACGTTGGATGTGTAGTCTACCACA
GAAGGG
ACGTTGGATGGGAGGTCATGAAGA
AAGAGG
AAGGTCCTTGGAATGTTCTTAG
rs7108861 Nesfatin ACGTTGGATGGAGGTTACCTTTGG
TTATGAG
ACGTTGGATGACAGGAAAATACAC
AGTAGG
GTTGGAAAAATACATATGGAAAG
rs7937091 Nesfatin ACGTTGGATGTCAGTGTTACCTGA
AGGTCC
ACGTTGGATGAAAGTCTGGAAGTC
CTGGTG
TCAGTCCTGGTGCCAACATTCTGA
rs2302510 Nesfatin ACGTTGGATGCCGAACAGTAAGT
GTGTACC
ACGTTGGATGGTTCATCACCCCATT
CTAAC
TCTAACTATGAAATCATGAAAAATG
rs3741203 Nesfatin ACGTTGGATGTTTGGGTAGTCTTT
CCTCTG
ACGTTGGATGTTGAAGTTACTCCC
CTTCCC
GCAATAATAATGGCATTATGAAAAAA
rs6486364 Nesfatin ACGTTGGATGAGTGATTATCCTGC
CTCAGC
ACGTTGGATGTGGAGAAACCCCAT
TTCTAC
CCCATTTCTACTAAAAATACAAAATT
A
rs12292418 Nesfatin ACGTTGGATGGTTTCTGAAGCTCA
TCTGCC
ACGTTGGATGGCAACAGTTCTTCA
CAGAGG
ATGAAAATATTATTGCTTTACAAGAA
AA
rs3115758 Apelin ACGTTGGATGGTCTCCTTAGGACT
GAAGGG
ACGTTGGATGTCCAGAGAAGCAGA
CCAATC
GAGGAGACATAACCGC
rs3761581 Apelin ACGTTGGATGATCAGCTCCTCCCC
ACTGTT
ACGTTGGATGTAGAATGAGGACAG
CTCCAG
AGGGAACAAGAAAGGG
rs5975126 Apelin ACGTTGGATGCAAGCAAAAGGGG
AGAAAGC
ACGTTGGATGAGCAGGAATAGCAC
CCTCTC
AGTAGGGGCCATCACCAG
rs2281068 Apelin ACGTTGGATGTGGTTCTCTTACAT
CCTGGC
ACGTTGGATGTAGCGGCAGGGAGA
CTAAAG
GAGACTAAAGTGAAGCATG
rs3131264 Apelin ACGTTGGATGCCCAATAGTATCCA
GTTGAC
ACGTTGGATGAAAGGATGATGGGC
AGAGAC
GCCACCAGGGTCTATGGAAC
rs3115759 Apelin ACGTTGGATGTTCATTTGGGCCTT
CCTTCC
ACGTTGGATGGAAAACAAGGGATC
TGCTGG
GGGAGCCCACAGAAGGGAGCA
rs2235307 Apelin ACGTTGGATGACAAGGCTCACCC
TGATCAC
ACGTTGGATGCTTGGTTCACTTCA
CAAGGC
CTTATCAGCATCATTCAGATCC
rs2235310 Apelin ACGTTGGATGAGGAGTGTACGTG
GTGGTAG
ACGTTGGATGGTCTGTCCTGACTT
GAAATG
TGTCCTGACTTGAAATGTCCACCC
CCG
rs909657 Apelin ACGTTGGATGGACATGCTGCTGAA
GGTGAC
ACGTTGGATGTGAGACCAGATTTA
GAGACC
CATGAATATTTGAGAATGAATAAATG
A
rs2235308 Apelin ACGTTGGATGCTAGGTCTGCAGA
GAAGAAC
ACGTTGGATGACGCAATGGGAGGG
ATGCAA
GGGATGCAAGAAGCC
rs2235306 Apelin ACGTTGGATGTTCCTGGGTAGATG
GCAATG
ACGTTGGATGAATAACAGTCTCTCT
CCCCC
CTGCACACCATCTGAT
rs2235312 Apelin ACGTTGGATGTTTGCTCCCTCTGT
TACCTG
ACGTTGGATGAGACCTGAACACGA
AGTGAG
ACCACAGTAAGAAGTGGG
rs41334247 Apelin ACGTTGGATGGTTTGATGGATGTG
TCTGGC
ACGTTGGATGCTCTGTTCAGTGGA
CAGTGC
TGGACAGTGCTAAAGCGGAG
rs3810622 Adiponutrin ACGTTGGATGCTCTGCTCCAGAAA
AACCAG
ACGTTGGATGAGCTACATCCTGCC
ATCTTC
CCCTCCTGGAGCCAC
rs4823104 Adiponutrin ACGTTGGATGCCGTACATTTGAAT
CTTGTCC
ACGTTGGATGAGAAACAAACCCTC
CGTCTG
ACACAGGTACCCACA
rs2076212 Adiponutrin ACGTTGGATGCAGACACCAGAAC
GTTTTCC
ACGTTGGATGAATGTCCACCAGCT
CATCTC
TCATCTCCGGCAAAATA
rs12483959 Adiponutrin ACGTTGGATGGCAATCCTGTATGT
AGCACC
ACGTTGGATGGAGCACGTAGTCTG
TAATGG
ATGGGAGGCTCCTAATG
rs35764214 Adiponutrin ACGTTGGATGTGTCGTACTCCCCA
TAGAAG
ACGTTGGATGATGGAGGAGTGAGT
GACAAC
AATGCCAAAACAACCATCA
rs139051 Adiponutrin ACGTTGGATGTTTGTTGCCCTGCT
CACTTG
ACGTTGGATGCCTGTGAAAGCAAA
GGAGAG
GCAAAGGAGAGAGAAGTTA
rs2294917 Adiponutrin ACGTTGGATGCCTGAAACACATGG
AGGAAG
ACGTTGGATGAATGTGGGTCCACC
GTAGC
CCCGTAGCTCAGACTGCACAC
rs738410 Adiponutrin ACGTTGGATGCTAAACAGCCAGCA
CTTGTC
ACGTTGGATGTGCTACAGAGCAGT
CAGCAG
AGAGCAGTCAGCAGGCACCAC
rs738408 Adiponutrin ACGTTGGATGTCTCCTTTGCTTTC
ACAGGC
ACGTTGGATGCTGAAGGAAGGAGG
GATAAG
TAGGGATAAGGCCACTGTAGAA
rs9625964 Adiponutrin ACGTTGGATGTGTGACCTCAGGC
AAGTTAC
ACGTTGGATGTGAGGTCGGTTTTC
CTATCC
TCGGTTTTCCTATCCATATATTG
rs2294916 Adiponutrin ACGTTGGATGACCTTTCCCTGCTT
ATCTGG
ACGTTGGATGAAGACTTCCCGTTG
GATGAG
CCCGTTGGATGAGTCTCTTTGAG
rs738407 Adiponutrin ACGTTGGATGGGAGCGCTTATGAA
AGCATC
ACGTTGGATGATTTGCCTGTATCCT
CAGGG
GGGTCTAGCAGAGAGAAGATAAT
rs9625961 Adiponutrin ACGTTGGATGCCTAGTAGCTGGG
ACTATGG
ACGTTGGATGTGATGAAACCCAGT
CTCTAC
ACACAGTCTCTACAAAAATTACAGA
rs16991187 Adiponutrin ACGTTGGATGATAGCAAGAGAGG
CCATACC
ACGTTGGATGTTTCCGTGAGCTCC
TGAGAG
GCCGTGAGCTCCTGAGAGCCCGTA
G
rs1977081 Adiponutrin ACGTTGGATGAGAGTCTTGCTCTG
TTGCCC
ACGTTGGATGGCAGGAAAATGGCT
TGAACC
AGGAAAATGGCTTGAACCTCGGAA
G
rs34179073 Adiponutrin ACGTTGGATGTTAGGGCAGATGTC
GTACTC
ACGTTGGATGTGAGTGACAACGTA
CCCTTC
CACCGTGTCCCCCTT
rs16991170 Adiponutrin ACGTTGGATGGCAAACATGAGTCT
GGATTC
ACGTTGGATGAGGTGGTCTAGCAG
CTCATC
CCAAGGCAGCCGACTC
rs35726887 Adiponutrin ACGTTGGATGATCACCAAGCTCAG
TCTACG
ACGTTGGATGACCAACTCACCTTG
AGATCC
AGGTAGAGGTTCCCTG
rs2294918 Adiponutrin ACGTTGGATGCTCTGCTTTGGTCT
CTGCTG
ACGTTGGATGATGCACACCTGAGC
AGGAC
TGGACTCCCTGCTCCCCC
rs2294919 Adiponutrin ACGTTGGATGCACTACACAGCAAT
GCGGAG
ACGTTGGATGTCTGTGAGTCACTT
GAGGAG
AAGTTTCCCATCTTTGTG
rs734561 Adiponutrin ACGTTGGATGATGTGGGAACAGA
CAAGTGC
ACGTTGGATGAACCTGCAGCCAGT
TGCATC
CCTCTGTTTAACCTTGTTTG
rs139047 Adiponutrin ACGTTGGATGCTTTCGGTCCAAAG
ACGAAG
ACGTTGGATGCCATCCCAAAACAG
CTTTTC
AAACAGCTTTTCTAACTTGA
rs1883350 Adiponutrin ACGTTGGATGAGTTTCACAGATGC
AGGCTC
ACGTTGGATGACCACCTTATTGCCC
ATAGC
GGGCAGGCAGCTTTTGCTACA
rs6006460 Adiponutrin ACGTTGGATGCAGCAGGTACTTTA
TTGCCC
ACGTTGGATGAGCAGAGACCAAAG
CAGAGG
CCGCGGTCCATCCTCAGGTCCA
rs9626056 Adiponutrin ACGTTGGATGTGCCACTGGCATCT
GATGTA
ACGTTGGATGGTCAGGAAGATGCC
TATGAG
AACGGGTGATGACACAGCATCTC
rs2394443 SIRT1 
promoter
ACGTTGGATGTTAAACCCCATCAC
GTGACC
ACGTTGGATGACCCGTAGTGTTGT
GGTCTG
CCGCCCCCGCCCTCT
rs932658 SIRT1 
promoter
ACGTTGGATGTGTTGCGTCTACCG
CTCCG
ACGTTGGATGGAATTTGGCTGCAC
TACACG
GCGGCCGGCGGCCCT
rs12778366 SIRT1 
promoter
ACGTTGGATGCTAAGGTCCTATCT
ACATCC
ACGTTGGATGTAAGGCTTCTAGGA
CTGGAG
TCATCTGGTCACCACT
rs3758391 SIRT1 
promoter
ACGTTGGATGGCCATAACAAACAC
TGGCTC
ACGTTGGATGGCACACTGTGACTC
CATATC
CTGGCTCTAGATCTACCA
rs12250285 SIRT1 
promoter
ACGTTGGATGCATCATACTGGTCA
GGCTGG
ACGTTGGATGAAATCCCAGCACTTT
GGGAG
TCCTGACATCAGGTGATC
rs10740280 SIRT1 
promoter
ACGTTGGATGAGCAAGAGCGAAA
CTCCGTC
ACGTTGGATGGGTTTGCTGCACCA
ATCAAC
GAAACTCCGTCTCAAAAAAA
A3. Sequencing PCR primers
Gene Region PCR primer 1 PCR primer 2
Annealing 
temperature (ºC)
Magnesium 
Concentration 
(mM) Q solution
SIRT1 Exon 1a CGGAGAGATGGTCCCGGCCT TAGGAGCCCGGGGAGAGGGA 50 1.5 Yes
SIRT1 Exon 1b AGTGTTGTGGTCTGGCCCGC AGGCCGGGACCATCTCTCCG 50 3 Yes
SIRT1 Exon 2 CCCCATAGGCATGCTTTACA AGTGAGGTGGGGCAAGGT 55 3 No
SIRT1 Exon 3 TACAGCTGAAGGGGGTCTTC TGCACTCAGTTTTTGGCAGT 65 3 No
SIRT1 Exon 4 TTTCTGAAATAAGGGTAGGGTTG CTTACTCCGCCACAGTAGCA 60 3 No
SIRT1 Exon 5 TAGGTGTGTGTCGCATCCAT TGTCAAGGCCAATACTTCTGTTT 60 3 No
SIRT1 Exon 6 TCTGCAGTGTGTTCTGAGGTTT TTTTACCAAAATTCCCAAATGC 60 3 No
SIRT1 Exon 7 TCCATAGCTTTTCTGTTTTGTTTTT GGGCAACAAGAGGGAAACTC 60 3 No
SIRT1 Exon 8 AAGTATTTAGTGCATGGGTCTTTTT GATTTACCTTTCTGATTACGAACTG 60 3 No
SIRT1 Exon 9a CATGCCTCCCAGTTGTTTTT CCGATGGCTTTTTGAAAACT 60 3 No
SIRT1 Exon 9b TTTACTTGTGAACTCGATAGAGCA CCAAAGCATTTATTTGTTTTTCA 60 3 No
SIRT1 Exon 9c GGAGAGCACTCGGTTGTCTT TGGTCCTAGCTGGGTGTTTT 60 3 No
SIRT1 Exon 9d GCCCTAGTATTATGGAGATGAACA GATCAGCACCATCAGGGTTT 60 3 No
SIRT1 Promoter 1 CGAATTTGGCTGCACTACAC CCATCTTCCAACTGCCTCTC 50 1.5 Yes
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SIRT1 Promoter 2 GGTGTGAGGAGAGTGGGAAA CGTGTAGTGCAGCCAAATTC 55 1.5 Yes
SIRT1 Promoter 3 GAAACGGCTAGATAGCTCACG AAATCACTACCGCCGGAAC 60 3 Yes
SIRT1 Promoter 4 CCTTAGCGATATATTTCCAGCTTT CAGCTTGGCTTCAAACGTG 60 3 No
SIRT1 Promoter 5 AGGCTGGTGTGCAATGGT GAGCACAGCGTTTCTATCTGTTT 60 3 No
SIRT1 Promoter 6 TTGGGATACTGACTCTCAACATT GGACAGATCACCTGAAGTCG 60 3 No
SIRT1 Promoter 7 GCCACCACTCTGGGCTAA CACTCCTCCCAATTCCTGAC 60 3 No
SIRT1 Promoter 8 TCCTGGGTTCACGCCATT TGCAGTATGCTTTTCAGGTAGG 60 3 No
SIRT1 Promoter 9 ACAGGAATGTGCCACCACAC ATAAATTGGCCTGCCAAGCA 60 3 No
SIRT1 Promoter 10 CCTTCCACCTCAGCTTCCTA CCCTACTTCACACAATATACGAAA 60 3 No
SIRT1 Promoter 11 ACTACAGGCGCCCACCAC GGATCAAGAAAGAACTTTTTAGCAA 55 3 No
Apelin Exon 1 GGAGCGGTTGTAGGTTGTC GATGCCAAAGGCCGAGTTGA 60 1 Yes
Apelin Exon 2 GTAGGTTCCGTTTGTCCCAG CAGACGAGGAGATCGTCTGT 60 3 No
Apelin Promoter 1 TGCCTCCTGGGGGATGCAGG CCGCGAGCCCACTTGGTCAT 60 3 No
Apelin Promoter 2 GAGGGAAGCAGCCCCATGCC CCTGGTCCTTGCCCTTGCCG 60 3 No
Apelin Promoter 3 TGGCACACACGCACCCTGTC TTGTTCCCTGGAGCTGTCCTCA 60 3 No
Apelin Promoter 4 AGGGGTGCCATGCTTCACATGC TCAGCAAGCCAGGCAGTTTGC 60 3 No
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A4.   Primer Sequences Used in DNA Methylation Study 
Gene PCR primer 1 PCR Primer 2 Sequencing Primer
POMC TTTAAAGTGGAATAGAGAGAATATGA CACAAAAAACAACTCCCC TTATAGTTTTTAAATAATGGGGAAA
POMC GTAGTTGAGTTGGAGGGTTTA CAACCTAACCAACATAAAAAAA TCACCCCTTTACTCTCCAACA
Leptin AAATTTTTGGGAGGTATTTAAG AAAAAAACCAACAAAAAAAAA TTTTTGGGAGGTATTTAAGG
Leptin TTGTTGGTTTTTTTTGGTAGG ATACCCAAAACAATTTCCAATAC ATACCCAAAACAATTTCCAA
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A 6. R scripts
Data was read from a tab-delimited text  file  with  column titles indicating the names of  the 
variables. The phrase “file name” indicates that the full path and file name should be inserted 
e.g “C:/Documents and Settings/sjclark/Desktop/FILENAME.txt"”.
A 6.1. Correction of transcript data for covariate effects using linear regression
Table<-   read.table("file  name",  header=TRUE,  sep="",  na.strings="NA",  dec=".", 
strip.white=TRUE)
linearRegr<- lm(Transcript~age+bmi+sex, data=Table)
residuals<-residuals(linearRegr)
write.table(residuals, file="file name")
A 6.2 Correction of BMI or transcript data for effects of relatedness using clustering
Table<-   read.table("file  name",  header=TRUE,  sep="",  na.strings="NA",  dec=".", 
strip.white=TRUE)
library(Ecdat)
 LSDV <- lm(BMI ~ Family, data=Table)
 gcenter <- function(df1,group) {
variables <- paste(
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 rep("C", ncol(df1)), colnames(df1), sep=".")
 copydf <- df1
 for (i in 1:ncol(df1)) {
 copydf[,i] <- df1[,i] - ave(df1[,i], group,FUN=mean)}
 colnames(copydf) <- variables
 return(cbind(df1,copydf))}
centerTable <- gcenter(Table[,1:65], Table$Family)
fmlm <- lm(C.BMI ~ C.Family, data=centerTable)
library(sandwich)
 M <- length(unique(Table$Family))
 dfcw <- fmlm$df / (fmlm$df - (M -1))
 library(lmtest)
 coeftest(fmlm, dfcw*vcov(fmlm))
clx <-
function(fm, dfcw, cluster){
 library(sandwich)
 library(lmtest)
 M <- length(unique(cluster))
 N <- length(cluster)
 dfc <- (M/(M-1))*((N-1)/(N-fm$rank))
 u <- apply(estfun(fm),2,
 function(x) tapply(x, cluster, sum))
 vcovCL <- dfc*sandwich(fm, meat=crossprod(u)/N)*dfcw
 coeftest(fm, vcovCL) }
 clx(fmlm, dfcw, Table$Family)
residuals<-residuals(clx)
write.table(residuals, file="file name")
A 7. Statistical power calculations for locating SNPs in LD with associated 
variants
The following calculates the probability of finding a SNP (assuming such a SNP exists) with 
certain MAF that is in LD with an associated SNP (with MAF =0.13, as was observed in the 
controls  for  rs11599176,  the  most  significantly  associated  SNP in  the  SIRT1 gene)  when 
sequencing 10 samples that are homozygous for the minor variant of the associated SNP. 
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r 2=
H q
2
Ap . Aq . B p .Bq
Where r2 is the correlation coefficient of LD between two markers A and B (A being the 
associated SNP and B the marker that is being discovered), Hq is the frequency of the 
haplotype, H containing the minor alleles of markers A and B, Aq and Bq are the minor allele 
frequencies of markers A and B and Ap and Bp are the common allele frequencies of markers A 
and B.
By inputting an r2 value of 0.8, an Aq of 0.13 and a Bq of 0.05, the value of Hq is determined:
0.8=
H q
2
0.87 .0.13 .0.95 .0.05
0.00425=H q
2−0.0130H q
0.00425=(H q−0.00650)
2−0.006502
√0.00425+0.00652=H q−0.00650
0.072=H q
Thus the probability of a sample having the haplotye, H, given that the sample has the minor 
allele of the associated SNP is:
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0.072
0.13
=0.55
And the probability of at least one in 20 samples (10 diploid samples) containing the haplotype 
given that they each contain the minor allele of the associated SNP:
1−(1−0.55)20=0.99999
Thus there is a probability of >99% of the minor allele of marker B being present in at least one 
sample out of ten samples that are homozygous for the minor allele of marker A if the MAF of 
marker A = 0.13, the MAF of marker B =0.05 and LD (r2) between the two SNPs is 0.8..
Calculating the probability using r2 = 0.5 and Bq = 0.01:
 0.5=
H q
2
0.87 .0.13 .0.99 .0.01
0.0224=H q
0.0224
0.13
=0.172
1−(1−0.172)20=0.977
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Thus there is a probability of 97% of the minor allele of marker B being present in at least one 
sample out of ten samples that are homozygous for the minor allele of marker A if the MAF of 
marker A = 0.13, the MAF of marker B =0.01 and LD (r2) between the two SNPs is 0.5..
Calculating the probability using r2 = 0.5 and Bq = 0.001:
0.5=
H q
2
0.87 .0.13 .0.999 .0.001
0.0076=H q
0.0076
0.13
=0.0588
1−(1−0.0588)20=0.702
Thus there is a probability of 70% of the minor allele of marker B being present in at 
least one sample out of ten samples that are homozygous for the minor allele of marker 
A if the MAF of marker A = 0.13, the MAF of marker B =0.001 and LD (r2) between the 
two SNPs is 0.5.
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